SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW NEURAMINIDASE INHIBITORS DERIVED FROM SIALIC ACID AS POTENTIAL ANTIVIRAL AGENTS by P. LA ROCCA
  
 
PhD course in Biochemical Sciences, XXXI cycle 
Department of Medical Biotechnology and Translational Medicine 
 
 
 
Synthesis and biological evaluation of new 
neuraminidase inhibitors derived from sialic acid as 
potential antiviral agents 
 
Paolo LA ROCCA 
Matr.: R11334 
 
Supervisor: Prof. Pietro ALLEVI 
Coordinator: Prof. Sandro SONNINO 
 
 
A.Y. 2017/2018 
 I 
 
 
Index 
ABSTRACT 1 
1. INTRODUCTION 3 
1.1 The Sialic acids: an extended family 5 
 1.1.1 N-acetylneuraminic acid structure 5 
 1.1.2 Metabolism in mammalians and bacteria 6 
 1.1.3 N-acetylneuraminic functions 7 
1.2 Sialidases superfamily: general and common characteristics 8 
 1.2.1 Sequence and structure 9 
 1.2.2 Proposed catalytic mechanisms 10 
1.3 A brief introduction to sialidase inhibitors 13 
 1.3.1 The 2,3-unsaturated inhibitors 13 
 1.3.2 The 3,4-unsaturated inhibitors 15 
 1.3.3 Other inhibitors 16 
1.4 Viral neuraminidases (viral sialidases) 18 
 1.4.1 Influenza viruses 18 
 1.4.1.1 The virus, some of its key proteins and the neuraminidase 
active site 
18 
 1.4.1.2 Zanamivir: an example of the strategy to develop new 
inhibitors 
21 
 1.4.1.3 150-cavity, a second sialic acid binding site and new 
generation inhibitors 
21 
  
 
 
 II 
 
1.4.2 Newcastle disease virus (NDV) 23 
 1.4.2.1 The virus, its lifecycle and the key proteins 23 
 1.4.2.2 NDV-HN structure, catalytic site (Site I) and role of the second 
binding site (Site II) 
26 
 1.4.2.3 Studies on NDV-HN Site I and Site II inhibition 31 
 1.4.3 Human parainfluenza viruses (hPIVs) 31 
 1.4.3.1 The virus and its lifecycle 31 
 1.4.3.2 hPIVs-HN structure and catalytic/active site (Site I) 32 
 1.4.3.3 hPIVs-HN second sialic acid binding site (Site II) 34 
 1.4.3.4 Studies on hPIVs-HN inhibitors 36 
1.5 Mammalian sialidases 37 
 1.5.1 Human NEU3 (hNEU3) 37 
 1.5.2 Specific hNEU3 inhibitors 38 
2. AIM OF THE WORK 40 
3. RESULTS AND DISCUSSION 42 
3.1 The 2,3-unsaturated derivatives: C5 substitutions 44 
 3.1.1 Chemical synthetic approach 44 
 3.1.1.1 Synthesis of the C5 modified 2,3-unsaturated derivatives 45 
 3.1.2 Neuraminidase inhibition assay 47 
 3.1.2.1. Neuraminidase inhibition assay (NI) on NDV-HN 47 
 3.1.3 Docking simulation studies and further biological evaluations 49 
 3.1.3.1 Rigid docking simulations on C5 substituted derivatives 49 
 3.1.3.2 Neuraminidase inhibition assay on hNEU3: Preliminary 
studies on selectivity 
53 
 3.1.3.3 Cytotoxicity test on compound 2c 54 
 III 
 
3.2 The 2,3-unsaturated derivatives: C4/C5 combined substitutions 55 
 3.2.1 Docking simulation studies 55 
 3.2.1.1 Rigid and Induced Fit docking simulations 55 
 3.2.2 Chemical synthetic approach 60 
 3.2.2.1 Synthesis of all C4/C5 substituted derivatives 60 
 3.2.3 Biological assays 63 
 3.2.3.1 Neuraminidase inhibition assay (NI) on NDV-HN 63 
 3.2.3.2 Hemagglutinin inhibition assay (HI) on NDV-HN: Preliminary 
results 
65 
 3.2.3.3 Neuraminidase inhibition assay (NI) on hNEU3: Preliminary 
studies on selectivity 
66 
3.3 The 3,4-unsaturated derivatives 68 
 3.3.1 Chemical synthetic approach 68 
 3.3.1.1 Setting up of optimal Ferrier reaction conditions using MeOH 
as nucleophile 
69 
 3.3.1.2 Setting up of optimal Ferrier reaction conditions for other 
alcoholic and thiolic derivatives 
74 
 3.3.1.3 Achievement of the deprotected 3,4-unsaturated Neu5Ac 
analogues and study of their stability 
75 
 3.3.1.4 A simple method for the anomeric configuration attribution to 
the 3,4-unsaturated derivatives 
77 
 3.3.2 Neuraminidase inhibition assay (NI) on NDV-HN and hNEU3 80 
4. CONCLUSIONS AND FUTURE PERSPECTIVES 82 
5. EXPERIMENTAL 85 
5.1 Chemistry 86 
5.2 Biological materials and methods  137 
 IV 
 
5.3 Computational methods 140 
6. BIBLIOGRAPHY 142 
   Abstract 
1 
 
ABSTRACT 
The development of new, potent and selective bacterial, viral and human sialidase 
(neuraminidase) inhibitors is an important issue to be pursued in order to achieve both useful 
therapeutical and biochemical tools. In fact, these hydrolytic enzymes can represent a good 
target since they play key roles in some physio-pathological processes by regulating the levels 
of sialic acid (such as the N-acetyl neuraminic acid; Neu5Ac) presents in glycoconjugates. In 
addition, in the design of inhibitors against a specific member of this class of enzymes is 
critical to take into account that these proteins share some common features such as the 
tridimensional structure of their catalytic domain, but, on the other hand, they show a very 
low sequence identity. Indeed, the only conserved residues are some active site amino acids 
essential for the catalytic mechanism.  
This thesis work was focused on the synthesis of hemagglutinin-neuraminidase (HN) 
inhibitors against the Newcastle virus (NDV), a member of the Paramyxoviridae family and 
strictly related to human parainfluenza viruses (hPIVs). NDV is a single-stranded RNA virus 
which could affect most species of both domestic and wild birds, causing significant and 
substantial economic losses in the poultry industry. To date, vaccination is the preferential 
instrument to border the infection, but when this procedure is not applicable, an efficient 
antiviral therapy could be the only useful way to control NDV outbreaks. At this purpose, the 
HN glycoproteins of paramyxoviruses represent an excellent target to be hit because they have 
some key roles in viral lifecycle: a) allowing viral attachment to the target cell; b) promoting 
the fusion process and, finally c) ensuring the release of the neo-synthesized virions. 
Over the past years, while some 2,3-unsaturated Neu5Ac derivatives (DANA derivatives) 
have been marketed as inhibitors against influenza virus neuraminidases (belonging to 
Orthomyxoviridae family), no compounds reach the clinical phase for paramyxoviruses 
treatment. In particular, few molecules have been developed for NDV-HN, and the N-
trifluoroacetyl derivative of DANA (FANA) was still the best inhibitor until my thesis work. 
So, the necessity to find new, potent and possibly selective inhibitors against 
paramyxoviruses-HNs remain a key issue. 
At this purpose, the successful strategy, resulted fundamental to develop new NDV-HN 
inhibitors, was based on a multidisciplinary approach that combined the use of a) the chemical 
synthetic procedures, b) the computational docking studies and c) some biochemical activity 
assays. More in detail, the attention was directed to the study of two classes of inhibitors:  
 Some C5 or C4/C5 modified 2,3-unsaturated DANA derivatives, as reversible 
inhibitors. 
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 Some scarcely investigated C2 modified 3,4-unsaturated Neu5Ac analogues, as 
irreversible ones.  
We finally reached satisfying results, regarding both classes of inhibitors:  
a) The understanding of the influence of the C5 N-perfluorinated substituents on the 
inhibitory activity of some 2,3-unsaturated DANA analogues, as potent and reversible 
NDV-HN inhibitors. 
b) The discovery of a new C5 N-perfluorinated inhibitor against NDV-HN as potent as 
FANA (the best NDV-HN inhibitor previously published) but more selective for NDV-
HN towards human NEU3. 
c) The significant achievements of five new, potent and selective C4 and C5 modified 2,3-
unsaturated DANA derivatives. All these compounds, combining the C4 azido or C4 p-
toluensolfonamido group with the C5 N-perfluorinated chains, showed IC50 values in the 
nanomolar range; thus, they are up to 15-fold more potent than FANA. 
d) The set-up of more efficient synthetic procedures to achieve the 3,4-unsaturated Neu5Ac 
derivatives in high yields and β-anomeric stereoselectivity.  
e) The set-up of a smart and rapid method to unequivocally attribute the C2 configuration of 
the 3,4-unsaturated Neu5Ac inhibitors, via a 1,7-lactonization reaction. 
f) The mechanism elucidation of an unreported and unexpected chemical scrambling 
between the C4 and the C5 position of Neu5Ac derivatives (through a previously 
uncharacterized reaction intermediate). 
In addition, the rigid and induced fit docking simulation results permitted me to speculate on 
the interactions of the synthesized inhibitors with some active site amino acids, such as 
Lys236, a well know key residue involved in NDV-NH catalytic site activation mechanism 
and in fusion promotion activity. The comprehension of ligand/receptor interactions could 
lead to the development of molecules able to block, not only the neuraminidase activity of 
NDV-HN or other paramyxoviruses-HN, but also other viral functions mediated by these 
enzymes. 
Some of the obtained results allowed the publication of two scientific articles: 
 Rota, P., La Rocca, P., Piccoli, M., Montefiori, M., Cirillo, F., Olsen, L., Orioli, M., Allevi, P., and 
Anastasia, L. (2018) Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase, 
ChemMedChem 13, 236-240. 
 Rota, P., Papini, N., La Rocca, P., Montefiori, M., Cirillo, F., Piccoli, M., Scurati, R., Olsen, L., Allevi, 
P., and Anastasia, L. (2017) Synthesis and chemical characterization of several perfluorinated sialic 
acid glycals and evaluation of their in vitro antiviral activity against Newcastle disease virus, 
MedChemComm 8, 1505-1513. 
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This introduction aims to provide some information, referring to the current state of the art, 
useful for the understanding of my PhD thesis project directed to study the hemagglutinin-
neuraminidase of Newcastle disease virus (NDV-HN) role in the virulent processes and to 
develop some new and potent NDV-HN inhibitors.  
Initially, a brief description of sialic acids family (Sias), having N-acetylneuraminic acid 
(Neu5Ac) as the most representative member, is given. In particular, the structures, the 
functions and the metabolism of these acidic 9-carbon backbone carbohydrates, have been 
clarified in order to introduce the natural substrates of the enzymes object of our interest: the 
sialidases/neuraminidases (N). Then, a brief overview about these enzymes, able to catalyze 
the hydrolysis of terminal sialic acids present in glycoconjugates, their classification and their 
catalytic mechanism, are presented.  
In addition, considering the important role played by sialidases in viral lifecylce, cleaving 
sialic acid residues and permitting to the newly formed virions to leave the target cell 
(enhancing the infection process), they represent the ideal pharmacological target to block 
viral infection. Thus, al lot of sialidase inhibitors have been synthesized and, to date, the main 
compounds derive from Neu5Ac. In particular, during these last years, a great interest has 
been directed to the 2,3-unsaturated Neu5Ac derivatives, with a well assessed inhibitory 
activity against viruses and bacteria sialidases1-5. On the other hands, few reports are dedicated 
to the investigation of the chemistry and the therapeutically applicability of the 3,4-
unsaturated analogues6, 7. 
Finally, starting from the description of bacterial, viral and mammalian sialidases, a particular 
focus it has been directed to hemagglutinin-neuraminidase of Newcastle disease virus, a viral 
envelope tetrameric glycoprotein, with crucial roles in different phases of viral lifecycle, in 
order to better understand the characteristic of its peculiar and flexible active site. 
Furthermore, a comparison between the characteristics of the NDV-HN active site and the 
parainfluenza virus hemagglutinin-neuraminidase (hPIVs-HN) one is herein proposed, 
showing how the high degree of similarity makes possible to transpose the obtained results on 
hPIVs-HN. 
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1.1 The sialic acids: an extended family 
As previously anticipated, the chemical diversity of sialic acids (Sias) family contribute to the 
huge variety of glycan structures on cell surfaces and the peculiar “makeup” of different cell 
types. This heterogenicity of compounds derived, principally, from the presence of 
modifications of the three “core” Sia molecules: N-acetylneuraminic acid (Neu5Ac), N-
glycolylneuraminic acid (Neu5Gc) and ketodeoxynonulosonic or 3-deoxy-non-ulosonic acid 
(KDN)8 (Figure 1.1).  
 
Figure 1.1 Sialic acids family: the three main derivatives 
These modifications include the substitutions on the hydroxyl groups at C4, C7, C8, and C9 
with O-acetyl, O-methyl, O-sulfate, or O-lactyl functions. This variety of modifications can 
determine their recognition and their biological functions. 
1.1.1 N-acetylneuraminic acid structure 
The most common member of this family, in human, is N-acetylneuraminic acid (Neu5Ac), a 
negatively charged sugar forming a pyranosidic ring in solution via intramolecular hemiketal 
condensation. It is classically named 5-acetamido-3,5-dideoxy-D-glycero-D-galacto-2-
nonulosonic acid and the carbon atoms of the molecule are numbered consecutively giving 1 
to carboxylic carbon and 2 to the anomeric carbon, as shown in Figure 1.1. 
 
 Figure 1.2 N-acetylneuraminic acid: α and β anomers. 
This sugar, in solution, exists as equilibrium of α/β anomer mixture (Figure 1.2). Usually, 
Neu5Ac molecules are present in the most stable β anomer configuration form (90%). On the 
contrary, when this sugar is bound to glycans it is in its α configuration, with the exception 
for the complex CMP-Neu5Ac (the activated form of Neu5Ac)8, 9. 
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1.1.2 Metabolism in mammalians and bacteria 
The sialic acids metabolism follows a specific anabolic pathway from the synthesis (a) to the 
transport inside the cell compartments, the glycan attachment and the transfer on the cell 
membrane (b). On the other hand, the catabolic way provides the Sias removal from glycans, 
operated by sialidases (c), followed by their recycling or degradation (d)8, 9. In detail:  
(a) Synthesis of Neu5Ac. 
 The first step to obtain Neu5Ac is common to all species and it consists in the 
transformation of UDP-N-acetylglucosamine (UDP-GlcNAc) into N-acetyl-D-
mannosamine (ManNAc) performed by the enzyme UDP-GlcNAc-2-epimerase, 
called also ManNAc kinase (Figure 1.3). 
 Then, in mammalians ManNAc is phosphorylated by the same enzyme to ManNAc-
6-phosphate, which is condensed with phosphoenolpyruvate (PEP), by Neu5Ac-9-P 
synthase, to obtain Neu5Ac-9-phosphate. Finally, dephosphorylation by a specific 
phosphatase gives Neu5Ac released in the cytoplasmic compartment (Figure 1.3). In 
contrast, in bacteria, the Neu5Ac biosynthesis involves directly the condensation of 
ManNAc with phosphoenolpyruvate catalyzed by Neu5Ac synthase8, 9. 
 
Figure 1.3 Crucial phases of sialic acids biosynthesis in mammalians (Varki et al., 2015). 
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(b) The transport inside the cell compartments, the glycan attachment, the transfer on the cell 
membrane. 
 In mammalians, Neu5Ac reaches the nucleus where the activated form of sialic acid, 
CMP-sialic acid, is generated by CMP-Neu5Ac synthetase using cytosine triphosphate 
(CTP) as donor (Figure 1.3). The synthesized CMP-Neu5Ac is delivered into the Golgi 
compartments where sialyl residues were transferred to newly synthesized 
glycoconjugates by a family of linkage-specific sialyl-transferases (STs). On the 
contrary, in bacteria, CMP-Neu5Ac is synthesized in the cytoplasm and directly used 
in the assembly of cell-surface glycans8-10. 
(c,d) The Neu5Ac removal operated by sialidases and the final recycling/degradation process 
 During sialic acid catabolism an important role is assigned to sialidases, specific 
enzymes involved in sialic acid removal from membrane glycoconjugates8, 9.  
In mammalians, specific sialidases, having different functions, are localized in 
different cellular compartments: the lysosomal NEU1, the cytosolic NEU2, the plasma 
membrane NEU3 and the mitochondrial/lysosomal/intracellular membranes NEU411. 
Cleaved Neu5Ac is released into the lysosome of a mammalian cell and then, it is 
delivered back to the cytoplasm by a specific exporter called Sialin, to be reused. On 
the other hands, if Neu5Ac is not immediately recycled it is degraded by cytoplasmic 
Neu5Ac-specific pyruvate lyases, that cleave the molecule into N-acetyl-
mannosamine and pyruvate8.  
Interestingly, bacteria catabolism involves sialidase too, although the occurrence is 
limited to a handful of species. The main roles of these enzymes in bacteria are: a) the 
removal of Sias from higher-order gangliosides present in mucous surfaces, b) the 
unmasking of toxin receptors and c) the biofilm formation. The canonical degradation 
pathway involves five enzymes able to transform free Neu5Ac into N-
acetylglucosamine-6-P (GlcNAc-6-P), via N-acetylmannosamine (ManNAc) and 
phosphoenolpyruvate (PEP) intermediates. Finally, the GlcNAc-6-P is converted into 
fructose-6-P (Fru-6-P), which is a substrate in the glycolytic pathway12-14. However, 
some different variations have been reported and, consequently, this discussion cannot 
be generalized to all procariotes14. 
1.1.3 N-acetylneuraminic acid functions 
The different functions exerted by Sias present in membrane glycoconjugates (Figure 1.4) are: 
 modulation of transmembrane signaling processes (e.g. cellular cross-talking); 
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 regulation of cell growth and differentiation (e.g. involvement in tumor progression); 
 binding and transport of different types of ions and drugs; 
 stabilization of the conformation of proteins protecting them from proteases or 
glycosidases attack with the subsequent extension of the cell lifetime; 
 modulation of the viscosity of mucins, sialoglycoproteins present in the mucous 
secretion of the respiratory and gastrointestinal tracts; 
 masking action of antigenic sites and receptors; 
 ligand for the binding of a variety of viral, bacterial and animal lectin-like proteins 
(hemagglutinin) and sialidases8, 9. 
 
Figure 1.4 Membrane glycoconjugates: glycosphingolipids, O-glycan, N-glycan, secreted glycoprotein and 
free glycans (Xiong et al., 2017). 
1.2 Sialidases superfamily: general and common characteristics 
Sialidases belong to a family of proteins called glycoside hydrolase, a group of enzymes that 
hydrolyze the glycosidic bond between carbohydrates or between a sugar and a non-
carbohydrate moiety. In particular, sialidases can hydrolyze the α2-3, α2-6 and α2-8 
glycosidic bonds present at the terminal sialic acid residues of oligosaccharides, 
glycoproteins, glycolipids and other natural or synthetic substrates. They could be classified, 
according to Carbohydrate Active Enzymes database (CAZy), in different families: GH33 
(includes bacterial and eukaryotic enzymes), GH34 (includes influenza viruses enzymes), 
GH83 (includes other viral sialidases) and, finally, GH58 (includes bacteriophage 
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endosialidases)15. Nowadays the term “sialidase” is preferred over the older term 
“neuraminidase”, currently used only for viral enzymes (for historical reasons)9.  
1.2.1 Sequence and structure 
Considering the primary structure, the comparison among different bacterial neuraminidase 
catalytic domains gives a general medium/low sequence identity (≈30%)16. In addition, a very 
low identity has been demonstrated, also, within viral neuraminidase (and hemagglutinin-
neuraminidase) group by different sequence alignments. Thus, as we can observe in literature, 
only the catalytic site amino acids resulted conserved passing from bacterial to viral 
neuraminidases (Table 1.1)17.  
 
 
 
 
 
 
Table 1.1 The conserved active site amino acids of some bacterial and influenza virus sialidases (Colman et 
al., 1993). 
Furthermore, considering mammalian sialidases, for example NEU2 (the only crystallized 
human one), it is well known that they share, with bacterial and viral neuraminidases, the same 
active site amino acids, their architecture and the spatial disposition. These highly conserved 
residues are: a) the arginine triad that binds the carboxylate group of the ligand, b) a 
tyrosine/glutamate nucleophile pair and c) an aspartate that acts as the acid/base catalyst15. 
This strengthens the hypothesis of a common ancestor of sialidases despite the low sequence 
identity18. The resolved 3D structures of the catalytic domain of viral sialidases, bacterial and 
the human NEU2, until now obtained, show a typical common beta-propeller fold structure, 
consisting of six four-stranded, antiparallel beta-sheets arranged as blades of a propeller 
around a pseudo-six-fold axis (Figure 1.5) 14, 15. They also show the presence of a T/FYRI/VP 
motif (a conserved N-terminal motif containing one arginine of the arginine triad) and a 
variable number of Asp-box motifs on the beta-propeller structure. The Asp-boxes have 
always the same position and might be involved in the secretion process16. In conclusion, 
despite the large divergence in primary structure, all sialidases share some structural features 
and a well conserved positioning of the active site amino acids (essential for their catalytic 
activity).  
SIALIDASE FROM: ACTIVE SITE RESIDUES 
Influenza Virus Arg118 Asp151 Arg224 Glu276 Arg292 Arg371 Tyr406 Glu425 
C. sordelli Arg55 Asp80 Arg115 Glu253 Arg270 Arg330 Tyr365 Glu380 
C. perfringens Arg37 Asp62 Arg97 Glu235 Arg252 Arg312 Tyr347 Glu362 
S. thyphimurium Arg37 Asp62 Arg97 Glu236 Arg251 Arg309 Tyr342 Glu364 
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1.2.2 Proposed catalytic mechanisms 
The catalytic mechanism of sialidases could be based on a retention or an inversion of 
anomeric configuration. This thesis will focus on the retention one, typical of sialidases 
belonging to GH33, GH34 and GH83 families. This particular mechanism has been, firstly, 
proposed and studied for β-glycosidases, providing for two different theories: 
A. Koshland, in 1953, proposed a catalytic mechanism where one carboxylic group acts as 
an acid catalyst, protonating the oxygen involved in glycosidic bond, thus promoting the 
glycosidic linkage cleavage and a second carboxylic group that operates as nucleophile, 
generating at the anomeric position a covalent glycosyl-enzyme intermediate. At this point 
the deglycosilated portion diffuses away from the active site, being replaced by a molecule 
of water and the reverse process take place: the carboxylated side-chain group 
deprotonates the water molecule, that attacks the anomeric center displacing the newly 
formed covalent glycosyl-ester bond. Both the steps involved transition-states having a 
substantial oxocarbenium-ion character19-21 (Figure 1.6, A). 
B. Phillips, in 1967, proposed a variant of the previously described mechanism, which 
involves a long-lived oxocarbenium-ion intermediate rather than the formation of a 
covalent glycosyl-enzyme one22 (Figure 1.6, B). 
 Figure 1.5 On the left: up) a 3D representation of the beta-propeller structure; down) the common beta-
propeller fold structure, consisting of six four-stranded, antiparallel beta-sheets. On the right: an example of 
catalytic site of a bacterial sialidase crystallized with the molecule 2,7-anhydro-Neu5Ac. 
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Figure 1.6 -glycosidase catalytic mechanism of retention of configuration, in according to Koshland model 
(left, A) or Phillips model (Right, B). 
Now, focusing specifically on sialidases, one of the firstly proposed catalytic mechanism was 
published by Chong, Von Izstein and coworkers, which sustained the presence of an ionic 
intermediate (Figure 1.6B). In fact, they studied viral sialidases catalytic process using some 
isotope effects and NMR methods, confirming the formation of an electrostatic environment 
in enzyme active site, which is favorable to the charged reaction intermediate23-25. According 
to these data, some literature reports implicitly assume that the glycal sialidase inhibitor 5-
acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-non-2-enoic acid (DANA) is a 
good mimic of the oxocarbenium transition state25, 26. More recent theories are favorable to a 
mechanism based on a covalent intermediate (Figure 1.6A), in fact, despite the absence of a 
glutamate (or an aspartate) correctly positioned to perform the nucleophilic attack, as in other 
glycosidases, it has been demonstrated that a tyrosine could support this role. Phenolic group 
of this amino acid presents a poor nucleophilic tendency but anyhow, its central role in the 
catalytic mechanism, leading to the formation of a covalent sialosyl-enzyme intermediate, has 
been demonstrated in bacteria and viruses (Figure 1.7)14, 25, 27-29. In addition, the same 
mechanism has been, independently, proposed for hNEU211. In conclusion, some divergencies 
about the catalytic mechanism explanation are evident: “has the enzyme-bound intermediate 
covalent or ionic nature?”, this question has not a unique response nowadays. Certainly, the 
existence of a long-lived oxocarbenium ion has never been empirically demonstrated, on the 
contrary, a lot of mutagenesis experiments and difluoro-sialic acids studies confirmed the 
presence of the putative covalent-bound intermediate (Figure 1.6 and 1.7)25. These data 
1.Introduction 
 
 
12 
 
permitted to reformulate, more precisely, the general catalytic mechanism for sialidases 
(Figure 1.7) and resulted extremely useful to identify new generation “mechanism-based” 
sialidase inhibitors (see paragraph 1.3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.7 Catalytic mechanism of sialidases with the formation of a covalent intermediate. The substrate 
binds to the active site in a 2C5 chair conformation, then, after a conformational change, the active site 
tyrosine acts as a nucleophile reacting with the anomeric carbon of the substrate in a B2,5-like boat 
conformation (not shown). So, a covalently bound sialosyl-enzyme intermediate (in a 2C5 chair conformation) 
is formed. Finally, hydrolysis of this intermediate via a B2,5 boat conformation specie (not shown) formation 
and a subsequent conformational change is followed by the diffusion of the product out of the active site (From 
Chan and Bennet, 2012).
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1.3 A brief introduction to sialidase inhibitors 
To better understand the different types of sialidase inhibitors it is worth mentioning the 
difference between reversible and irreversible inhibition. 
 Reversible inhibitors: these types of inhibitors bind reversibly to the enzyme with 
only weak interactions, so the inhibitor-enzyme complex could easily dissociate. They 
are defined competitive inhibitors, if the formation of the complex can be biased to 
favor the binding of the substrate, simply increasing its concentration. Instead, they 
are defined as uncompetitive inhibitors if the binding of the substrate to the active site 
create an allosteric site where the inhibitor could bind, blocking the enzyme activity. 
And finally, they are defined non-competitive inhibitors if they interact with a pre-
existing allosteric site causing some structural rearrangements in the protein, resulting 
in a reduction of binding affinity of the substrate in the active site. 
 Irreversible inhibitors: they bind tightly to the active site by a covalent or strong non-
covalent binding, or they irreversibly modify a functional group that is essential for 
the enzymatic activity. 
1.3.1 The 2,3-unsaturated inhibitors 
DANA (5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-non-2-enoic acid, Table 
1.2) was the first 2,3-unsaturated sialidase inhibitor discovered and its activity was deeply 
investigated by Meindl and coworker30, 31. They demonstrated its reversible and competitive 
inhibition at micromolar level against viral, bacterial and mammalian sialidases (Table 1.2)30, 
32, 33
. In fact, this high inhibitory activity could be explained by its 2,3-unsaturated structure 
mimicking the transition state proposed in the catalytic mechanism (Figure 1.7). Furthermore, 
this compound has used as reference molecule in a lot of sialidase inhibition studies. The 
group of Meindl30 also described the high inhibitory activity of trifluoroacetyl derivative of 
DANA, the FANA (Table 1.2) on bacterial and viral sialidases. Unfortunately, both these 
inhibitors are scarcely selective, showing micromolar inhibitory activity against viral and 
bacterial enzymes, but also towards human silaidases.30, 32 
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Starting from these evidences, in the last years, a large number of DANA derivatives, as new 
potent sialidases inhibitors, have been studied. Von Izstein research group, very active in this 
field, developed Zanamivir (Table 1.2), which possess a very high inhibitory activity against 
influenza virus neuraminidases. In 1999, following the success in clinical trials, Zanamivir 
was approved by the US Food and Drug Administration (FDA) as the first neuraminidase 
inhibitor targeting influenza virus, with the trade name of Relenza®.1 Successively, a lot of 
differently substituted DANA derivatives have been developed as possible sialidases 
inhibitors, directed towards influenza and parainfluenza viruses1-5, 36, pathogenic bacteria33, 37-
39
 
and human sialidases34, 40, 41 (Figure 1.8). 
 Vibrio cholerae Newcastle disease virus Influenza A virus Influenza B virus hNeu3 
DANA 30 µM 13 µM 20-30 µM 90 µM 7.7 µM 
FANA 2.5 µM 1.9 µM 5 µM 21 µM - 
Zanamivir 52 µM - ~1x10-3 µM* ≈4x10-3 µM* 4.0 µM 
Table 1.2 IC50 values relative to the neuraminidase inhibition assay performed with DANA, FANA and 
Zanamivir on different sialidases published in various literature works.30, 34, 35. 
*these IC50 values are taken from the literature35 but they could variate considering the different Influenza A 
and B virus strains. 
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Figure 1.8 Representation of some of the most active inhibitors of viral, bacterial and human sialidases2, 34, 36, 38 
1.3.2 The 3,4-unsaturated inhibitors 
Another class of sialidase inhibitors belongs to the family of 3,4-unsaturated sialic acid 
derivatives (Figure 1.9). Despite the presence of an unsaturation, they do not mimic the 
transition state. This double bond, as postulated by Maudrin and coworkers in 1994, could be 
useful to generate some putative irreversible inhibitors42. 
O
CO2H
HN
HO
H
OH
OH
O
OR
 
They hypothesized that a 3,4-unsaturated derivative could be recognized as substrate analog 
by the enzyme and consequently hydrolyzed in an open-chain molecule, able to generate a 
conjugated unsaturated α-keto-acid (Figure 1.10). Indeed, this structure presents an 
electrophilic carbon susceptible to a Michael-type addition that could occur with a nucleophile 
group (Asp, Glu or Tyr) present in enzyme active site, forming an irreversible covalent bond. 
Unfortunately, they finally experimentally demonstrated42 that these molecules, against 
influenza virus neuraminidases, are reversible competitive inhibitors (Ki = 7mM), instead 
irreversible ones. Probably, because influenza virus neuraminidase does not possess a 
nucleophile residue in the close proximity of the double bond or the inhibitor is unable to form 
a covalent bond by a Michael-type reaction. 
Figure 1.9 3,4-unsaturated derivatives. 
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            Figure 1.10 Hypothetical Michael-type addition on a putative α-keto-acid in the enzyme active site. 
Similar results have been achieved by Ikeda and coworkers, who studied some 3,4-unsaturated 
derivatives and their competitive nature, determining IC50 values by a neuraminidase 
inhibitory activity assay performed towards human parainfluenza  virus 1 (IC50 = 2.9-94 mM)6, 
7
. On the other hand, these results do not exclude the possibility that, in other sialidases with 
a slightly different active site, a covalent binding could be formed. 
1.3.3 Other inhibitors 
Focusing on viral neuraminidase inhibitor world, other compounds, having a structure derived 
from DANA, have been developed against influenza virus neuraminidases, such as BANA113 
with an aromatic scaffold, Oseltamivir having a cyclohexene scaffold and Peramivir 
containing a five-membered ring scaffold (Figure 1.11)1, 43-45. Unfortunately, extensive use of 
Zanamivir and Oseltamivir led to the development and diffusion of inhibitor-resistant viral 
strains46. 
 
 
In addition, some new generation inhibitors have been recently developed and classified as 
mechanism-based inactivators. An example of this class of compounds are the 2,3-difluoro-
sialic acids derivatives (Figure 1.12), that mimic the structure of the substrate. The presence 
of a fluorine atom at C3, adjacent to the anomeric position, serves (due to its high 
electronegativity) to destabilize the formation of a positive charge at the anomeric carbon. 
Figure 1.11 Other neuraminidase inhibitors mimicking the scaffold of DANA and directed towards influenza A 
or B virus neuraminidases: BANA113, Oseltamivir and Peramivir (and their IC50 values)1. 
1.Introduction 
 
 
17 
 
This situation slows down the rate of glycosylation and de-glycosylation and reduces the 
lifetime of the putative oxocarbenium transition state. On the other hand, the presence of a 
second fluorine atom (as good releasing group) at C2 accelerate the phase of glycosylation 
favoring the accumulation of the covalent intermediate. Thus, these mechanism-based 
inactivators are chemically inert and require specific activation by the catalytic machinery of 
the enzyme27, 47. A lot of molecules based on the 2,3-difluoro backbone have been proposed 
as viral neuraminidases and hemagglutinin-neuraminidase inhibitors3, 29, 48 (Figure 1.12). 
Interestingly, some of the mechanism-based inhibitors have been demonstrated to act, also, as 
irreversible, suicide inhibitors for sialidases49.  
 
 
Finally, to complete this general overview, it is important to cite the high number of natural 
extracts and naturally derived molecules that have been, recently, demonstrated to act as 
neuraminidase inhibitors50, 51. 
  
Figure 1.12 A 2,3-difluorosialic acid derivative tested against paramyxoviruses. 
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1.4 Viral neuraminidases (viral sialidases) 
Viral neuraminidases represent a very interesting and attractive therapeutic target due to their 
involvement, as key enzymes, in the viral lifecycle. Two important groups of viruses will be 
considered in this thesis: 
 Orthomyxoviruses group, which contains human and animal influenza type A viruses 
and human type B and type C ones. 
 Paramyxoviruses group, which comprises Newcastle disease virus, mump and 
parainfluenza type 1-4 viruses52. 
Viral neuraminidases have some typical structural characteristics common to all sialidases 
but, unlike bacterial and mammalian ones, they maintain some peculiar features such as a 
flexible active site presenting, in most cases, large cavities adjacent to C4 and C5 positions. 
In general, they are involved in the phase of viral progeny release but some viruses belonging 
to paramyxoviruses group possess enzymes which maintain both the neuraminidase and the 
hemagglutinin activities (hemagglutinin-neuraminidase, HN)53. These HNs are, also, involved 
in the phase of viral attachment to the target cell. In the next paragraphs, the two above cited 
groups will be deeply described, considering influenza A virus as an example of 
orthomyxoviruses and, on the other hand, Newcastle disease virus (NDV) and human 
parainfluenza viruses (hPIVs) as examples of paramyxoviruses. Finally, particular emphasis 
is given to the description of the double function of NDV and hPIV hemagglutinin-
neuraminidases (NDV-HN and hPIVs-HN, respectively), its biological significance and its 
implication in enzyme inhibitors development. 
1.4.1 Influenza viruses 
1.4.1.1 The virus, some of its key proteins and the neuraminidase active site 
As above anticipated, influenza viruses belong to the orthomyxoviruses group 
(Orthomyxoviridae family), which is classified into three serologically distinct types: A, B 
and C (influenza C virus does not seem to cause significant disease in humans). 
Influenza A virus, the most clinically relevant and widely studied, presents three key protein 
on its envelope (Figure 1.13), essential for its lifecycle:  
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 An M2 ion-channel protein: it is a pH-
activated proton channel that mediates 
acidification of the internal region of viral 
particles entrapped in endosomes. For this 
reason, it results important in endocytosis 
and in virion assembly and budding; 
 The lectin-like hemagglutinin protein (H): it 
is a protein formed by three identical 
subunits and anchored to a viral envelope. 
This glycoprotein seems to play two 
substantial roles: a) ensure an initial point of 
contact for the virus to target the cell-surface 
glycoconjugates and b) to trigger the virus 
internalization process through the fusion of the viral envelope with the host cell 
membrane. To date, there are 18 hemagglutinin protein subtypes, classified by their 
antigenic properties, named from H1 to H1854 (Latest data from: Center for Disease 
control and Prevention U.S. Department of Health & Human Services). 
 Finally, the neuraminidase (N) it is an enzyme formed by four identical disulfide-
linked subunits attached to the viral membrane. Each subunit is constituted by four 
distinct domains: the crystallized and well characterized "head” (or catalytic) domain1, 
55, 56
, a "stem" domain (connecting the head to the transmembrane one), the 
transmembrane domain and, finally, the cytoplasmic one. The significant role of this 
protein is to assist in the movement of virus particles through the upper respiratory 
tract as well as in the release of newly formed virion progeny from infected cells57. 
There are 11 distinct subtypes of neuraminidase proteins, named N1 to N11. In 
according to phylogenetic analysis and structure, the subtypes are divided into three 
distinct groups: group 1 comprises N1, N4, N5, N8, group 2 N2, N3, N6, N7, N9, and 
group 3 includes influenza A-like N10 and N1158 (Latest data from: Center for Disease 
control and Prevention U.S. Department of Health & Human Services).This 
classification, together with the hemagglutinin one, result useful to name the different 
influenza A virus strains (H1N1, H1N3, etc). 
Figure 1.13 Influenza virus with its envelope 
glycoprotein: M2 ion channel, hemagglutinin 
and neuraminidase. (From http://ricochet 
science. com). 
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In general, influenza virus neuraminidase (N) “head” domain is characterized by the typical 
beta-propeller fold structure and the active site presents the common characteristic residues1, 
57
, previously described (paragraph 1.2.1). More specifically, in the catalytic site (Figure 
1.14): 
 C1-C3 portion: constituted by the arginine triad (Arg118, Arg292, and Arg371), the 
Asp151 considered important in the catalytic mechanism and the Tyr406, orienting its 
hydroxyl group very close to the C1-C2 bond of the substrate. 
 C4 portion: presents an interesting peculiarity, in fact it is constituted by cavity with 
two negatively charged amino acids: Glu119, interacting with the C4 substituent and 
Glu227, interacting via a water molecule to NH at C5. Thanks to this basic 
information, some computational docking screenings have been applied to develop a 
large number of inhibitors, supported by the presence of well define crystal structures.1 
 C5 portion: forms a pocket, able to accommodate the sialic acetyl moiety and 
characterized by the presence of Ile222, Trp178 and Arg152 (which makes an 
interaction with the acetyl oxygen).  
 Sidechain portion: characterized by the Arg224 and Glu276, involved in H-bonding 
with the sidechain hydroxyls. 
Figure 1.14 Influenza virus neuraminidase active site represented with Neu5Ac and their interactions. (Adapted 
from Von Itzstein, 2007) 
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1.4.1.2 Zanamivir: an example of the strategy to develop new inhibitors 
Antiviral drugs, like Zanamivir, Oseltamivir and Peramivir (Figure 1.15) have been 
synthesized after the understanding of the neuraminidase mechanism of action. The 
development of Zanamivir, the first sialidase-targeting anti-influenza drug commercialized 
with a Ki in low nanomolar range against influenza virus neuraminidases, is a perfect example 
of strategy involving a modern computational approach. Indeed, Von Itzstein and coworkers 
used computational tools (docking and molecular dynamic simulations) to evaluate the 
insertion of new functionalities on DANA backbone, determining the energetically favored 
interactions between the different substituent groups and the amino acids inside the catalytic 
pocket1, 59, 60. Considering the presence of a negatively charged region at the C4, they decided 
to test the insertion of an amino group at C4 position. This substituent resulted in a better 
inhibition than the normal hydroxyl moiety, due to its capacity to give a salt bridge with 
Glu119. Successively, after deeper analysis they demonstrated that enzyme active site C4 
cavity was large and it could accommodate also bulkier substituents than amino one. 
Consequently, they assumed that the guanidino group, with its double aminic function, could 
well interact with both the two conserved glutamate residues. This hypothesis has been, 
successively, confirmed by experimental data1.  
1.4.1.3 150 cavity, a second sialic acid binding site and new generation inhibitors 
Recent interesting studies, regarding the discovery of new peculiarities of influenza virus 
neuraminidase protein, permitted the rational development of new generation inhibitors. 
Specifically, in the last years a 150-cavity (a region adjacent to C3 position in enzyme active 
site) and a second sialic acid binding site have been discovered. The presence of the 150-
cavity was confirmed only in group 1 neuraminidases. Thus, the development of a new C3 
modified inhibitor (3-(p-tolyl)allyl-Neu5Ac2en, Figure 1.15) has been accomplished in the 
last years34. This molecule, with Ki values in low micromolar range (1.7-25 µM against N1 
strains) and highly selective for group 1 neuraminidase, showed a inhibitory activity towards 
neuraminidases with oseltamivir acquired resistence36, 61. 
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Figure 1.15 Representation of DANA, Zanamivir, Oseltamivir, Peramivir and the recently discovered C-3 
substituted DANA derivative (3-(p-tolyl)allyl-Neu5Ac2en) targeting the 150 cavity (Rudrawar et al., 2010). 
More recently, a couple of new potent and selective influenza virus neuraminidase inhibitors, 
based, for example, on the classical Oseltamivir backbone and active in low nanomolar range, 
have been also developed. Some of them (guanidino and triazole Oseltamivir derivatives, 
Figure 1.16) showed Ki values ranging from 0.46 to 430 nM. A reduced susceptibility to 
Oseltamivir resistance mutations was also observed in the guanidino derivative. Instead, the 
triazole ones seemed to be able to interact, additionally, with residues in the 150-cavity46, 62. 
 
Figure 1.16 Representation of two example of new generation influenza virus neuraminidase inhibitors. A 
guanidino derivative and a triazole one (which is able to target the 150 cavity). 
Finally, the discovery of a second binding site for sialic acid in viral neuraminidases resulted 
crucial. It seems to be composed by residues extremely conserved in avian strains but no in 
human and swine ones63, 64. The role of this Site II seems to be the enhancement of the catalytic 
efficiency64 of neuraminidase activity and for this reason it could be considered an additional 
target for a future new generation drugs development. 
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1.4.2 Newcastle disease virus (NDV) 
1.4.2.1 The virus, its lifecycle and the key proteins 
Newcastle disease (ND) is one of the highly 
pathogenic viral diseases affecting avian species. It 
was first reported in Indonesia (1926) and in the 
Newcastle upon Tyne in England (1927), then it 
diffused in different parts of the world. In particular, 
lately reported outbreaks, confirmed the high 
persistence of this disease65 (Latest data from United 
States Department of Agriculture). This pathology 
could affect most species of domestic birds 
(chickens, turkeys, ducks, geese, pigeons, quails, 
pheasants, guinea fowls and ostriches) and many 
species of both caged and wild fowls (Figure 1.17). 
ND is caused by Newcastle disease virus (NDV, 
called also APMV-1), the most studied among the twelve different serotypes of avian 
paramyxoviruses (APMVs) and belonging to the Paramyxoviridae family under genus 
Avulavirus (Avian Rubulavirus). NDV strains could be classified as lentogenic (low 
virulence), mesogenic (moderate virulence) and velogenic (high virulence). Velogenic ones 
could be viscerotropic or neurotropic and they may result in 100% mortality in poultry66, 67. 
These reasons account for the strong impact of this pathology and the subsequent large 
economic losses on the poultry industry. Nowadays, commercial vaccines are available for 
the prevention of this infection but in some cases, if the vaccination procedure is not 
applicable, an efficient antiviral therapy could be the only useful way to fight and control the 
contagion.  
This virus, as the other Paramyxoviruses, is a pleomorphic enveloped virus around 200–300 
nm of diameter, with a genome composed by a non-segmented, negative sense, single-
stranded RNA (Figure 1.18). The RNA molecule is coated by the nucleocapsid protein NP, 
which has the role to cover and protect the genome by the action of nucleases. Another 
essential viral protein is the large RNA polymerase protein L which synthesizes the viral 
mRNA and assists in genomic RNA replication. It also performs the 5’capping methylation 
and poly A polymerase activity on the newly transcripted mRNAs. Finally, a phosphoprotein 
P functions as a homo-oligomer with a crucial role in viral replication and transcription.  
Figure 1.17 A chicken affected by NDV 
infection: acute respiratory diseases, 
tremors, paralysis, depression and diarrhea 
are the principal symptoms, that could cause 
the 100% of mortality in chickens. In 
humans, NDV could cause only 
conjunctivitis, fever, headache and mild 
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In fact, L and P protein associate together 
and form the viral polymerase complex (L-
P complex). Then, the helical 
nucleoprotein complex, formed by RNA 
coated by NP protein acts as a template 
which is recognized by the L-P complex to 
form an active viral polymerase complex 
permitting the transcription/replication to 
start. 
Then, a hydrophobic peptide located 
between the nucleocapsid and the viral 
envelope called matrix protein M, 
performs different functions: a) it controls 
the viral RNA synthesis; b) it interacts with 
actin; c) it helps in assembling virion on 
the host cell membrane; d) it might be responsible for maintaining the spherical shape of the 
nucleocapsid and e) it helps in the virus budding process by interacting with the host cell 
plasma membrane. The viral envelope, composed by a lipid bilayer, is dressed with the fusion 
protein F which mediates the fusion with the host cell membrane. It is synthesized as an 
inactive precursor F0 which is cleaved by a cellular protease into two subunits, F1 and F2. 
Further, these subunits are processed in the trans Golgi network, inside the mammalian cell, 
forming the disulfide-linked F1–F2 active protein. The active form of the protein causes the 
viral envelope/host cell fusion, permitting the viral particles to penetrate inside the cell. It can 
also lead to cell-cell fusion with the formation of syncitya (multinucleate cells), enhancing 
virus spread66, 67. 
The hemagglutinin-neuraminidase protein HN is a glycoprotein present on viral envelope, as 
a tetramer, and it is involved in different crucial phases of the viral lifecyle66-68. About that, 
the paramyxoviruses lifecycle can be divided into 4 different phases69 (Figure 1.19): 
 Binding. It consists in the attachment of the virus, mediated by the HN protein, to 
sialic acid residues present on the receptors of the target cell. 
 Fusion. The fusion of the viral envelope with the target cell is mediated by the 
active form of the F protein. The entire fusion process is triggered and enhanced 
by HN protein. 
Figure 1.18 Representation of a Paramyxovirus and its 
essential proteins: NP, L, P, M, F and HN (from Moscona, 
2005). 
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 Uncoating and genome replication. After the entrance of the viral genome inside 
the cell, its replication, mediated by L-P complex interacting with helical 
nucleoprotein complex, could be accomplished. 
 Budding and release. The newly synthesized virion particles are ready to leave the 
infected cells. In this step, the sialidase activity of the HN protein is used to 
hydrolyze and release the sialic acid residues bound to host cell glycans, allowing 
the virus to leave the cell. 
 
  
Figure 1.19 Schematic representation of paramyxoviruses lifecycle phases: 1) binding, 2) fusion, 3) uncoating 
and genome replication, 4) budding and release (from Moscona, 2005). 
1.Introduction 
 
 
26 
 
1.4.2.2 NDV-HN  structure, catalytic  site (Site I)  and role of  the second sialic acid  binding  site  
(Site II) 
As above described, a key protein in NDV 
life cycle is the hemagglutinin-
neuraminidase (NDV-HN, figure 1.20) 
and for this reason, it could be a very 
interesting pharmacological target for the 
development of new antiviral strategies.                                                                                                                                                     
Most evidence confirmed that HN is 
present on Paramyxoviridae surface as 
covalently linked dimers, usually disulfide-
linked via Cys12353, 70-73, associated to form 
a tetramer. Anyhow, the absence of this linkage does not interfere with the formation of non-
covalently linked dimers and tetramers, permitting to conclude that this disulfide bond is only 
responsible for the enhancement of the structure stability53, 72. The entire structure is 
composed, as influenza virus neuraminidase, by four different domains: “head” (catalytic) 
domain, a “stalk” domain, a transmembrane domain and a cytoplasmic domain. The complete 
head globular region of this protein has been crystallized by Crennell and coworkers53 in 
various conditions, obtaining dimers in three different crystal forms: 
 An orthorhombic crystal form (resolved at 2.5 Å), obtained at pH 4.6, as ligand-free 
structure (PDB: 1e8t);  
 A hexagonal crystal form (resolved at 2.8 Å), obtained at pH 6.5 by co-crystallization 
with Neu5Ac, observing the final presence of DANA bound in the active site (Figure 
1.22) (PDB: 1e8v); 
 An orthorhombic crystal form (resolved at 2.0 Å) achieved at pH 4.6 by co-
crystallization with 2,3-sialyllactose, affording the -anomer of Neu5Ac linked in the 
active site (Figure 1.23) (PDB: 1e8u). 
By comparing the two orthorhombic crystal forms with the hexagonal one, it was observed 
that the overall structure of the single monomer is very similar, showing the six-bladed -
propeller fold typical of all neuraminidases. All these structures contain HN in its dimeric 
form, but the association of monomers is dramatically different among the two orthorhombic 
structure and the hexagonal one. By studying the hexagonal crystal form, it can be 
extrapolated a clear picture of the catalytic site53 (Figure 1.21, 1.22): 
Figure 1.20 Representation of NDV-HN with DANA 
(pink) co-crystallized in its active site (Adapted from 
Crennell 2000, PDB:1e8v). 
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 C1-C3 portion: there is the typical arginine triad (Arg174, Arg416 and Arg498) which 
well interact with the carboxylic group and Arg174 it is stabilized by Glu547, then a 
Tyr526 orienting its hydroxyl group very close to the C1-C2 bond interacting with 
Glu401. In addition Asp198 (equivalent to Asp 151 of influenza virus) is considered 
important in the catalytic mechanism but, in this case, it is positioned on a flexible and 
disordered loop pointing out from the active site; 
 C4 portion: as demonstrated by some published studies, C4 pocket is a very large 
hydrophobic cavity in which the hydroxyl group of DANA does not give any 
interaction. Some of the amino acids surrounding this cavity are conserved across all 
HNs (Ile192, the methylene side groups of Arg174 and Asp198), while others are not 
conserved (Ile175), maintaining anyway the hydrophobic character of this region. The 
cavity is also lined with some polar and basic side chains (Asn190 and Lys236). This 
peculiar binding pocket seems to be a specific of paramyxoviruses family.53, 74 
 
 
 
 C5 portion: It can accommodate the acetyl moiety, in fact the methyl group gives a 
hydrophobic interaction with Tyr299 while N5 interacts via a water molecule with 
Figure 1.21 NDV-HN active site represented with DANA and their interactions. (Adapted from Crennell, 
2000). 
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Ser237, Tyr317 and Glu401. A peculiarity of this region, in NDV-HN, is that it could, 
theoretically, accommodate also bulky groups than the acetyl one (Figure 1.22). 
 Sidechain portion: The glycerol chain is accommodated in a region with a highly 
conserved sequence in virus strains (Glu258, Tyr317, Tyr262 and Ser418). A 
peculiarity of HNs is that all the three hydroxyl groups seem to be fundamentally 
involved in the interaction within active site53. 
 
 
 
 
 
 
 
 
 
 
 
 
Proceeding by comparing the two orthorhombic crystal forms with the hexagonal one, we 
could find substantial differences, leading to postulate that the NDV-HN active site is very 
flexible and it could exist in two different states: a catalytic (switched on) state and a sialic 
acid binding (switched off) state (Figure 1.23).  
The hexagonal crystal form, previously described, represents the catalytic or “switched on” 
form. On the other hands, the orthorhombic one represents the “switched off” or sialic acid 
binding state, which differs from the first one for an unusual positioning of some key amino 
acids (Figure 1.23)53,64: 
 Arg174 is not in its usual position (forming the arginine triad) but it is swung within 
the large C4 cavity; 
 Lys236 moves out of the cavity to enable accommodation of Arg174, maintaining the 
charge equilibrium. Thus, Lys236 reaches the C5 moiety interacting with the acetyl 
group. 
 Tyr526 moves out from the catalytic position (after Ile175 rotation). 
Figure 1.22 3D representation of NDV-HN active site crystallized with DANA and their interactions (From 
Crennel 2000). 
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These data sustain the double function accomplished by a single enzymatic site having both 
hemagglutinin (binding) and neuraminidase (catalytic) activities53. On the contrary, other 
works, sustained the presence of two sites having the two distinct functions71, 75. In reality, we 
know that the truth lies somewhere in between, in fact, it has been recently demonstrated that, 
while the catalytic site possesses both neuraminidase and hemagglutinin activities53, a second 
binding site (Site II), located at monomers interface, presents only a very strong hemagglutinin 
activity76-80. This second binding site was detected using a disaccharide thiosialoside (Figure 
1.24), that was co-crystallized with NDV-HN (PDB: 1usr, 1usx), revealing DANA in the 
active site and the disaccharide bound to a symmetrical site at the HN dimer interface76. Site 
II presents some peculiar characteristics: 
 Six conserved water molecules; 
 Five hydrogen bonds involving the main chain; 
 Arg516 seems to be important in the hydrogen bond network; 
 The acetamido group is accommodated in a hydrophobic pocket (that seems to be 
conserved in all paramyxoviruses) formed by Gly169, Leu552 and Phe553 of one 
monomer and Phe156, Val517 and Leu561 from the other one. 
Figure 1.23 Representation of NDV-HN active site in its switched on or catalytic state and in its switched off or 
“sialic acid binding” state (Adapted from Crennell, 2000). 
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Figure 1.24 Disaccharidic thiosialoside able to bind Site II. 
Finally, it can be concluded that that NDV-HN binds to sialic acid-containing receptors 
through two separates sites, one at the catalytic pocket (in its “switched off” state) and the 
other site around Arg51680. In addition, it was, recently, proposed that both the binding sites 
(Site I and Site II) play an important role, also, in the membrane fusion process.77 Briefly: 
 The binding and the subsequent cleavage of sialic acid receptors, in the catalytic site, 
cause conformational changes triggering and promoting the fusion by F protein. In 
other words, if a molecule, for example Zanamivir, well interacts with this site, 
mimicking the transition state intermediate, could produce these conformational 
changes. These modifications are reflected, through the dimer interface, to site II 
activating its binding activity and promoting the fusion process. In fact, it has been 
well demonstrated that, after the engagement of site II, the F protein is triggered to 
insert its fusion peptide into the target membrane and, consequently, fusion can ensue 
(Figure 1.25).  This data, also, confirmed the ability of HN to transmit conformational 
changes from the head to the stalk domain of the protein77. 
 In addition, the activation of the second binding site it is important to maintain a close 
proximity of the cell membrane and the viral envelope, during the entire fusion 
process. In fact, a loss of the second binding site, by mutation, cause a less efficient 
fusion promotion activity, leading to a slower viral growth76, 80. 
 
 
 
 
 
 
 Figure 1.25 Schematic representation of fusion activation process triggered by HN protein (From 
Porotto, 2012). 
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1.4.2.3 Studies on NDV-HN Site I and Site II inhibition  
Some NDV-HN inhibition studies demonstrated that the Site I of this enzyme is sensitive to 
the three transition state analogs inhibitors: DANA, Zanamivir and BCX-2798 (Figure 1.26). 
On the other hands, the NDV-HN Site II is not affected by Zanamivir or BCX-2798 and only 
in a limited extent by DANA78-80. Furthermore, the trisaccharide 2,3-sialyllactose (Figure 
1.26) is a proven inhibitor of binding, inhibiting both Site I and Site II activity. More 
specifically, it has been experimentally demonstrated that it is able to directly bind Site I, 
blocking its activity, and to inhibit indirectly Site II. In fact, after the binding to Site I, it is not 
capable to induce the conformational changes necessary to activate the secondary site79. 
 
Figure 1.26 Representation of DANA, FANA, Zanamivir and BCX-2798(left); 2,3-sialyllactose (right). 
Apparently, it seems that the interplay between the two sites is needed for a proper activation 
of the fusion mechanism and it results essential for the development of new generation 
inhibitors. In view of the above, it seems necessary to find molecules which are able to block 
Site I without activating Site II (as 2,3-sialylactose) or molecules which are able to block both 
sites. At the moment, FANA remains the most active inhibitor of NDV-NH, reported in the 
literature, showing an IC50 of 1.9 µM for neuraminidase activity compared to the value of 13 
µM obtained for DANA. Unfortunately, FANA did not affect Site II binding, resulting in no 
detectable inhibition of hemagglutinin acitivity30.  
1.4.3 Human parainfluenza viruses 
1.4.3.1 The virus and its lifecycle 
Human paramyxoviruses (hPIVs), as avian paramyxoviruses (APMVs), are pleomorphic 
enveloped RNA viruses, belonging to the Paramyxoviridae family. They are the cause of 
different respiratory diseases in infants, children, immunocompromised and chronically ill 
people and elderlies. There are four antigenically distinct types of hPIVs: 
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 hPIV-1 is the leading cause of croup (acute laryngotracheobronchitis) in children, a 
respiratory inflammation of the larynx and trachea, associated with infection and 
breathing difficulties. It is responsible for outbreaks of croup in the autumn; 
 hPIV-2 causes croup in children, but doctors detect it much less often than hPIV-1, 
because it is frequently overshadowed by hPIV-1 or hPIV-3 infections; 
 hPIV-3 causes infection generally associated with pneumonia and bronchiolitis, 
involving swelling from inflammation in the smallest airways in lungs. It, regularly, 
causes infections in the spring and early summer, but it appears throughout the year. 
 hPIV-4 (A or B) is rarer than the other one, in fact only a small number of studies have 
reported on the isolation or epidemiology of this viral strain. Unlike the others, there 
are no known seasonal patterns81. 
It is, also, important to underline that the four parainfluenza viruses are divided into two 
different genera: parainfluenza types 1 and 3 belong to the Respirovirus genus, and 
parainfluenza types 2, 4 (A and B) belong to the Rubulavirus genus. In general, hPIVs possess 
a genome composed by a non-segmented, negative sense, single-stranded RNA and they 
present the same viral protein asset and envelope composition previously described for NDV 
(Figure 1.18). They share, also, the same lifecycle organization which is common for all 
paramyxoviruses69, 81 (Figure 1.19). 
1.4.3.2 hPIVs-HN structure and catalytic/active site (Site I) 
Hemagglutinin-neuraminidase of human parainfluenza viruses (hPIVs-HN) is a tetrameric 
glycoprotein with a crucial role in different phases of the viral lifecycle. Each subunit is 
composed, as influenza neuraminidase and NDV-HN, by four different domains: globular 
head (catalytic) domain, a “stalk” domain, a transmembrane domain and a cytoplasmic 
domain. In particular, HN of hPIV-3, which shares 24% of sequence identity with NDV-HN, 
is the only crystallized protein among hPIVs81, 82. Instead, no crystal structures of hPIV-1 or 
hPIV-2, but only a homology model of hPIV-1, constructed on the basis of hPIV-3 structure, 
has been described in literature4. Lawrance and coworkers82, in 2004, obtained the crystal 
structure of hPIV-3 in its dimeric form (PDB: 1v3d) and they defined the main structural 
characteristics. These key features, compared with those of NDV-HN are: 
 The secondary structure generally well conserved, with variations in some of the loop 
lengths and in some other little regions; 
 Five of the seven cysteine residues present in its structure are conserved in NDV-HN; 
 Ca2+ ion, also present in NDV-HN, is located in a specific loop; 
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 One glycosylation site (Asn351) is conserved from hPIV-3-HN to NDV-HN. The 
protein present two additional glycosylation sites (Asn308 and Asn323), different 
from those of NDV-HN; 
 The general conformation of the two monomers is very similar to that of NDV-HN 
monomers; 
 In contrast to NDV-HN, the dimeric associations into the hexagonal and orthorhombic 
crystal structures are very similar. 
While, from a careful analysis of the hPIV-3 HN catalytic site crystallized with DANA, some 
peculiar characteristics can be resumed (Figure 1.27):  
 
Figure 1.27 hPIV-3 HN active site, crystallized with the inhibitor DANA (From Lawrence, 2004). 
 C1-C3 portion: there is the arginine triad (Arg192, Arg424, and Arg502) well 
interacting with the carboxyl group and Tyr530 with its hydroxyl group very close to 
the C1-C2 bond, interacting with Glu409;  
 C4 portion: this pocket is a large hydrophobic pocket and the hydroxyl group at C4 
of DANA do not give any interaction with the active site residues. It is well known 
that this region could accommodate large hydrophobic substituents, as demonstrated 
by a couple of recent studies3, 5. In fact, the presence of a large cavity at C4 (216-
cavity) which is locked by a loop called “216 loop” (from amino acidic residue 210 to 
221), gives some flexibility to the enzyme active site permitting the accommodation 
also of the molecule with bulky groups83. This 216-cavity seems to be a peculiarity of 
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hPIV-3 HN, even if, at the moment, there are no crystal structures of the other hPIVs-
HN. 
 C4/C5 portion: Lys 254 (corresponding to Lys236 of NDV-HN) is hydrogen bonded 
with Asn208 and via a water molecule with Asp1. It could also interact with some C4 
bulky substituents3. 
 C5 portion: the C-5 pocket region could accommodate the acetyl moiety: the methyl 
group gives a hydrophobic interaction with the aromatic ring of Tyr319. This region 
could also accommodate bulkier substituents, such as the isopropyl group of BCX-
2798 (Figure 1.26). 
 Sidechain portion: The glycerol chain interacts with the conserved Glu276. 
Considering the other hPIVs-HN, recent experiments, supported by simulation data on the 
homology model, demonstrated that hPIV-1 HN active site presents some peculiar differences 
if compared to that of hPIV-3 HN, reflecting, also, the different inhibitory effect exploited by 
the tested inhibitors4.  
1.4.3.3 hPIVs-HN second sialic acid binding site (Site II) 
Finally, it is important to report a recently discovered feature regarding both hPIV-1 and hPIV-
3 HN. It seems that they possess some “hidden second sialic acid binding sites” at the dimer 
interface revealed performing some mutagenesis experiments. This is an important discovery, 
because, while it is well known, that NDV-HN contains two distinct receptor binding sites, it 
has never been clarified if other viruses of the genera Respiravirus and Rubulavirus presented 
this peculiarity. In this regard: 
 In hPIV-3 a second sialic acid binding site was not identified through the simple 
analysis of the crystal structure, but it needed some deep investigations. In fact, some 
published data, from biochemical and computational studies proposed a second sialic 
binding site positioned in correspondence of Asn552 at the dimer interface (very close 
to the Site I)84, 85. It resulted sensible, as Site I, to DANA but insensible to Zanamivir 
and it is involved in fusion promotion activity84. The existence of this site was 
sustained by some crystallographic data obtained performing some difluorosialic acid 
analogues experiments86. On the contrary, in some recent works, Alymova and 
coworkers87, 88 belittled the presence of a second binding site close to Asn552, because 
this residue resulted distant from the location of the conserved hydrophobic pocket 
typical of NDV-HN Site II and capable to accommodate acetamido group. They 
alternatively, proposed and demonstrate the presence of a new Site II masked by a 
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glycosylation at position Asn523 which correspond to the same site in NDV-HN and 
it is in close proximity of the previously cited hydrophobic pocket, formed by Leu174, 
Thr186, Val187 and Phe563 (corresponding to Phe156, Thr168, Phe553 and Leu561 
of NDV HN). In addition, Arg173, as Arg516 of NDV HN, seems to be important in 
the interaction with carboxylate group87, 88. The unmasking of this site (mutating the 
corresponding residue) lead to a decreasing in infection multiplicity in cell culture but 
an increase of infectivity in vivo88. Anyhow, further investigations on the effect and 
the nature of these mutations are needed. 
 In hPIV-1 it was, at first, proposed the presence of a putative Site II in correspondence 
of Asn523 of naturally occurring mutants89. Contrarily, mutations in this site seem to 
not affect the fusion promotion activity and the grow kinetics. More recently, 
Alymova87, 90 proposed (as for hPIV-3) the presence of a masked (by a glycosylation) 
second sialic acid binding site at Asn173 (activated after the interaction of substrate or 
substrate analogues at Site I). It has been demonstrated that this site is located in 
correspondence of the analog in NDV-HN: the hydrophobic pocket is composed by 
Leu176, Leu555, Phe563, and Leu521 (which would correspond to Phe156, Phe553, 
Leu561, and Val517 of NDV-HN). In addition, the key residue Arg516 in NDV-HN, 
which interacts with the sialic acid carboxylate group, is conserved in hPIV-1 HN 
(Arg520)87.  
The mutated strain at this glycosilation site (N173S) remain sensitive to BCX-2798 
(Figure 1.28) for neuraminidase activity but they were more than 10,000-fold less 
sensitive to the compound in hemagglutinin inhibition tests if compared to wild-type 
(WT)87 (Table 1.3). 
 
 
 
Table 1.3 HA, NA and growth cell inhibition observed in wt and N173 mutant strains. 
The advent of this theory, indicating that hPIVs could utilize Site II for binding, might change 
the strategy for new HN inhibitors design. In addition, the recently obtained results on NDV-
HN77, about the engagement of site II in fusion promotion activity, seem to be applicable to 
all paramyxoviruses77, 84, 85. In fact, it has been hypothesized that, also in hPIV-HN, the 
conformational changes could be efficiently transmitted from the head to the stalk domain of 
Virus (hPIV-1) HA activity (IC50 µM) NA activity (IC50 µM) Growth in cells (EC50  µM) 
WT 0.11 ± 0.020 0.06 ± 0.03 1.3 ± 0.040 
N173S >1000 0.08 ± 0.03 6.5 ± 0.30 
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the protein. Altogether, these findings supported the biological role and the importance of Site 
II. Nowadays, some naturally evolved mutants, lacking the glycosylation site and 
consequently showing a second binding site, has been isolated. In fact, in a relatively recent 
work88, hPIV-3 mutants exhibiting the loss of the N-linked glycan at Asn523 were found in 
one to three clones (ten clone total) in four human samples, confirming the circulating of 
viruses presenting the unmasked second binding site in nature. So, their clinical relevance 
could be prominent, but it is not yet clarified88.  
1.4.3.4 Studies on hPIVs-HN inhibitors 
BCX-2798 was one of the firstly reported, potent and specific, hPIVs-HN inhibitors. It was 
designed starting from the crystal structure of NDV-HN and it resulted in a very potent 
neuraminidase and hemagglutinin activity inhibitor against all the hPIVs, showing substantial 
differences in IC50 values passing from one strain to another, ranging from 0.020 to 20 µM for 
neuraminidase inhibitory activity (NI) and from 0.10 to 4.8 µM for hemagglutinin inhibitory 
activity (HI)2, 4, 5, 91-93. Successively, in some recent works, a new family of BCX-2798 
derivatives has been synthesized. They were C4 triazole substituted compounds and they have 
been designed considering the previously described 216 cavity in hPIV-3 (Figure 1.28). These 
inhibitors show IC50 values against hPIV-3 of 2.7 µM (NI) and 1.5 µM (HI)3, 5, 83. Finally, a 
very recent study demonstrates the presence of a previously unexplored pocket adjacent to C3 
position of hPIV-3 HN that is occluded after ligand engagement. This discovery could open 
the possibility to develop new classes of C3 substituted inhibitors94. It is not yet known if this 
feature is common to all paramyxoviruses HNs, such as NDV-HN. 
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         Figure 1.28 Representation of BCX-2798 and two examples of its C4 substituted triazole derivatives. 
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1.5 Mammalian sialidases 
Mammalian sialidases are enzymes involved in different crucial biological processes, 
including the regulation of cell proliferation and differentiation, control of cell adhesion and 
migration, metabolism of gangliosides and glycoproteins, immune system cells function, 
receptor remodeling, remyelination processes and tumors. They are encoded by different 
genes and classified, as anticipated in the first part of this introduction, in lysosomal (NEU1), 
cytosolic (NEU2), plasma membrane (NEU3) and mitochondrial/lysosomal/intracellular 
membranes (NEU4) sialidases. All these proteins differ in their subcellular localizations, 
optimal pH, kinetic properties, responses to external stimuli and substrate specificities. Even 
if, there seems to be little overlap in function of the individual sialidases, they share a common 
mechanism of action11. In detail: 
 NEU1 has a lysosomal/endosomal localization with an involvement in cell-surface 
molecules recycling; 
 NEU2 has a cytosolic localization with a still unknown function. It has been 
hypothesized an involvement in muscle cell differentiation and tumoral processes. It 
is the only crystallized human sialidase11, 18 (PDB: 1snt); 
 NEU3 is plasma membrane sialidase that is specific for gangliosides and it is involved 
in cell signaling, apoptosis and cell-cell contacts; 
 NEU4 has a lysosomal, mitochondrial and endoplasmic reticulum localization and it 
is, probably, involved in different physio-pathological processes, such as 
differentiation (neuronal differentiation) and cancer cells metastasis11, 15, 95. 
All the structural information has been collected thank to the crystal structure of NEU2. 
Indeed, structural models of NEU1, NEU3, and NEU4 have been generated by molecular 
replacement based on the atomic coordinates of the NEU2 crystal structure (homology 
modeling)96. 
1.5.1 Human NEU3 (hNEU3) 
Now, human NEU3 sialidase will be considered, since its extracellular localization, it can be 
well compared with viral envelope neuraminidases. This protein shows a high level of 
sequence identity with NEU2 and, together with NEU4 and NEU1, shares the same β-barrel 
structure (Figure 1.29) as demonstrated by homology modeling96. The NEU3 active site (as 
in other NEUs), presents some interesting characteristics: 
 C4 portion: Mammalian sialidases present only a small cavity in correspondence of 
C4 position, formed by invariant residues (Glu43, Arg45, Asp50, Asn88 for NEU3). 
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This pocket is capable to accommodate only a low range of small substituents 
(hydroxyl group of DANA or guanidino group of Zanamivir)34, 53, 96.  
 Sidechain portion: A very large pocket is present in correspondence of the sidechain 
(formed by the conserved residues Val222, Val224, Pro247, and His277 for NEU3), 
so large substituent attached at C7/C9 of DANA backbone could be efficiently 
accommodated34, 97. 
Concerning its biological function, it is important to underline that this enzyme is able to 
modify the ganglioside pattern, not only of the cells where it is located, but also of adjacent 
cells, suggesting a possible involvement in cell-to-cell interactions. Another noteworthy 
characteristic of this specific plasma membrane enzyme, is the connection to viral contagion: 
in fact, during virus (for example NDV) infection sialic acid-containing molecules act as 
receptors, so it may be reasoned that an extensive modification of the cell-surface ganglioside 
pattern, induced by the overexpression of NEU3, may interfere with the virus-host 
interaction11. 
 
 
 
 
 
 
 
 
 
Figure 1.29 3D structure of hNEU3 obtained from homology modeling (starting from NEU2 structure) 
(Magesh et al., 2006). 
1.5.2 Specific hNEU3 inhibitors 
In the last years, selective inhibitors for NEU3 have been identified in a library of DANA 
analogues where oxime- and amino-linked aromatic groups replaced the glycerol side chain. 
One inhibitor resulted in a high inhibitory activity and selectivity against hNEU3, showing an 
IC50 value in micromolar range34, 98. Successively, considering that the one of the most active 
viral inhibitors against hNEU3 is Zanamivir (IC50 = 4.00 µM)34, 41, 97 and the importance of 
the large C9 cavity, two new potent and selective hNEU3 inhibitors have been, very recently, 
proposed (Figure 1.30). They showed an IC50 value of 0.58 µM and 0.61 µM, respectively34. 
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Figure 1.30 Two C9 substituted Zanamivir derivatives, resulted in potent and selective hNEU3 inhibitors.
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My PhD work, detailed in the next chapters, is a part of a great, stimulating and ambitious 
project directed to the development of new and selective Neu5Ac derivatives as inhibitors of 
sialidases (neuraminidases) and haemagglutinin-neuraminidases of bacteria, viruses, and 
mammalians. This hard-working aim can be achieved through a multidisciplinary approach 
which combines the use of a) chemical synthetic procedures b) computational docking studies 
and c) biochemical activity assays. More in detail, I focused my three years PhD work on the 
study and development of specific and selective inhibitors directed versus a specific 
sialidase, the hemagglutinin-neuraminidase of NDV (NDV-HN), not only to obtain more 
potent antiviral molecules against this specific virus but, also, to collect important information 
about its highly flexible active site. 
At this purpose some specific objectives have been defined:  
1. Synthesize and fully physico-chemical characterize some new inhibitors belonging to 
the two classes of the 2,3-unsaturated and 3,4-unsaturated Neu5Ac derivatives, using 
also the support of rational design; 
2. Set-up a smart biological screening of the synthesized inhibitors based on IC50 values 
calculations, in order to select the most potent compounds; 
3. Extend the biological evaluation of the most active molecules; 
4. Perform some computational docking simulations to investigate ligand-
enzyme interactions. 
To achieve these ambitious goals, I have also planned to collaborate with other national and 
international research groups, such as the molecular modeling group of Prof. L. Olsen at the 
University of Copenhagen and the Istituto Zooprofilattico Sperimentale delle Venezie direct 
by Dr C. Terregino. 
Overall, the collected data could, finally, help to clarify the role of HN inhibitors in 
modulating the three main HN functions: a) neuraminidase b) hemagglutinin and c) fusion 
promotion activities. Furthermore, considering the high similarity of some key amino acids 
involved in the catalytic process within paramyxoviruses (see Introduction section), the 
acquired information on NDV-HN could also be useful to better understand the role of 
hemagglutinin-neuraminidase of human parainfluenza viruses.
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In this chapter, the results obtained during my 3 years PhD project, finalized to improve the 
knowledge on sialidase/inhibitor interactions and to develop new and potent inhibitors against 
NDV-HN, will be presented and discussed. Main attention will be focused on two different 
classes of compounds: some 2,3-unsaturated DANA analogues and the 3,4-unsaturated 
derivatives of Neu5Ac. For clarity, the collected data, including synthetic protocols, biological 
evaluations and computational studies will be divided in three different sections: 
 In the first section, an interesting study on the influence of the C5 substituents on the 
inhibitory activity of the 2,3-unsaturated DANA (Figure 3.1) analogues, as potent and 
reversible NDV-HN inhibitors, will be described. This goal has been accomplished by 
a chemical synthesis approach and an in-depth biological investigation, also supported 
by docking simulation studies, in collaboration with the molecular modeling group of 
Prof. L. Olsen of the University of Copenhagen. 
 In the second section, new C4 and C5 modified 2,3-unsaturated derivatives will be 
discussed. After the description of preliminary computational screening results, 
necessary to select the best molecules to be synthesized, the relationship between 
C4/C5 modifications and biological inhibitory activity will be elucidated.  
 In the last section, the attention will be concentrated on the 3,4-unsaturated molecules 
(Figure 3.1), as both potential irreversible inhibitors of NDV-HN and/or useful 
intermediates for the synthesis of new 2,3 modified derivatives. Starting from the few 
literature data regarding their synthesis and biological activity6, 7, 42, it has been decided 
to set up more efficient synthetic procedures to achieve these molecules. In addition, 
some important aspects concerning the attribution of the anomeric configuration of 
these compounds, their stability in protic solvents and the unexpected formation of an 
interesting synthetic intermediate, will be clarified. Finally, the biological inhibitory 
activity against NDV-HN and their selectivity will be illustrated. 
 
Figure 3.1 Structures of DANA and 3,4-unsaturated derivatives. 
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3.1 The 2,3-unsaturated derivatives: C5 substitutions 
The 2,3-unsaturated derivatives of Neu5Ac (based on DANA backbone), as anticipated in the 
introduction, are deeply studied sialidase inhibitors1-4, 34. In particular, I focused my attention 
on the investigation of the inhibitory activity, on NDV-HN, of some C5 modified Neu5Ac 
glycals, having both a normal 4α or epimeric 4β configuration. The choice to study these 
modifications was based on an in-depth literature analysis, in fact, it was noteworthy, before 
my PhD thesis work, that the most active inhibitor towards NDV-HN was FANA (Figure 3.2), 
with an IC50 value of 1.9 µM30. In addition, previously published studies2 demonstrated that 
an isopropylic chain at the C5 amido group could well fit inside the corresponding cavity in 
enzyme active site of NDV-HN and other paramyxoviruses (hPIVs-HN). In fact, the 
compound BCX-2798 (Figure 1.26), bringing this group at C5, showed a well assessed high 
inhibitory activity towards all hPIVs-HN (0.002-20 µM)2, 92. So, in order to define the more 
suitable C5 modification, considering the fluorofilic properties of C5 cavity (as showed for 
FANA), I decided to use fluorinate alkylic chains as substituents. Moreover, fluorine atoms 
insertion during inhibitor development both mimic the C-H linkage and give unique properties 
to these molecules99-101: they increase the inhibitor stability and bioavailability and they give 
a sort of “polar-hydrophobicity”, permitting the stabilization of hydrophobic forces but also 
the formation of Van der Waals (VdW) and other weak interactions. 
The synthetic protocols used to obtain these C5 perfluorinate inhibitors and their biological 
screening, will be reported below. Then, the evaluation of the C5 cavity fluorophilic properties 
achieved by the support of some docking studies, will be illustrated. Finally, some in-depth 
biological evaluations on selectivity of these inhibitors towards sialidases will be described, 
together with a cytotoxicity evaluation of the most active (and selective) one. 
3.1.1 Chemical synthetic approach 
At first, I set up two chemical protocols to achieve all the selected C5 substituted derivatives 
of DANA 1a, compounds 1b,c, 2a-e, 3a and 4a-c). These two different synthetic protocols 
allowed to achieve, respectively:  
 Protocol A. 4α and 4β perfluorinated derivatives (2a-c and 4a-c, respectively) were 
achieved using a protocol involving a N-transacylation reaction, a procedure recently, 
published by our laboratory102-104. This reaction permits the achievement of N-
perfluorinated derivatives with a one-pot rapid and chemoselective way (Scheme 3.1). 
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 Protocol B. Longer 4α perfluorinated derivatives (2d,e) and 4α unfluorinated 
molecules (1b,c) were achieved by a normal acylation of the deprotected amine, 
obtained from a laborious pathway4 (Scheme 3.2). 
 
Figure 3.2 C5 substituted 4α and 4β derivatives synthesized in my thesis work. 
3.1.1.1 Synthesis of the C5 modified 2,3-unsaturated derivatives 
In order to synthesize all the inhibitors above cited, I started from a common precursor the 
glycal 5105, already described in the literature. The synthesis of 4α compounds 1a and 2a-c 
was achieved as reported in scheme 3.1. DANA 1a was obtained after a rapid two-step 
hydrolysis procedure directly accomplished on intermediate 5105, using Zemplén reaction 
followed by saponification with K2CO3 in MeOH/H20 (10:1, v/v)106-108. Perfluorinated 
compounds 2a-c were achieved by basic N-transacylation performed on precursor 5105, using 
the appropriate perfluorinated anhydride and Et3N in CH3CN, through the intermediates 6a-c 
and successive two-step hydrolytic procedure. The hydrolysis of 6b,c was identical to that 
above described, instead that used to achieve 6a needed Et3N in MeOH and H20 mixture109, 
for the presence of a labile trifluoroacetyl amido group (Schema 3.1).  
On the other hand, the synthesis of the corresponding 4β epimers 3a and 4a-c was achieved 
via intermediate 7110 formation achieved from 5105 through three synthetic steps: a) oxazoline 
formation, b) ring opening and c) re-acetylation of the 4β hydroxyls109-111. The compound 3a, 
with a normal N-acyl group was obtained after two-step hydrolytic procedure applied directly 
on compound 7110, while inhibitors 4a-c were yielded after N-transacylation of intermediate 
7110, followed by selective hydrolysis (Scheme 3.1). All the final compounds were obtained 
in good total yields (71-87%) after final hydrolysis. They were purified by preparative HPLC 
and fully characterized using 1D and 2D NMR analysis and MS-spectrometry for the correct 
structures attribution. The presence of the perfluorinated group in the molecule was confirmed 
by the well defined coupling constant values between the amidic carbonyl carbon (~159 ppm) 
and the α-carbon fluorine atoms (37 Hz for 2a and 4a and 26 Hz for 2b,c and 4b,c). 
The two perfluorinated 4α compounds 2d,e were, otherwise, synthesized starting from the 
known intermediate 94 obtained,  according to literature4, from the common glycal precursor 
5105 after few steps (Scheme 3.2). Then, after acylation of 94 with the opportune perfluoroacyl 
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chlorides in Et3N using CH2Cl2 and successive deprotection, compounds 2d,e were achieved. 
Finally, following the same protocol (using unfluorinated acyl chlorides), I accomplished the 
synthesis of the 4α unfluorinated analogues 1b,c to compare the inhibitory activity of these 
compounds to the corresponding fluorinated analogues (2b,c). These studies should give me 
additional information on the role of fluorine in inhibitor-active site interactions.  
 
 
Scheme 3.1 Synthesis of compounds 1a, 2a-c, 3a and 4a-c. Reaction conditions: i) NaOMe, MeOH, 23°C, 1h, 
80%; ii) for 5, 6b,c and for 7, 8b,c: K2CO3, MeOH/H20 (10:1, v/v), 23°C, 12h, 71-75% and for 6a and 8a: 
Et3N, MeOH/H20, 23°C, 12h, 87%; iii) perfluorinated anhydride, Et3N, CH3CN, 0°C to 135°C, 5-15 min, 78-
82%; iv) BF3Et2O, CH2Cl2, 80°C, 15 min; v) Ac2O, Et3N in H20 23°C, 12h, 92%. 
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Scheme 3.2 Synthesis of compounds 2d,e and 1b,c. Reaction conditions: i) see Ref. [4]; ii) perfluorinated acyl 
chloride or normal acyl chlorides: Et3N, CH2Cl2, 0°C to 23°C, 3-5 h, 75-78%; iii) NaOMe, MeOH, 23°C, 1h, 
80%; iv) K2CO3, MeOH/H20 (10:1, v/v), 23°C, 6-24h, 71-72%. 
3.1.2 Neuraminidase inhibition assay 
After the synthesis and the full physco-chemical characterization of all the obtained molecules 
1a-c, 2a-e, 3a and 4a-c, in order to investigate their inhibitory potency towards HNs, I decided 
to perform a fluorimetric neuraminidase inhibition assay (NI) on NDV-HN. 
3.1.2.1 Neuraminidase inhibition assay (NI) on NDV-HN 
The NI assay was performed on all the free final compounds 1a-c, 2a-e, 3a and 4a-c, using in 
toto purified active NDV and 4-methylumbelliferyl α-D-N-acetylneuraminic acid (4-MU-
Neu5Ac) as fluorescent substrate112. The obtained results were expressed as IC50 values, 
corresponding to the concentration causing the 50% inhibition of neuraminidase activity, and 
calculated plotting the percentage of inhibition against the concentration of each compound. 
The final values were reported in Table 3.1.  
At first, I confirmed the DANA 1a and FANA 2a IC50 values (14.6 µM and 2.42 µM, 
respectively), which are in agreement with the literature data (13 µM and 1.9 µM, 
respectively)30. Then, I performed the same assay on NDV-HN for all the synthesized 
compounds (Table 3.1). Analyzing, in detail, the results, I found that perfluorinated 
compounds belonging to 4α (2a-c) and 4β series (4a-c) showed a very interesting and peculiar 
trend concerning their inhibitory potency and it is strictly related to the chain length. In fact, 
moving from trifluoroacetamido (2a and 4a) to the corresponding pentafluropropionamido 
derivatives (2b and 4b) the inhibitory potency decreases, passing from IC50 values of 2.42 µM 
and 4.16 µM (for 2a and 4a, respectively) to five times higher ones: 11.6 µM and 20.8 µM 
(for 2b and 4b, respectively). Interestingly, the NI activity was, successively, restored passing 
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from pentafluoroproprionamido (2b and 4b) to heptafluorobutyrramido derivatives (2c and 
4c) reaching an inhibitory potency of 3.73 µM and 6.38 µM, respectively, not statistically 
different to that of their trifluoroacetyl homologues, FANA 2a and its 4β epimer 4a.  
 
 
 
 
 
 
 
 
 
Table 3.1 NI IC50 values of perfluorinated 4α and 4β inhibitors and the 4α unfluorinated ones on NDV-HN. 
aEach value represents the mean of three independent experiments carried out in triplicate. 
In contrast, this C5 length dependent trend was not observed in the 4α unfluorinated 
compounds (1a-c), which showed a progressive decrease in inhibitory activity passing from 
DANA 1a (14.6 µM) to the propionyl derivative 1b (25.7 µM) and from 1b to its butirryl 
homologue 1c (46.2 µM).  
Taken together these results confirmed that the C5 cavity is large and could accommodate 
bulkier groups than acetyl or trifluoroacetyl ones, but the only presence of a hydrophobic 
chain is not sufficient to maintain a high inhibition level. In fact, the formation of additional 
Compound IC50 (µM)a 
FANA 2a 2.42 ± 0.29 
2b 11.6 ± 1.4 
2c 3.73 ± 0.11 
2d 43.0 ± 3.4 
2e 151 ± 20 
Compound IC50 (µM)a 
4a 4.16 ± 0.48 
4b 20.8 ± 2.9 
4c 6.38 ± 0.87 
Compound IC50 (µM)a 
DANA 1a 14.6 ± 1.2 
1b 25.7 ± 4.8 
1c 46.2 ± 3.0 
3a 12.2 ± 1.6 
3. Results and Discussion 
 
 
49 
 
interactions, ensured by fluorine atoms, is required. These hypotheses were supported and 
confirmed by some rigid docking studies (see paragraph 3.1.3).  
Another important observation regards the similar grade of inhibitory activity showed by 4α 
and 4β series if compared together (Table 3.1). These results demonstrated that, considering 
the well documented large dimensions of the C4 cavity in NDV-HN5, 53, an inversion of 
hydroxyl geometry cause, only, a limited reduction in inhibitory potency, except for β epimer 
3a (12.2 µM) which maintain an IC50 value not statistically different to that of its α analogue 
DANA 1a (14.6 µM). In light of this, I could speculate that this slight reduction observed 
passing from 4α to 4β fluorurated derivatives may be attributed to the C4 hydroxyl group 
involvement in some steric interactions, that could favor a better positioning of perfluorinated 
chains (of 4α derivatives) inside the C5 cavity.  
Finally, focusing on the results obtained with longer perfluorinated chains derivatives 2d and 
2e, as depicted in Table 3.1, the molecules showed a dramatic chain length-dependent 
decrease of inhibitory potency (43 µM and 151 µM, respectively). This suggested the 
difficulty of the active site to accommodate C5 substituents longer than heptafluorobutyryl 
amido one. 
3.1.3 Docking simulation studies and further biological evaluations 
Some rigid docking studies have been performed on compounds 1a and 2a-c using NDV-HN 
crystal structure (PDB: 1e8v), to better elucidate and explain the interesting trend above 
observed in fluorinated compounds. In fact, rigid docking permits to obtain, rapidly, some 
suggestions about the ligand/active site interactions maintaining a certain rigidity in active site 
amino acids113. I decided to use this technique because it could give me some useful 
information about the possible accommodation of the perfluorinated chain in C5 cavity and it 
could suggest the possible target amino acids. In addition, I decided to accomplish some 
further biological investigations on compounds 2a-c, exploring their selectivity. Finally, on 
the most potent and selective compound, I performed a cytotoxicity test. 
3.1.3.1 Rigid docking simulations on C5 substituted derivatives 
4α erfluorinated compounds 2a-c, were subjected to rigid docking simulations and the 
obtained results were compared with that of DANA 1a. I started the computational studies 
performing a validation of the method quality. At this purpose, DANA 1a was docked in 
NDV-HN active site (PDB: 1e8v) and the experimental binding mode could be reproduced 
(RMSD of 0.5 Å). In addition, the overall binding mode and the interactions resulted the same 
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as these previously reported in the literature for this compound53. Then, after the docking of 
FANA 2a, the most stable pose was compared to that of DANA 1a (Figure 3.3), observing 
that: 
 The general binding mode is identical for both compounds, with exception for an 
additional interaction showed in FANA 2a docking pose. In fact, trifluoroacetyl group 
seems to be able to interact with the hydroxyl group of Tyr299, giving some VdW 
interactions. The presence of these supplementary bond could explain the higher 
activity of FANA if compared to DANA.  
 Both 1a and 2a showed the presence of a putative hydrogen bond between hydroxyl 
function at C4 and the carbonyl group of the amide at C5. The presence of this 
interaction could be essential for the correct C5 trifluoroacetyl orientation in the C5 
cavity.  
 DANA 1a showed a hydrogen bond between the second hydroxyl of the sidechain (at 
C-8) and Glu401, on the other hands in FANA 2a the same hydroxyl seems to lose 
this interaction, binding to the pyranosidic ring oxygen. 
Moreover, I docked the two perfluorinated 4α derivatives 2b,c, comparing their poses to that 
of FANA 2a. It results clear that a modification in the entire inhibitor orientation occurred 
(Figure 3.3 and 3.4). I observed: 
 For compounds 2b,c, the breaking of the intramolecular hydrogen bond between 
oxygen at C4 and the carbonyl group at C5 present in FANA 2a, probably to allow the 
correct accommodation of the longer fluorinated chains in the large cavity. 
 In FANA 2a the first hydroxyl group of the sidechain (at C-7) interacts with Glu258 
and the second one (at C-8) with the pyranosidic oxygen. Instead, in both compounds 
2b and 2c the hydroxyl at C7 interacts with Glu401 and that at C8 seems to bind to 
Glu258, instead of the pyranosidic oxygen. 
 The Van der Waals interaction with Tyr299, observed for FANA 2a (and essential to 
maintain its high activity), seems to be loss in both 2b and 2c. This event may be 
responsible of a reduction in inhibitory activity. 
 Interestingly, 2c showed an additional interaction performed by the terminal fluorine 
atoms of the C5 chain with Lys236. In fact, it seems to be able to reach the adjacent 
large C4 binding pocket, where this amino acid is located. This issue could explain the 
inhibitory activity improvement showed by compound 2c if compared to derivative 
2b. 
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Taken together, these computational results tentatively explain the peculiar IC50 trend 
previously observed. In addition, these studies could clarify the improvement in inhibitory 
potency showed by perfluorinated groups when compared to alkylic chains, due to the 
formation of new key interactions. Finally, it should be stressed that compound 2c, with its 
C5 heptafluorobutyrryl chain, is able to reach and interact with the key amino acid Lys236, 
which is located in the adjacent large C4 cavity. This issue indicates a possible involvement 
of this inhibitor in active site conformational changes, previously detailed in the 
“Introduction” chapter. 
 
 
Figure 3.3 Docking poses of compound 1a, DANA and 2a, FANA. The compounds are colored in: magenta 
(1a) and yellow (2a). The interactions between the inhibitors and the enzyme are showed as yellow dashed 
lines, and the distances are measured in Å. Amino acid numeration is kept as in the PDB crystal (1e8v) 
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Figure 3.4 Docking poses of compound 2b and 2c. The inhibitors are colored in: light grey (2b) and ciano 
(2c). The interactions between the inhibitors and the enzyme are showed as yellow dashed lines, and the 
distances are measured in Å. Amino acid numeration is kept as in the PDB crystal (1e8v). 
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3.1.3.2 Neuraminidase inhibition assay on hNEU3: Preliminary studies on selectivity 
I decided to evaluate whether the selected inhibitors 1a and 2a-c would affect the human 
sialidase activity. This is a fundamental issue, in fact the low selectivity of viral inhibitors 
(DANA, for example) is a great problem due to their ability to interact also with human 
sialidases, leading to unpredictable side-effects. I focused my attention specifically on the 
human sialidase NEU3 (hNEU3), firstly, because it could be easily reached by the hydrophilic 
inhibitors as it is exposed on the outer leaflet on the cell membrane. Secondly, becouse 
modifications of the ganglioside pattern, mediated by NEU3, may interfere with the virus-
host interaction11. At this purpose, I performed, in collaboration with the biological unit of our 
research group, a preliminary test to evaluate neuraminidase activity on hNEU3. The 
fluorimetric assay provided the use of 4-MU-Neu5Ac as substrate and a protein extract from 
human embryonic kidney cells 293 (Hek293) overexpressing NEU3. Despite it is well known 
that the results obtained with this substrate could be different from that achieved using the 
natural glycolipidic one, I choose 4-MU-Neu5Ac because it allows to compare selectivity on 
different sialidases. 
 
 
 
 
 
Table 3.2 IC50 values of DANA and the perfluorinated compounds obtained in hNEU3 inhibition assay. 
 
aEach value represents the mean of three different experiments carried out in triplicate. 
As shown, DANA has a micromolar activity around 4.00 µM (Table 3.2) similar to literature 
data on purified NEU3 (around 7.00 µM)34, 98. FANA has been tested on hNEU3, for the first 
time, showing inhibitory potency (3.8 µM) not statistically different from that of DANA. 
Thus, I can conclude that both DANA 1a and FANA 2a have a low selectivity towards hNEU3 
and viral HNs. Compound 2b and 2c showed no inhibitory activity towards hNEU3, indicating 
that, the reduced dimension of C5 cavity of human sialidases, permits only the 
accommodation of small substituents. Taken together, these results permit to select compound 
2c as a good candidate inhibitor, due to the inhibitory potency (not statistically different to 
that of FANA on NDV-HN), and for its high selectivity. 
 
Compound IC50 (µM) a 
DANA 1a  3.90 ± 0.90 
FANA 2a 3.80 ± 0.70 
2b >1000 
2c >1000 
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3.1.3.3 Cytotoxicity test on compound 2c 
I decided to perform, on the most promising inhibitor found inhibitor 2c, an MTT assay using 
COS7 cells and, in order to investigate the role of fluorine atoms on cytotoxicity, I compared 
the results with those of DANA 1a. I tested both DANA 1a and inhibitor 2c at two different 
concentrations (3.73 and 10 µM). As it shown in Figure 3.5, DANA give only a little but not 
significative cytotoxicity. On the other hand, cells treated with the inhibitor 2c showed no 
citotoxicity at 3.73 µM (the IC50 of 2c against NDV-HN) and 10 µM. These results confirmed 
the absence of cell toxicity in presence of the selective perfluorinated inhibitor 2c, which could 
be considered a promising potent HN candidate inhibitor. 
 
Figure 3.5 Representation of MTT assay results (each value represents the mean of three different experiments 
carried out in triplicate). 
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3.2 The 2,3-unsaturated derivatives: C4/C5 combined substitutions 
In the previous section, I focused my attention on the contribution of the C5 perfluorinated 
substituents on the inhibitory potency of selective HN inhibitors. I observed that the addition, 
at the C5 position, of these perfluorinated chains it is important to increase the interactions 
with some amino acids present in the active site. Then, in order to find new more potent 
inhibitors, I thought to simultaneously functionalize also the C4 position, keeping in mind that 
the corresponding C4 cavity in paramyxoviruses is a very large and prevalently hydrophobic 
pocket.53 I selected this position considering that some literature works reported the high 
inhibitory activity of C4 substituted DANA derivatives against hPIVs-HN and they described 
some key ligand/active interactions3-5, 29, 114, 115. However, only one work performed 
crystallographic studies on NDV-HN using C4 modified DANA analogues74 and no C4 
substituted inhibitors have been tested on this virus.  
To find suitable C4 substituents, I set up, in collaboration with a research group of University 
of Copenhagen, a computational study to screen some different C4 modified derivatives, in 
order to discover C4 moieties that could well fit inside the corresponding pocket. Then, I 
synthesized and fully characterized some of the molecules selected by the docking study. 
Finally, I performed some biological assays to test their neuraminidase and hemagglutinin 
inhibitory activity towards NDV-HN and I evaluated also their selectivity towards human 
sialidases. 
3.2.1 Docking simulation studies 
In the setting-up of a rational design, docking simulation studies could represent a potent tool 
to screen a variable number of molecules to find substituents that could well fit inside enzyme 
active site pocket. In this type of studies, the availability of crystal structure of the protein with 
ligands resulted important. Thus, docking software are able to quickly predict the orientation 
of the ligand inside enzyme active site in order to quantify the binding, using shape and 
interactions (Van der Waals, electrostatic and hydrogen bonds). The sum of all these 
interactions is approximated by a docking score (GScore value), which represents potentiality 
of binding116. In light of this, I choose this smart tool to operate an initial screening on a large 
number of C4 substituted DANA derivatives. 
3.2.1.1 Rigid and Induced-Fit docking simulations 
The first purpose was to find the best C4 substituents which would better fit inside the 
corresponding binding pocket of the catalytic site, in terms of both dimension (bulky) and 
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polarity (hydrophobic). So, starting from this evidence, I performed a preliminary 
computational screening using NDV-HN structure crystallized with DANA (PDB:1e8v) in 
order to dock different C4 substituted compounds into its active site. This study revealed that 
compound 12a (Figure 3.6) well satisfy all the requirements. More precisely, compound 12a 
showed a GScore value (-10.97 of kcal mol-1) higher than DANA 1a one (-9.33 kcal mol-1), 
confirming, an increased free energy of binding and, thus, a better accommodation in enzyme 
active site of p-toluensulfonyl amido compound 12a, with the formation of some new 
interactions in C4 pocket (Figure 3.6). 
 
 
Figure 3.6 Rigid docking interaction map of ligand 12a. See the above legend for a complete description of all 
the elements presented in the scheme. 
After this preliminary analysis, to obtain a more reliable simulation of the possible interactions 
involved, I set up more detailed docking experiments on compound 12a. At this purpose, I 
decided to perform an Induced Fit Docking (IFD) simulation, that, permits the bond flexibility 
of both the ligand and the amino acids around the active site. In my case this type of analysis 
allows me to better evaluate the effect of amino acids movement after the insertion of a large 
substituent at the C4 position. The simulation was performed as described in Material and 
Method (see paragraph 5.3.3) and the results confirmed those previously described by rigid 
docking. In fact compound 12a showed a Gscore value of -11.03 of kcal mol-1 higher than that 
12a 
3. Results and Discussion 
 
 
57 
 
of DANA 1a, -10.28 kcal mol-1. Then, I decided to perform a qualitative analysis of the IFD 
best scored poses (Figure 3.7, 3.8 and 3.9). Thus, the superimposition of DANA to its 
crystallographic pose, suggested that all the interaction with the active site were maintained, 
with a RMSD of 0.40 Å. Then, comparing IFD poses of both 12a and DANA 1a it seemed 
that, beyond the classical interaction common in both compounds, some additional ones, 
involving the C-4 group (Figure 3.8 and 3.9), were established: 
 The sulfonyl oxygen of the p-toluensolfonyl amido group at C4 could give a 
hydrogen bond with Lys236; 
 The aromatic ring, perfectly positioned inside the C4 cavity, formed a -cation 
interaction with Lys236 and Arg174, which are probably responsible of the 
stabilization of this hindering group inside the enzymatic pocket.  
These preliminary results led me to postulate that compound 12a could retain a high inhibitory 
activity on NDV-HN. 
 
Figure 3.7 Induced Fit Docking best poses for DANA 1a (purple) and compound 12a (cyano). The colours of 
protein surface reproduce the amino acid electrostatic properties: positively charged amino acids (blue); 
negatively charged amino acids (red); neutral residues (grey). 
 
Compound 12a DANA 1a 
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Figure 3.8 Induced Fit Docking interaction map of DANA 1a (up) and compound 12a (down). See the above 
legend for a complete description of all the elements presented in this scheme. 
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Figure 3.9 Two different views of the Induced Fit Docking pose of compound 12a. The inhibitor is colored in 
cyano. The interactions between the inhibitors and the enzyme are showed as yellow dashed lines, and the 
distances are measured in Å. Amino acid numeration is kept as in the PDB crystal (1e8v). 
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3.2.2 Chemical synthetic approach 
Prompted by the promising docking results, I proceed with the setting up of a synthetic 
protocol directed to the p-toluensolfonamido derivative 12a achievement. Noteworthy, to 
obtain the final molecule the synthesis via an azido intermediate (Scheme 3.3) resulted 
necessary. In addition, azido derivative of DANA, BCX-2798 have been reported to possess 
a high inhibitory activity against hPIVs-HN2, probably ensured by new interactions given by 
the negative charge present at the terminal portion of azido group. Thus, I decided to obtain, 
also, the free azido derivative 13a, in order to investigate the inhibitory activity of both these 
compounds. Successively, I planned a synthetic pathway to achieve C4/C5 modified 
derivatives combining the just selected modifications with the previously tested C5 
perfluorinated chains. At this purpose, for the first time, the direct N-transacylation reaction 
was successfully applied on a molecule containing a very instable azido group, achieving the 
desired compounds (12b-d and 13b-d, Figure 3.10) in good yields. 
O CO2H
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HN
HO
H
OH
OH
O
O CO2H
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O
12a R = NHSO2C6H4Me
13a R = N3
12b R1= NHSO2C6H4Me; R2= CF3
12c R1 = NHSO2C6H4Me; R2 = C2F5
12d R1 = NHSO2C6H4Me; R2 = C3F7
13b R1 = N3R2 = CF3
13c R1= N3R2 = C2F5
13d R1= N3 R2= C3F7
 
Figure 3.10 p-Toluensolfonamido and azido derivatives differently substituted at C5 and synthesized in this 
thesis. 
3.2.2.1 Synthesis of all C4/C5 substituted derivatives 
Starting from oxazoline 14110 (Scheme 3.3), the protected azido intermediate 154 was 
obtained, using trimethylsilyl azide (TMS-N3) in t-BuOH, according to literature4, 37, 117. Then, 
the protected azido derivative was subjected to catalytic reduction using Lindlar catalyst in 
EtOH under H2 atmosphere. In this way, compound 17117 was obtained after acylation of the 
free amino intermediate 164 with p-toluensulfonylchloride. Finally, compound 154 and 17117 
were subjected to deacetylation with NaOCH3 in methanol, followed by basic hydrolysis with 
K2CO3 in MeOH/H20 (10:1, v/v), to give the free acid derivatives 13a and 12a, respectively 
(Scheme 3.3). These compounds were tested for their ability to inhibit NDV-HN 
neuraminidase activity and resulted very potent nanomolar NDV-HN inhibitors (See 
paragraph 3.2.3.1).  
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Scheme 3.3 Synthesis of compounds 12a and 13a. Reaction conditions: i) See. [Ref. 4] ii) NaOMe, MeOH, 
23°C, 1h, 80%; ii) K2CO3, MeOH/H20 (10:1, v/v), 23°C, 12h, 72-77%; iv) H2, Lindlar catalyst, EtOH, 23°C, 
overnight, 70%; v) p-toluensulfonyl chloride, Et3N, CH2Cl2, 0°C to 23°C, 4h. 
Successively, I set up a protocol (Figure 3.4) to obtain the p-toluensolfonamido and azido 
derivatives with the perfluorinated chains at C5 previously selected (trifluoroacetyl, 
pentafluorpropionyl and heptafluorobutyryl chains). Using the common precursor 154, I 
performed an N-transacylation reaction with different perfluorinated anhydrides 
(trifluoroacetic, pentafluorpropionic and heptafluorobutyric anhydrides) directly on the azido 
derivative in order to obtain compounds 18b-d. Then, these three intermediates were subjected 
to hydrogenation with Lindlar catalyst giving compounds 19b-d, as reported above, and they 
were subsequently acylated with p-toluensulfonyl chloride, in presence of Et3N in CH2Cl2 to 
obtain protected inhibitors 20b-d. The obtained molecules, 18b-d and 20b-d were 
deacetylated performing Zemplén reaction and then selectively hydrolyzed using K2CO3 in 
methanol/water (9:1) for compounds 18c,d and 20c,d and Et3N in acqueous methanol, for 
compounds 18b and 20b. All the protected new free acidic azido (13b-d) and p-
toluesolfonamido (12b-d) derivatives were investigated for their inhibitory potency against 
NDV-HN. 
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Scheme 3.4 Synthesis of compounds 12b-d and 13b-d. Reaction conditions: i) perfluorinated anhydride, Et3N, 
CH3CN, 0°C to 135°C, 15 minuti, 78-80%; ii) NaOMe, MeOH, 23°C, 1h, 80%; ii) for 12c,d and 13c,d: K2CO3, 
MeOH/H20 (10:1, v/v), 23°C, 12h, 68-75% and for 12b and 13b: Et3N, MeOH/H2O (2:1 v/v), 23°C, 12h, 68-
72%; iv) H2, Lindlar catalyst, EtOH, 23°C, overnight, 68-75%; v) p-toluensulfonyl chloride, Et3N, CH2Cl2, 0°C 
to 23°C, 2-5h, 75-81%. 
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3.2.3 Biological assays 
In the next section, I will present the biological investigations in order to evaluate the 
inhibitory potency and selectivity of the previously synthesized azido and p-
toluensolfonamido derivatives. A neuraminidase inhibition assay (NI) and a hemagglutinin 
inhibiton test (HI) were performed on NDV-HN. Then, a NI was accomplished, also, on 
human NEU3 to obtain some preliminary information about the synthesized inhibitors 
selectivity. 
3.2.3.1 Neuraminidase inhibition assay (NI) on NDV-HN 
The NI assay was, firstly, performed on unfluorinated compounds 12a and 13a, using in toto 
purified NDV and 4-methylumbelliferyl α-D-N-acetylneuraminic acid as fluorescent 
substrate112. The obtained results were expressed as IC50 values, corresponding to the 
concentration causing the 50% inhibition of neuraminidase activity. The final values were 
reported in Table 3.3. As depicted in the graph, both 12a and 13a showed a nanomolar activity 
against NDV-HN, with IC50 values of 0.178 µM and 0.543 µM, respectively. Surprsingly, 
azido compound 13a and the p-toluensolfonamido derivative 12a were 5 times and 14 times 
respectively, more active than FANA (2.42 µM). These results unequivocabilly confirm the 
large size of the C4 cavity and its ability to perfectly accommodate a bulky hydrophobic 
substituent (as p-toluensolfonamido one) as predicted by docking simulation studies. On the 
other hand, compound 13a, due to the negative charge at the terminal portion of azido group, 
could probably interact with some basic active site amino acid, such as Lys236, giving 
additional interactions that justify the higher IC50 value if it was compared to DANA or 
FANA.  
Using the same assay, I evaluate the inhibitory activity against NDV-HN of all the C5 
perfluorinated derivatives 12b-d and 13b-d. The IC50 values obtained, reported in Table 3.3, 
were divided into two different series: p-toluensolfonamido series and azido series.  
An accurate analysis of IC50 values in p-toluensolfonamido series revealed that the 
trifluoroacetyl derivative 12b posseses a high nanomolar activity against NDV-HN (0.191 
µM), not statistically different from that of its unfluorinated analogue 12a (0.178 µM). This 
result suggested that, fluorine atoms of trifluroacetyl group are not able to enhance the 
inhibitory potency of the molecule in presence of a bulky C4 substituent, as p-
toluensolfonamido one. Then, considering longer perfluorinated chains, I observed a 
dramatically decrease in inhibitory activity.  Pentafluoropropionyl derivative 12c and its 
heptafluorobutyryl homologue 12d showed IC50 values of 62.0 µM and 186 µM, respectively, 
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indicating that the large p-toluensolfonamido group is able to interfere with the accomodation 
of longer perfluorinated chains. 
On the other hand, analyzing azido series, it was observed that trifluroacetamido compound 
13b possess a IC50 value of 0.166 µM, which is 3 times lower if compared to that of its 
unfluorinated analogue 13a (0.543 µM). This indicate that, the presence of a realtively small 
substituent such as azido group, lead to an increase in inhibitory potency after the addition of 
a  trifluoroacetyl group at C5 (as observed for the previusly described 4α-OH derivatives of 
DANA, see paragraph 3.1.2.1). Then, considering the interestingly nanomolar IC50 value of 
0.166 µM showed by compound 13b and that of its pentafluoropropionamido homolog 13c 
(7.43 µM), a reduction in inhhibitory potency is evident. This decrease was followed by an 
improvement in activity passing from compound 13c to its heptafluorobutyryl homolog 13d, 
which showed a IC50 value of 0.213 µM, not statistically different, from that of trifluoroacetyl 
derivative 13b (0.166 µM). Analysing the azido series IC50 trend, it is noteworthy that despite 
it is similar to that previuolsy reported for the corresponding C4 hydroxy analogues (see 
paragraph 3.1.2.1), the overall activities measured showed lower IC50 values, confirming the 
capacity of the azido group to be well accommodated in enzymatic pocket even in presence 
of C5 perfluorinated chains of different length. 
 
 
  
 
 
 
 
 
 
Taken together, these results regarding both the azido and p-toluensolfonamido series permit 
me to speculate about the inhibitor/active site interactions, hypothesizing that the strong 
binding of the p-toluensulfonamido group to the C4 pocket region of NDV-HN could induce 
Compound IC50 (µM)a 
12a 0.178 ± 0.013 
12b 0.191 ± 0.007 
12c 62.0 ± 10.6 
12d 186 ± 27.5 
Compound IC50 (µM)a 
13a 0.543 ± 0.022 
13b 0.166 ± 0.061 
13c 7.43 ± 0.29 
13d 0.213 ± 0.035 
Table 3.3 NI IC50 values of p-toluensolfonamido and azido derivatives on NDV-HN. 
 
aEach value represents the mean of three independent experiments carried out in triplicate 
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a remodeling of the region adjacent to C5 (C5 binding cavity), decreasing its ability to 
accommodate longer (than trifluoroacetamido one) perfluorinated chains. On the other hand, 
the azido group give some important interactions, but it is not sufficient to affect the 
accommodation of C5 chains.  
In addition, taking into account all the collected data from both biological investigations on 
C5/C4 substituted derivatives and the docking simulations, I hypothesized that Lys236 could 
be the key amino acidic residue targeted by our inhibitors. In fact, as suggested by Induced 
Fit docking results, when p-toluensulfonamido derivative well accommodate in the 
corresponding pocket, the sulfonyl group and the aromatic ring could give two distinct type 
of interactions with Lys236. On the other hand, when a small C4 substituent is present, also 
C5 heptafluorobutyryl perfluorinated chains could reach and interacts with this amino acid (as 
shown for 4α hydroxy derivatives, see paragraph 3.1.3.1).  
Thus, as known Lys236 together with Arg174 are two key amino acids involved in the NDV-
HN active site activation and both residue are implicated in a series of conformational 
changes, interesting the head domain, which should activate the fusion promotion activity of 
this protein76, 118. These findings led me to hypothesize that, all the synthesized inhibitors, 
could be implicated not only in inhibition of the neuraminidase activity but also they could 
have an important role in modulating viral fusion promotion activity exploited by HNs. At 
this purpose future investigations will be necessary. 
3.2.3.2 Hemagglutinin inhibition assay (HI) on NDV-HN: Preliminary results 
I decided to investigate, also, the possible role of the most active molecules (12a,b and 13b,d) 
in inhibiting the hemagglutinin activity of NDV-HN. At this purpose, a collaboration with 
“Istituto Zooprofilattico Sperimentale delle Venezie” was necessary. I set up a protocol to 
perform a hemagglutinin inhibition assay (HI), using chicken red blood cells (cRBC) and 
NDV (LaSota), on DANA 1a, FANA 2a and compounds 12a,b and 13b,d. I reported the 
qualitative results of some preliminary assay in the table below (Table 3.4). All the tested 
compounds did not inhibit hemagglutination of RBCs even at the maximum screening 
threshold of 300 µM. These results suggested that the synthesized molecules, potent and 
selective neuraminidase activity inhibitors which well bind and inhibit Site I of NDV-HN, are 
unable to reach Site II and block its hemagglutinin activity. 
3. Results and Discussion 
 
 
66 
 
 
 
 
 
 
 
 
 
3.2.3.3 Neuraminidase inhibition assay (NI) on hNEU3: Preliminary studies on selectivity 
Finally, I evaluate the inhibitory potency of FANA 2a and all the azido and p-
toluensolfonamido derivatives (12a-d and 13a-d) on the human membrane sialidase NEU3 
(hNEU3) performing, the same test previously reported for hydroxyl derivatives (see 
paragraph 3.1.3.2).  
As shown in Table 3.5, unlike FANA (the most effective NDV-HN inhibitor used as a 
reference in literature), all the tested compounds lack of inhibitory activity against hNEU3 
even at the maximum threshold of 1mM, with the exception of azido derivatives 13a and 13b, 
which showed a micromolar inhibitory activity against the human protein (IC50 value of 78.0 
µM and 128.0 µM, respectively), which are, otherwise, 100- and 700-fold higher than those 
of the same compounds tested toward NDV-HN. All these values are in agreement with the 
notion that mammalian sialidases possess a small C4 binding pocket and, consequently, bullky 
groups at C4 and/or at C5, are not well tolerated. 
 
 
 
 
Compound IC50 (µM)a 
DANA 1a >300 
FANA 2a >300 
12a >300 
12b  >300 
13b >300 
13d >300 
Table 3.4 HI assay performed on p-toluensolfonamido and azido derivatives on HN of inactivated strain of NDV. 
 
aEach concentration for each inhibitor is tested in duplicate and the experiment repeated three times. 
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Compound IC50 (µM)a 
13a 78.0 ± 22 
13b 128 ± 35 
13c >1000 
13d >1000 
Compound IC50 (µM)a 
12a >1000 
12b >1000 
12c >1000 
12d >1000 
Table 3.5 NI assay performed on p-toluensolfonamido and azido derivatives on hNEU3. 
aEach concentration for each inhibitor is tested in duplicate and the experiment repeated three times, 
obtaining identical results. 
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3.3 The 3,4-unsaturated derivatives 
As above anticipated, in this section a study of a relatively poorly investigated class of 
molecules, some Neu5Ac derivatives presenting an unsaturation at the C3/C4 position6, 7, 42, 
will be presented. In particular, the set-up of more efficient synthetic procedures to achieve 
these 3,4-unsaturated derivatives 21a,b and 22a-f (Figure 3.11) will be reported. In addition, 
a study of some important aspects concerning their anomeric configuration, their stability in 
protic solvents and the unexpected formation of an interesting synthetic intermediate, will be 
performed. Finally, the biological inhibitory activity evaluation on NDV-HN and the 
selectivity towards human NEU3 will be accomplished. 
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3.3.1 Chemical synthetic approach 
The synthesis of the 3,4-unsaturated sialic acid derivatives was firstly accomplished by 
Maudrin42, through a laborious multistep synthetic pathway and, only recently, these 
molecules have been achieved using a rapid method, proposed by Ikeda and coworkers, via a 
Ferrier glycosylation reaction6, 7. This interesting rearrangement involves a nucleophile 
substitution reaction combined with an allylic shift, occurring in glycals (2,3-unsaturated 
glycosides). This reaction could be performed in presence of various acid catalysts, such as 
Lewis acids (AlCl3, FeCl3, BF3Et2O, etc.) or other activating agents (activated acidic clays 
and resins)119.  
 
Scheme 3.5 3,4-unsaturated Neu5Ac derivatives: general retrosynthesis scheme. 
For the synthesis of this class of compounds, in high β stereoselectivity, Ikeda et al.6, 7 
proposed as best synthetic conditions, in their Ferrier reaction, a mixture of the acid Bi(OTf)3 
Figure 3.11 The 2α and 2β 3,4-unsaturated derivatives of Neu5Ac synthesized during my PhD thesis 
(SOct=SOctyl). 
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and the clay Montmorillonite K-10 in CH3CN. Despite, the high yields and β stereoselectivity 
obtained using methanol or ethanol as nucleophiles, the same reaction conditions applied to 
long- or branched-chain alcohols or thiols, caused a drastic reduction in yields. Unfortunately, 
they obtained, after hydrolysis, a random mixture of α and β anomers of the free molecules, 
thus, losing also in anomeric (C2) stereoselectivity. 
Starting from the literature results, I planned a retrosynthetic protocol (Scheme 3.5) to obtain 
3,4-unsaturated derivatives, via a Ferrier reaction and subsequent deprotection (preserving a 
high stereoselectivity), starting from oxazoline of Neu5Ac 14110, which was achieved, in three 
steps, from Neu5Ac,  
I decided to preferentially synthesize the β-anomers on the basis of some preliminary docking 
studies performed on NDV-HN using as model compounds 2O-methyl and 2S-ethyl 
derivatives. The obtained results suggested that, when the β-anomers of these derivatives enter 
inside the active site, their β substituents at C2 seemed to be orientated toward the large C4 
binding pocket in which they could be accommodated (Figure 3.12).  
 
Figure 3.12 Rigid docking pose of compound 22b, 2βS-ethyl 3,4-unsaturated derivative of NeuAc (green). 
3.3.1.1 Setting up of optimal Ferrier reaction conditions using MeOH as a nucleophile 
I started with the synthesis of the oxazoline derivative 14110 from Neu5Ac, in three steps, 
according to literature. Initially, I decided to perform the Ferrier reaction using the same 
conditions reported by Ikeda et al.6, 7 to obtain the desired, 3,4-unsaturated molecules 23a and 
24a, as a cromatographically unseparable mixture (Table 3.6). Briefly, oxazoline 14110 was 
solubilized in anhydrous CH3CN (0.2M) and then methanol was added. Subsequently, a 
mixture of Bi(OTf)3 and Montmorillonite K-10 (Montmorillonite 40% w/w loading of 20% 
w/w of Bi(OTf)3) was added, as an acid catalyst, and the reaction was stirred at 23°C, to obtain 
the protected molecules 23a and 24a. The results have been reported in Table 3.6. 
Unfortunately, the reaction, in my hands, did not work well as described by Ikeda, in fact, I 
22b 
C4 cavity 
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obtained lower yields (70% versus 95% obtained by Ikeda) and stereoselectivity (α/β ratio of 
13/87 versus 9/91 obtained by Ikeda) (Entry 1). These sub-optimal yields could be attributed 
to the formation of an unstable intermediate, detectable in TLC, but not isolable neither in 
TLC or flash chromatography, able to evolve in the more stable 4β-OH derivative of Neu5Ac, 
2537.  
Successively, I decided to investigate, the effect of temperature on this reaction, observing a 
general improvement in reaction times (Entry 2 and 3). An approximately doubling of the 
temperature (from 23°C to 50°C) led to a variation in the anomeric ratio (α/β ratio of 22/78), 
keeping the yields almost unchanged (Entry 2). Noteworthy, a further increase in temperature, 
close to the boiling point of the CH3CN (80°C), caused a marked reduction in C2 
stereoselectivity (α/β ratio of 45/55) (Entry 3). 
In addition, conducting the reaction at 80°C, I observed, in the final purified products mixture, 
the presence of a further by-product. This compound could correspond to the 4β-OMe 
derivative of DANA 26, in fact it showed NMR signals according to the structure of the C5-
trifluoro 4β-OMe derivative of DANA111 (that could form in acidic environment at high 
temperature), except for the signals at C5 (data not shown in this thesis). 
So, considering these preliminary results, I decided to evaluate the individual contribution of 
these two catalysts, at different temperatures. In particular, the use of Bi(OTf)3 led to a high 
reduction in reaction times, already at 23°C, but with a significative reduction in yields (40%) 
(Entry 4). Otherwise, increasing the temperature, from 23°C to 50°C, I registered an 
improvement in yield (from 40% to 60%, Entry 5) which, then decreases (40%) at 80°C (Entry 
7). Noteworthy, the 4-OMe by-product has been detected also using these conditions (10-25% 
at 50°C and 55% at 80°C, of the overall yields), suggesting that the real yields of the desired 
compounds 23a+24a were lower than those reported. In addition, the previously revealed 
temperature-dependent decreasing in stereoselectivity has been also registered (α/β ratio of 
43/57 at 50°C, Entry 6).  
Then, checking the effects of the exclusive use of Montmorillonite K-10 as an acid catalyst, 
at 23°C I observed very long reaction times (Entry 8). Surprisingly, the increase in temperature 
from 23°C to 80°C, led to a progressive great improvement in both reaction time and yields 
(2-3h, 85% respectively, Entry 10), not affecting the stereoselectivity (from α/β ratio of 17/83 
at 50°C to 18/82 at 80 °C, Entry 9-10).  
These collected crude Ferrier mixtures showed clean NMR spectra, without the presence of 
by-products, only the α/β anomers mixture signals were registered. This data suggested that 
Montmorillonite used alone, could be an optimal acid catalyst to obtain a clean reaction 
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without by-products formation. This is probably due to its capacity to absorb water and to 
catalyze the reaction steps in high regio- and stereo-selective way. In fact, montmorillonite is 
a clay belonging to phyllosilicate mineral group and its crystalline structure consists of 
multiple layers (each layer is made up of one octahedral alumina sheet sandwiched between 
two tetrahedral silica sheets). This structure permits to entrap cation and water. The crude 
mineral presents some native Lewis (Al3+ species) and Brӧnsted sites, but its acidic properties 
could be boosted by cation exchange processes (H+, Fe3+, Zn2+, etc.)119, 120. In general, 
Montmorillonite could probably eliminate the trace of water, present in Bi(OTf)3, the 
supposed responsible of the formation of the “unstable intermediate”. 
 
 
 
 
 
 
 
Entry Acid catalyst Temperature (°C) 
Reaction 
time (h) Yields (%)* Obtained products* 
Stereo-selectivity 
(α/β) 
1 
Bi(OTf)3 + 
Montmorillonite 
K-10 
RT >30 70 α+β 13/87 
2 50 1 68 α+β 22/78 
3 80 0.5 73 α+β + 15% by-product (4-OMe) 45/55 
4 
Bi(OTf)3 
RT 3-5 40 α+β 15/85 
5 30 1 50 α+β 28/72 
6 50 1 60 α+β + 10-25% by-product (4-OMe) 43/57 
7 80 0.5 40 α+β + 55% by-product (4-OMe) 40/60 
8 
Montmorillonite 
K-10 
RT >256 --- --- --- 
9 50 28 75 α+β 17/83 
10 80 2-3 85 α+β 18/82 
Table 3.6 Investigation of reaction conditions using MeOH as nucleophile and CH3CN as solvent. The effect of 
two acid catalysts at different temperatures on reaction time, yield and stereoselectivity has been tested. 
*after FLASH chromatography purification of the two chromatographically unseparable compounds. 
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To confirm, this hypothesis, I dedicated part of my work to understand the structure of the 
unstable intermediate, responsible for the yield decrease of Ferrier reaction. Initially, I 
attempted to isolate this unstable compound using preparative TLC or flash chromatography, 
but all the tentative failed and the only compound isolable was the 4β-OH derivative of 
Neu5Ac 2537. Thus, considering the hypothesis that this compound could form from the 
presence of water in an acidic medium, I simulate the moist acidic reaction conditions to 
obtain this by-product in high yield (Scheme 3.6). At this purpose, I dissolved oxazoline 14 
in a mixture of CH3CN/H2O (1:1; v/v) and trifluoroacetic acid (TFA) and then, the reaction 
was stirred at 23°C. The oxazoline depletion was monitored by TLC and after 5-15 min, the 
time necessary to transform the starting material entirely in the intermediate 27, the reaction 
was quenched by the addition of a weak basic resin (IRA-67), until neutral pH. Significantly, 
longer exposition times in these reaction conditions led to the formation of a mixture of both 
intermediate 27 and the final 4β-OH derivative 2537. 
 
 
Scheme 3.6 Intermediate formation and isolation. Reaction conditions: i) CH3CN/dH20, TFA; ii) After 5-15 
min basic resin IRA-67. 
In this way, I accomplished to isolate a molecule with the same TLC Rf value of the 
intermediate 27. In addition, the isolated compound was hydrolyzed in the same reaction 
conditions or in flash chromatography to the final 4β-OH NeuAc derivative 25, as aspected. 
Overall, the collected data allow me to assert, with reasonable certainty, that I have isolated 
the intermediate 27, which causes the decreasing in Ferrier’s products yield. This molecule 
was immediately characterized by 1H and 13C NMR spectroscopy and mass spectrometry, to 
get all the information necessary to reconstruct the chemical structure of this newly and 
previously uncharacterized intermediate. 
Then, a mechanism for the intermediate 27 formation, starting from oxazoline 14, was 
proposed according to all the collected data. This interesting issue will be not discussed here, 
but the detailed description has been reported in Scheme 3.7. 
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Scheme 3.7 Hypothesized chemical mechanism for intermediate 27 formation and the subsequent 
transformation in the more stable 4-OH by-product. Water present in solution could perform a nucleophilic 
attack on the oxazoline 14 ring and, in the same time, the acidic environment permits the protonation of the 
nitrogen group, leading to oxazoline ring opening and the formation of a 4-OAc derivative with a free amino 
group at the C-5 (the unstable intermediate 27). The presence of a free amine in β gives high instability to the 
molecule, in fact, it tends to react, immediately, with the acetyl moiety permitting the re-formation of a 
transient ring-close derivative. This molecule could, finally, evolve in the stable compound 25. 
Finally, to support the hypothesized mechanism and the reactivity of the newly synthesized 
molecule, a chemical approach based on the direct acylation of intermediate 27 was performed 
(Scheme 3.8).  
The protocol, depicted in Scheme 3.8, provided the formation of the intermediate 27 in the 
same conditions previously described, and the direct acylation of its amino group with 
propionyl chloride and weak basic resin (IRA-67), without any intermediate isolation. After 
the workup, compound 28 was isolated, having a propionyl amide at C5 and the acetyl residue 
at C-4, thus supporting expectations. At this point, I transformed the compound 28 into its 
oxazoline derivative 29, using the classic reaction conditions described above: BF3Et2O, in 
CH2Cl2 at 80°C. Unreported oxazoline 29, was achieved in good yield and high purity grade 
and completely chemical-physical characterized. Then, I decided to check whether the 
propionyl-oxazoline 29 had the same behavior (under moist acidic conditions) as the 
previously observed for acetyl-oxazoline 14, generating an intermediate 30 derived from the 
exchange of the propionyl group from C5 to C4 position. Thus, propionyl-oxazoline 29 was 
treated with moist TFA to afford a new C4-propionyl intermediate 30, derived from the 
expected scrambling. Finally, the treatment of compound 30 with acetyl chloride, in presence 
of basic resin, gave compound 31. 
In this way, I demonstrated that the acyl (both acetyl or propionyl) groups initially at position 
C5, after oxazoline formation and subsequent re-opening in acidic conditions, transpose at 
C4. This curious “scrambling” confirms the amine nature of the intermediates, able to react 
with different acylchlorides. Furthermore, this interestingly switch between position C5 and 
C4 could result useful for the future synthesis of new C4 and C5 substituted Neu5Ac 
derivatives.  
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Overall, these interesting investigations showed the important double role played by the use 
of Montmorillonite in Ferrier reaction: as a drying agent in the removing traces of water and 
as clean acid-catalyzer. 
 
Scheme 3.8 Demonstration and confirmation of the intermediate structure. Reaction conditions: i) 
CH3CN/H20, TFA; ii) After 6 min basic resin IRA-67 addition; iii) Propionyl chloride, basic resin IRA-67, 
CH3CN; iv) BF3Et2O, CH2Cl2, 80°C; v) Acetyl chloride, basic resin IRA-67, CH3CN. 
3.3.1.2 Setting up of optimal reaction conditions for other alcoholic and thiolic derivatives 
I decided to test the selected Ferrier conditions (Montmorillonite K-10, 80°C in CH3CN), 
using different alcoholic and thiolic nucleophiles (EtOH, iPrOH, nBuOH, EtSH and 
CH3(CH2)7SH) obtaining the cromatographically unseparable mixtures of 23b+24b, 23c+24c, 
23d+24d, 23e+24e and 23f+24f, respectively reported in Table 3.7 (using 23a+24a as 
reference mixture). Surprisingly, the reaction works well with the selected conditions giving 
very good yields (68-80%), high stereoselectivity (mean ratio of 15/85), accompanied by low 
reaction times (4-5h), for all the nucleophiles tested. Thus, my synthetic conditions permit to 
achieve high yields also with bulkier nucleophiles, on the contrary of those of Ikeda and 
coworkers6, 7 who found optimal conditions only for MeOH and EtOH. 
Excited by the results, I attempted to use these conditions with other different nucleophiles 
than alcohols or thiols. Unfortunately, this reaction did not work using ammines, azido 
derivatives and silyl enol ethers. 
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3.3.1.3 Achievement of the deprotected 3,4-unsaturated Neu5Ac analogues and study of their 
stability 
In order to achieve the free 3,4-unsaturated derivatives, initially, I set-up the hydrolytic 
conditions, using as model compounds the protected Ferrier product mixtures of 23a+24a and 
23b+24b (Scheme 3.9). They were subjected to deacetylation with NaOMe in methanol, to 
obtain the corresponding methyl ester mixtures, that they were, successively, purified by flash 
chromatography to afford the α and β anomers 32a and 33a, 32b and 33b. After a full physico-
chemical characterization, they were submitted to basic hydrolysis with KOH in water 
solution, using a different workup for 32a, 33a and for 32b, 33b. Alcoholic derivatives 32a 
and 33a were treated with a weak acidic resin until neutral pH, giving the corresponding 
derivatives, 21a and 22a as potassium salt. On the other hands, for thiolic derivatives 32b and 
33b a strong acidic resin (Dowex 50WX8, H+) was used to obtain the desired molecules 21b 
and 22b in the free acidic form.  
Compound Reaction Time (h) Yields* (%) Stereoselectivity (α/β) 
23a + 24a 2-3 85 18/82 
23b + 24b 4 68 14/86 
23c + 24c 2-3 80 16/84 
23d + 24d 5 70 15/85 
23e + 24e 5 68 14/86 
23f + 24f 5 70 15/85 
Table 3.7 Reaction time, yields and stereoselectivity of Ferrier reaction performed using the optimal conditions 
and different nucleophiles (SOct=SOctyl). 
*after FLASH chromatography purification of the two chromatographically unseparable compounds. 
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Scheme 3.9 Synthesis of the free acid or potassium salt form of 21a,b and 22a,b. i) NaOMe, MeOH, 23°C, 1h, 
80%; ii) KOH (aq) 0.5M, 23°C, 1h, then compounds 21a and 22a were obtained as Potassium salts after 
treatment with weak acidic resin (Amberlite CG50, H+); iii) KOH (aq) 0.5M, 23°C, 1h, then compounds 21b 
and 22b were achieved in their free acidic stable form by treatment with strong acidic resin (Dowex 50WX8, 
H+). 
This strategy was adopted on the basis of some preliminary results I performed on the stability 
of these compounds and by the support of the literature data42. Thiolic derivatives 21b and 
22b remained stable in their free acidic form. On the other hand, I demonstrated that the acidic 
compounds 21a and 22a in free form, having an alcoholic function suffered a partial C2-
epimerization both during the work-up with strong acidic resin (Dowex 50WX8, H+) or if 
dissolved in methanol solution. A similar instability has been registered also using water. 
Interestingly, all these observations were not taken into account from Ikeda and coworkers6, 
7
, who observed a dramatic change in α/β ratio and loss in yield, after deprotection. On the 
other hand, Maudrin et al.42, in the in the final hydrolytic step of their laborious protocol 
observed an epimerization of the C-2 configuration in acidic environments, too. 
Successively, all the other protected Ferrier product mixtures 23c+24c, 23d+24d, 23e+24e, 
23f+24f were subjected to deacetylation with NaOMe in methanol, to afford after flash 
chromatography the pure β anomers 33c-f in good yields (66%) (Scheme 3.10). Then, I 
performed the two-step hydrolytic procedure giving 22c-e as potassium salts or 22f in free 
acid form (Scheme 3.10).  
Before the biological activity evaluation, all the obtained final derivatives, and their precursors 
were submitted to an in depth characterization to assign all the NMR signals, performing 1H, 
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13C, COSY, HSQC and HMBC experiments. Then, the correct α or β anomeric configuration 
of the protected form, of their methyl esters and of the final deprotected ones, was determined 
using the method presented in the next paragraph (see paragraph 3.3.1.4). Finally, also mass 
spectrometry, elemental analysis and αD determination, were performed (See material and 
method section). 
 
 
Scheme 3.10 Synthesis of the free acid or potassium salt forms of compounds 22c-f. i) NaOMe, MeOH, 23°C, 
1h, 82%; ii) KOH (aq) 0.5M, 23°C, 1h, then compounds 22c-e were obtained as potassium salts after 
treatment with weak acidic resin (Amberlite CG50, H+); iii) KOH (aq) 0.5M, 23°C, 1h, then compound 22f 
was achieved in its free acidic stable form by treatment with strong acidic resin (Dowex 50WX8, H+). 
3.3.1.4 A simple method for the anomeric configuration attribution to the 3,4-unsaturated 
derivatives 
The assignment of the anomeric configuration to these 3,4-unsaturated derivatives it is a very 
difficult challenge. About this, literature works reported a series of empirical rules to 
determine the correct anomeric stereochemistry for classical saturated protected and 
unprotected sialosides121: 
1) A first one regards the chemical shift of the equatorial H3 proton (δ = 2.67-2.72 ppm 
for α-derivatives and δ = 2.25-2.40 ppm for β ones)122; 
2) A second one considers the chemical shift of H4 for protected122 or methylester form 
of O-sialosides123; 
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3) A third one interests the long-range coupling constants between C1 and the axial H3 
proton124, 125; 
4) Another important rule regards the coupling constant between H7 and H8 (6.2-8.5 Hz 
for α anomers and 1.5-2.6 Hz for β anomers)122, 126, 127; 
5) A last one involves the chemical shift difference between H9a and H9b (∆δ < 0.5 ppm 
for α-derivatives and ∆δ = 1 ppm for β ones)126. 
I decided to check these rules using as reference compounds the 2O-methyl derivatives 
23a+24a, 32a, 33a and 21a, 22a and the 2S-ethyl ones 23b+24b, 32b, 33b and 21b, 22b. 
After a deep and careful study, analyzing their NMR spectra, it could be observed that none 
of the literature proposed empirical rules could be used as predictive signals for the correct 
anomeric configuration attribution of the 3,4-unsaturated derivatives: 
 The first three rules are not applicable to these derivatives due to the presence of an 
unsaturation between H3 and H4; 
 The fourth one, valid only for protected derivatives, give no good matching in 2O-
methyl and 2S-ethyl derivatives, in fact the coupling constant between H7 and H8 was 
of 6.3 Hz for α anomer 23a and 5.4 Hz for β anomer 24a and 6.1 Hz and 4.8 Hz, 
respectively, for 23b and 24b. 
 The fifth rule, regarding the difference in chemical shift between H9a and H9b, is not 
respected in the protected compounds. In fact, I observed a ∆δ = 0.42 ppm for 23a and 
a ∆δ = 0.26 ppm for 24a, then a ∆δ = 0.38 ppm for 23b and a ∆δ = 0.33 ppm for 24b. 
The C2 configuration attribution of these Ferrier products, achieved only by the assignment 
in analogy to 2O-methyl 3,4-unsaturated derivatives 21a and 22a, it is not a good method, in 
fact, some errors could occur. About this, I decided to consider the use of 1,7-lactonization 
reaction as a practical and fast method to overcome these difficulties128, 129. This reaction was 
already published by my laboratory, regarding some saturated sialic acid derivatives106, 128, 
but, to date, no information about the use of this method to achieve the 3,4-unsaturated 
lactonic sialosides have been reported in literature. Thus, I successfully applied the classical 
lactonization protocol128 to achieve these new and never characterized unsaturated 1,7-
lactones (Scheme 3.11). I dissolved the potassium salts 21a and 22a and the free acids 21b 
and 22b in dimethylformamide (DMF) and tetrahydrofuran (THF) mixture. Then, 
triethylamine (Et3N) and benzyl chloroformate (CbzCl), were rapidly and sequentially added, 
at 0°. For derivatives 22a,b the reactions were maintained under stirring at 23°C and, after 30 
minutes, all the starting material disappeared, giving a TLC spot compatible with lactonic 
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rings 34 and 35, respectively. On the other hand, compounds 21a,b gave only the starting 
material, even up 2 hours. The structure of the 3,4-unsaturated 1,7-lactones have been 
confirmed by 1H and 13C NMR analyses. 
 
Scheme 3.11 Lactonization reaction to obtain compound 34 and 35. Reaction conditions: i) CbzCl, Et3N, 
THF/DMF, 0°C to 23°C, 15-60 minutes, 36-40%. 
This experimental procedure permits to identify, without ambiguities, α of β anomers (Scheme 
3.11). The first one could not lactonize under the described conditions, due to their spatial 
orientations. On the other hand, the β anomers afforded quite unstable but isolable and 
characterizable lactones. Finally, to further confirm these important results I saturated the 
obtained 3,4-unsaturated lactone 34 (Scheme 3.12), dissolving it in AcOEt in presence of Pd 
on carbon as catalyst, under H2 atmosphere. I obtained the corresponding saturated compound 
36, presenting a classical 5C2 chair conformation. The chemical properties of this molecule 
were perfectly superimposable to those of the lactone previously synthesized from the 
deprotected saturated β-derivative 37130 having a classical 5C2 chair conformation. This result 
definitively confirmed the identity of the isolated 3,4-unsaturated lactones. 
 
Scheme 3.12 Demonstration and confirmation of the 3,4-unsaturated lactone identity. Reaction conditions: i) 
H2, Pd on carbon, AcOEt, 23°C, 2h, 50%; ii) iv CbzCl, Et3N, THF/DMF, 0°C to 23°C, 15-60 minutes, 75%. 
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Finally, I dedicated part of my time to the identification of some potential diagnostic NMR 
signals, useful to determine some “new empirical rules” for the rapid and immediate 
assignment of the C2 configuration. At this purpose, focusing on 2O-methyl and 2S-ethyl 
derivatives (Table 3.8), I observed that α anomers present the C6 chemical shift values greater 
than 74.2 ppm (δ ≥ 74.2 ppm) while β ones present a value lower than 70.3 ppm (δ ≤ 70.3 
ppm). This difference becomes very significant in methyl esters and acid or salt compounds 
reaching a ∆δ (C6α-C6β) of 5.5 ppm (Table 3.8). Thus, C6 signal could be defined as a very 
important diagnostic one. It is obvious that, to definitively validate this new empirical rule, it 
is necessary to synthesized a higher number of molecules. I could anticipate that some 
preliminary studies on other alcoholic or thiolic derivatives confirmed this interesting new 
empirical rule. 
 
 
 
 
 
 
 
Table 3.8 C6 chemical shift for protected 2O-methyl and 2S-ethyl derivatives, their methyl esters and the 
corresponding free acid and salts. 
3.3.2 Neuraminidase inhibition assay (NI) on NDV-HN and hNEU3 
After the synthesis and the full physico-chemical characterization of the obtained 3,4-
unsaturated derivatives, I decided to screen, as suggested by preliminary docking simulations 
(indicating a possible accommodation of 2β substituents in C4 cavity, see paragraph 3.3.1), 
the synthesized β anomers (22a-f) as potential paramyxoviruses neuraminidase activity 
inhibitors, using NDV-HN as model. For this purpose, I evaluated their inhibitory potency 
towards NDV-HN by a fluorimetric assay (see Material and Methods) and the results were 
reported in Table 3.9.  
As shown in the graph, increasing the steric hindrance of the 2β substituents a statistically 
significative increase in inhibitory activity towards NDV-HN was registered passing from the 
2O-methyl sialoside 22a (IC50 > 1000 µM) to the 2O-isopropyl compound 22d (IC50 = 148 
Compound δC-6 α anomer δC-6 β anomer ∆δ (C6α-C6β) 
23a+24a 74.4 70.4 4.0 
23b+24b 74.2 70.6 3.6 
32a and 33a 77.2 71.7 5.5 
32b and 33b 77.3 71.8 5.5 
21a and 22a 75.8 70.3 5.5 
21b and 22b 77.4 71.8 5.6 
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µM). The addition of longer alkyl chains in compounds 22e and 22f, 2O-butyl and 2S-octyl 
respectively, led to a subsequent decrease in inhibitory potency. These results permit to 
hypothesize that the isopropyl group (IC50=148 µM) could be well accommodated inside the 
large C4 cavity but this is not sufficient to give new additional interactions.  
All these compounds have been tested, also, against human NEU3 (hNEU3), according to 
general procedure described in Materials and Methods, to evaluate both their ability to inhibit 
this enzyme and their selectivity. A shown in Table 3.9 all these derivatives resulted inactive 
towards hNEU3, showing a selective inhibitory activity versus NDV-HN. 
Successively, I decided to test also the inhibitory activity of 2α O-methyl 21a and 2α S-ethyl 
21b compounds, observing that 21a showed no activity towards NDV-HN and hNEU3 with 
an IC50 value above the selected threshold of 1mM. Interestingly, compound 21b resulted the 
most potent inhibitor among all the 3,4-unsaturated synthesized derivatives (IC50 =100 µM 
against NDV-HN), but, unfortunately it lack of selectivity (showing an IC50 value of 130 µM 
versus hNEU3).  
Taken together, these results permitted to speculate that, probably, the β anomers could be 
more selective for NDV-HN towards human NEU3, than α ones. This behavior could be 
associated to the different dimensions of the C4 cavity in paramyxovirues and mammalians. 
 
 
 
Compound IC50 (µM)a 
against 
NDV-HN 
IC50 (µM)a 
against 
hNEU3 
22a (2β-OMe) >1000 >1000 
 22c (2β-OEt) 384 ± 55 >1000 
 22b (2β-SEt) 248 ± 18 >1000 
 22d (2β-iPr) 148 ± 12 >1000 
22e (2β-OBu) 485 ± 118 >1000 
22f (2β-SOct) 406 ± 100 >1000 
  21a (2α-OMe) >1000 >1000 
21b (2α-SEt) 100 ± 25 130 ± 25 
Table 3.9 NI assay performed on all the 3,4-unsaturated synthesized derivatives against NDV-HN and hNEU3. 
In the table, all the IC50 values against NDV-HN and hNEU3 are reported. In the graph, the inhibitory 
activities against NDV-HN is depicted. 
aEach concentration for all the inhibitors is tested in duplicate and the experiment repeated three times, 
* p<0.05 (t-test) 
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My PhD thesis work was focused on the development of specific and selective inhibitors 
towards the hemagglutinin-neuraminidase of NDV, both as candidates for new drugs and as 
useful biochemical tools. In particular, I directed my attention to two classes of inhibitors 
derived from DANA through the use of a multidisciplinary approach. 
The importance of the results obtained is summarized here, for convenience, divided into two 
sections: the C5 and C4/C5 modified 2,3-unsaturated Neu5Ac derivatives and the 3,4- 
unsaturated analogues. 
 C5 and C4/C5 modified 2,3-usaturated Neu5Ac derivatives (sections 3.1 and 3.2) 
In this part of my PhD work, I elucidated the role played by some C4 and C5 DANA 
substituents in enhancing the inhibitory activity against NDV-HN. Remarkably, the combined 
approach of molecular docking, biological assays and organic synthesis allowed me to 
discover several new inhibitors that are 5- to 15-fold more active than the, previously reported, 
most active compound, the N-trifluoroacetyl derivative of DANA (FANA). Furthermore, the 
synthesized inhibitors showed a significant selectivity for NDV-HN, when compared to 
NEU3; these results are consistent with the different ability of Paramyxoviridae HN and 
human sialidases to accommodate bulky C4 substituents. In addition, a careful evaluation of 
the obtained results permitted me also to formulate some interesting hypothesis about the 
involvement of Lys236 as key basic amino acid in inhibitor-active site interactions. In fact, 
Induced Fit docking results, performed on one of the nanomolar inhibitors synthesized, 
compound 12a, having a p-toluensulfonamido substituent at C4, suggested that the sulfonyl 
group and the aromatic ring could give a hydrogen bonding and pi-cation interactions, 
respectively, with Lys236. Thus, considering the key role of this aminoacid in NDV-HN 
catalytic site (Site I) activation (together with Arg174) and its implication in a series of 
conformational changes triggering the fusion promotion activity and the activation of the 
second sialic acid binding site (Site II) 76, 118, some speculation about the potential additional 
roles of the synthesized inhibitors in hemagglutinin and fusion promotion activity, could be 
done. In this regards, some preliminary assays on the hemagglutinin inhibitory activity of 
these new inhibitors excluded their ability to directly block the second sialic binding site (Site 
II) present on NDV-HN, maintaining unaltered the hemagglutinin activity. On the other hand, 
further biological investigations are necessary to clarify their role in fusion promotion activity, 
investigating the real potentiality of these compounds as drug candidates. In light of this, I 
planned, in collaboration with the Virology Unit of Istituto Zooprofilattico Sperimentale delle 
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Venezie, some in-depth biological evaluations about the capacity of these molecules to inhibit 
viral replication in vitro and in vivo (unreported results).  
 3,4-usaturated Neu5Ac derivatives (sections 3.3) 
In the second part of my PhD work, I clarified some important issues of the synthetic protocols 
to achieved the 3,4-unsaturated derivatives of Neu5Ac in high anomeric β stereoselectivity. 
In particular, I understood the effect of the use of some catalysts on the Ferrier's reaction (the 
key reaction to achieve 3,4-usaturated Neu5Ac), and, as a consequence of this, I set-up the 
optimal conditions to obtain some 3,4-unsaturated derivatives of Neu5Ac, presenting different 
substitutions at anomeric carbon (C2) in high yields and high β stereoselectivity. In addition, 
I developed a smart tool for the rapid and correct anomeric configuration attribution, based on 
1,7-lactonization reaction. Furthermore, a deeply NMR spectra analysis allowed me to find a 
carbon signal that could be diagnostic for the discrimination between α and β anomers. 
All these findings permitted me to enrich the knowledge about these molecules, in order to 
give all the necessary tools to design new inhibitors based on these backbone, or to use them 
as useful intermediate in the synthesis of 2,3-unsaturated derivatives through a new and rapid 
way. 
Overall, these studies, focused on the development of specific and selective inhibitors towards 
the hemagglutinin-neuraminidase of NDV, contributed to enhance the knowledge about the 
highly flexible enzymatic active site of this protein and opened the way to the discovery of 
new potent paramyxoviruses HN inhibitors. 
The results presented in sections 3.1 and 3.2 allowed the publication of two scientific articles: 
 Rota, P., La Rocca, P., Piccoli, M., Montefiori, M., Cirillo, F., Olsen, L., Orioli, M., Allevi, P., and 
Anastasia, L. (2018) Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase, 
ChemMedChem 13, 236-240. 
 Rota, P., Papini, N., La Rocca, P., Montefiori, M., Cirillo, F., Piccoli, M., Scurati, R., Olsen, L., Allevi, 
P., and Anastasia, L. (2017) Synthesis and chemical characterization of several perfluorinated sialic 
acid glycals and evaluation of their in vitro antiviral activity against Newcastle disease virus, 
MedChemComm 8, 1505-1513.
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5.1 Chemistry 
General materials and methods. All chemicals and solvents used were of analytical grade 
and purchased from Sigma-Aldrich (St. Louis, MO, USA). Deionized water was prepared by 
filtering water on a Milli-Q Simplicity 185 filtration system from Millipore (Bedford, MA, 
USA).  All solvents were dried using standard methods and distilled before use. The progress 
of all reactions was monitored by thin-layer chromatography (TLC) carried out on 0.25 mm 
Sigma-Aldrich silica gel plates (60 F254) using UV light, anisaldehyde/H2SO4/EtOH solution 
or 0.2% ninhydrin in ethanol and heat as the developing agent. Flash chromatography was 
performed with normal phase silica gel (Sigma-Aldrich 230–400 mesh silica gel), following 
the general protocol of Still131.  
Nuclear magnetic resonance spectra were recorded at 303K on a Bruker AM-500 spectrometer 
equipped with a 5 mm inverse-geometry broadband probe and operating at 500.13 MHz for 
1H and 125.76 MHz for 13C. Chemical shifts are reported in parts per million and are 
referenced for 1H spectra, to a solvent residue proton signal (δ = 7.26 and 3.31 ppm, 
respectively, for CDCl3 and CD3OD) and for 13C spectra, to solvent carbon signal (central line 
at δ = 77.0 and 49.05 ppm, respectively, for CDCl3 and CD3OD). The chemical shifts obtained 
for D2O solution are referenced to the internal (CH3)3COH signal δ = 1.24 ppm for 1H spectra 
and δ = 30.29 ppm for 13C spectra.  The 1H and 13C resonances were assigned by 1H–1H 
(COSY) and 1H–13C (HSQC and HMBC) correlation 2D experiments.  The 1H NMR data are 
tabulated in the  following  order:  multiplicity  (s = singlet, d = doublet,  br  s = broad  singlet, 
t = triplet, m = multiplet),  coupling  constant(s)  (J)  are  given  in  hertz  ([Hz]),  number  of 
protons and assignment of proton(s). Optical rotations were taken on a Perkin-Elmer 241 
polarimeter equipped with a 1 dm tube; [α]D values are given in 10−1deg cm2g−1 and the 
concentrations are given in g per 100 mL. High-resolution mass spectrometry (HRMS) 
analyses were performed using a QTof  5600 ABSciexmass spectrometer equipped with an  
ESI  ion  source. The spectra were collected in continuous flow mode by connecting the 
integrated Harvard syringe pump directly to the ESI source. Compound solutions were infused 
at a flow rate of 0.01 mL min−1and the spray voltage was set at 4.5 kV in the negative ion 
mode with a capillary temperature of 400°C. Full-scan mass spectra were recorded by 
scanning a m/z range of 50–700. Mass spectrometry was performed by using a ABSciex 
4000Qtrap mass spectrometer equipped with an ESI ion source. The spectra were collected in 
a continuous flow mode by connecting the infusion pump directly to the ESI source. Solutions 
of the compounds were infused at a flow rate of 0.01 mL min−1, the spray voltage was set at 
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4.5 kV in the negative ion mode with a capillary temperature of 550 °C. Full-scan mass spectra 
were recorded by scanning a m/z range of 100–2000.  
The preparative HPLC purifications were performed on a Dionex Ultimate 3000 instrument 
equipped with a Dionex RS variable wavelength detector, using an Atlantis C-18-Preper T3 
ODB (5 µm, 19 X 10 mm) column and starting from 100% aqueous 0.1% (v/v) formic acid to 
100% CH3CN as the eluent. The crude product was dissolved in water and the solution was 
filtered (polypropylene, 0.45 µm, 13 mm ø, PK/100) and inJected into the HPLC, affording 
purified products. 
5.1.1 The 2,3-unsaturated derivatives: C5 substitutions (Chapter 3.1)  
5.1.1.1 Synthesis of precursor 7 
Preparation of methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dide-oxy-D-
glycero-D-talo-non-2-enonate (7). 
 
A solution of 5105 (615 mg, 1.3 mmol) in CH2Cl2 (7 mL) containing BF3Et2O (0.80 mL, 6.5 
mmol) was heated at 80°C for 15 min. Then, after cooling at 23°C Ac2O (2.8 mL, 30 mmol), 
Et3N (2.2 mL, 16 mmol) and H2O (2.3 mL, 130 mmol) were added and the solution was stirred 
for 10 min at 23°C. The crude was diluted with AcOEt and the organic layers were, at first, 
washed with saturated NaHCO3 solution then with water and dried over anhydrous Na2SO4. 
Then, a rapid chromatography (eluting with AcOEt) afforded glycal 7 (566 mg, 92 %): 1H 
NMR (500 MHz, CDCl3): δ = 6.15 (d, J3,4 = 5.4 Hz, 1H; H-3), 5.84 (d, JNH,5 = 10.1 Hz, 1H; 
NHCOCH3), 5.45 (dd, J7,6 = 2.1, J7,8 = 3.8 Hz, 1H; H-7), 5.26 (ddd, J8,9a = 2.7, J8,7= 3.8, J8,9b 
= 7.3 Hz, 1H; H-8), 5.11 (dd, J4,5 = 4.6, J4,3 = 5.4 Hz, 1H; H-4), 4.73 (dd, J9a,8 = 2.7, J9a,9b = 
12.4 Hz, 1H; H-9a), 4.53 (ddd, J5,4 = 4.6, J5,6 = J5,NH = 10.1 Hz, 1H; H-5), 4.24 (dd, J6,7 = 2.1, 
J6,5 = 10.1 Hz, 1H; H-6), 4.14 (dd, J9b,8 = 7.3, J9b,9a = 12.4 Hz, 1H; H-9b), 3.75 (s, 3H; 
COOCH3), 2.05 (overlapping, 6H; 2 X OCOCH3), 2.03 (s, 3H; OCOCH3), 2.01 (s, 3H; 
OCOCH3), 1.88 ppm (s, 3H; NHCOCH3). The other physico-chemical properties were in 
agreement with those previously reported110. 
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5.1.1.2 N-transacylation procedure for the synthesis of 4-hydroxy N-perfluoro 
acylneuraminic acid glycals 6a-c and 8a-c.  
General procedure.  
For 4α derivatives: to a solution of compound 5105 (0.20 mmol) in CH3CN (1 mL), Et3N (1.8 
mmol) and the appropriate perfluorinated anhydride (0.8 mmol) were added at 0 °C.  
For 4β derivatives: to a solution of compound 7110 (0.42 mmol), in CH3CN (2.1 mL), Et3N 
(3.8 mmol) and the appropriate perfluorinated anhydride (1.9 mmol) were added at 0 °C.  
The mixtures were warmed at 135 °C for 5-15 min in a sealed tube. Then, the reaction mixtures 
were cooled, quenched with methanol (10-20 µL) and evaporated under reduced pressure to 
afford crude residues. The crudes were diluted with AcOEt and the organic layers were, at 
first, washed with saturated NH4Cl solution then with water and dried over anhydrous Na2SO4. 
The organic solvents were concentrated under vacuum and the residues purified by silica gel 
chromatography using a suitable solvent system. 
Preparation of 4,7,8,9-tetra-O-acetyl-2,3-dehydro-2-deoxy-5-N-(2,2,2-trifluoroacetyl)-β-
neuraminic acid methyl ester (6a). 
 
The 4α-acetoxy glycal 5105 (95 mg, 0.20 mmol) was directly N-transacylated with 
trifluoroacetic anhydride (0.11 mL, 0.8 mmol) according to general procedure, to afford, after 
flash chromatography (eluting with hexane/AcOEt; 6:4, v/v), the fluorinated compound 6a as 
a white solid (83 mg, 79%): 1H NMR (500 MHz, CDCl3) δ = 7.21 (d, JNH,5 = 9.0 Hz, 1H; 
NHCOCH3), 5.97 (d, J3,4 = 2.6 Hz, 1H; H-3), 5.65 (dd, J4,3 = 2.6 Hz, J4,5 = 8.0, 1H; H-4), 5.47 
(dd, J7,6 = 3.0 Hz, J7,8 = 4.3, 1H; H-7), 5.29 (m, 1H; H-8), 4.71 (dd, J9a,8 = 2.6 Hz, J9a,9b = 12.4, 
1H; H-9a), 4.49 (dd, J6,7 = 3.0 Hz, J6,5 = 9.7, 1H; H-6), 4.34 (m, 1H; H-5), 4.18 (dd, J9b,8 = 7.3 
Hz, J9b,9a = 12.4, 1H; H-9b), 3.81 (s, 3H; COOCH3); 2.11 (s, 3H; OCOCH3 at C-7), 2.06 
(overlapping, 6H; 2 X OCOCH3), 2.04 ppm (s, 3H; OCOCH3). The other physico-chemical 
properties were in agreement with those previously reported102.  
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Preparation of 4,7,8,9-Tetra-O-acetyl-2,3-dehydro-2-deoxy-5-N-(2,2,3,3,3-pentafluoro 
propionyl)-β-neuraminic acid methyl ester (6b). 
 
The 4α-acetoxy glycal 5105 (95 mg; 0.20 mmol) was directly N-transacylated with 
pentafluoropropionic anhydride (0.16 mL, 0.8 mmol) according to general procedure to 
afford, after flash chromatography (eluting with hexane/AcOEt; 6:4, v/v), the fluorinated 
compound 6b as a white solid (90 mg, 78%): 1H NMR (500 MHz, CDCl3) δ = 7.10 (d, JNH,5 
= 9.3 Hz, 1H; NHCOCH3), 5.98 (d, J3,4 = 2.8 Hz, 1H; H-3), 5.70 (dd, J4,5 = 8.0, J4,3 = 2.8 Hz, 
1H; H-4), 5.43 (dd, J7,8 = 4.5, J7,6 = 3.0 Hz, 1H; H-7), 5.31 (m, 1H; H-8), 4.67 (1H, dd, J9a,9b 
= 12.4, J9a,8 = 2.9 Hz, H-9a), 4.51 (dd, J6,5 = 9.7, J6,7 = 3.0 Hz, 1H; H-6), 4.37 (m, 1H; H-5), 
4.19 (dd, J9b,9a = 12.4, J9b,8 = 6.8 Hz, 1H; H-9b), 3.84 (s, 3H; COOCH3), 2.13 (s, 3H; 
OCOCH3), 2.08 (s, 3H; OCOCH3), 2.06 (s, 3H; OCOCH3), 2.05 ppm (s, 3H; OCOCH3). The 
other physico-chemical properties were in agreement with those previously reported102. 
  
Preparation of 4,7,8,9-tetra-O-acetyl-2,3-dehydro-2-deoxy-5-N-(2,2,3,3,4,4,4-heptafluoro 
butanoyl)-β-neuraminic acid methyl ester (6c) 
 
The 4α-acetoxy glycal 5105 (95 mg; 0.20 mmol) was directly N-transacylated with 
heptafluorobutyric anhydride (0.19 mL, 0.8 mmol) according to general procedure to afford, 
after flash chromatography (eluting with hexane/AcOEt; 6:4, v/v), the fluorinated compound 
6c, as a white solid (102 mg, 81%): 1H NMR (500 MHz, CDCl3) δ = 7.21 (d, JNH,2 = 9.0 Hz, 
1H; NHCOCH3), 5.97 (d, J3,4 = 2.6 Hz, 1H; H-3), 5.70 (dd, J4,5 = 9.0, J4,3 = 2.6 Hz, 1H; H-4), 
5.43 (dd, J7,8 = 4.4, J7,6 = 2.8 Hz, 1H; H-7), 5.30 (m, 1H; H-8), 4.66 (dd, J9a,9b = 12.4, J9a,8 = 
2.6 Hz, 1H; H-9a), 4.53 (dd, J6,5 = 9.8, J6,7 = 2.8 Hz, 1H; H-6), 4.35 (q app., J5,4 = J5,6 = J5,NH 
= 9.0 Hz, 1H, H-5), 4.19 (dd, J9b,9a = 12.4, J9b,8 = 6.8 Hz, 1H; H-9b), 3.81 (s, 3H; COOCH3); 
2.14 (s, 3H; OCOCH3 at C-7), 2.07 (s, 3H; OCOCH3), 2.06 (s, 3H; OCOCH3), 2.00 (s, 3H; 
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OCOCH3). The other physico-chemical properties were in agreement with those previously 
reported102. 
Preparation of methyl 4,7,8,9-Tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-5-(2,2,2-trifluoro 
acetamido)-D-glycero-D-talo-non-2-enonate (8a) 
 
The 4β-acetoxy glycal 7110 (200 mg, 0.42 mmol) was directly N-transacylated with 
trifluoroacetic anhydride (0.26 mL, 1.9 mmol) according general procedure, to afford, after 
flash chromatography (eluting with hexane/AcOEt; 6:4, v/v), the fluorinated compound 8a as 
a white solid (186 mg, 84%): 1H NMR (500 MHz, CDCl3): δ = 6.76 (d, JNH;5 = 10.1 Hz, 1H; 
NHCOCH3), 6.21 (d, J3,4 = 5.5 Hz, 1H; H-3), 5.45 (dd, J7,6 = 2.5, J7,8 = 4.4 Hz, 1H; H-7), 5.30 
(ddd, J8,9a = 2.9, J8,7 = 4.4, J8,9b = 7.2 Hz, 1H; H-8), 5.26 (dd, J4,5 = 4.2, J4,3 = 5.5 Hz, 1H; H-
4), 4.72 (dd, J9a,8 = 2.9, J9a,9b = 12.4 Hz, 1 H; H-9a), 4.53 (ddd, J5,4 = 4.2, J5,6 = J5,NH = 10.1 
Hz, 1H; H-5), 4.39 (dd, J6,7 = 2.5, J6,5 = 10.1 Hz, 1H; H-6), 4.17 (dd, J9b,8 = 7.2, J9b,9a = 12.4 
Hz, 1H; H-9b), 3.80 (s, 3H; COOCH3), 2.10 (s, 3H; OCOCH3), 2.09 (s, 3H; OCOCH3), 2.07 
(s, 3 H; OCOCH3), 2.04 ppm (s, 3 H; OCOCH3). The other physico-chemical properties were 
in agreement with those previously reported110. 
Preparation of methyl 4,7,8,9-Tetra-O-acetyl-2,6-anhydro-5-(2,2,3,3,3-pentafluoropropion 
amido)-3,5-dideoxy-D-glycero-D-talo-non-2-enonate (8b) 
 
The 4β-acetoxy glycal 7110 (200 mg, 0.42 mmol) was directly N-transacylated with 
pentafluoro propionic anhydride (0.38 mL, 1.9 mmol) according to general procedure, to 
afford, after flash chromatography (eluting with hexane/AcOEt; 6:4, v/v), the fluorinated 
compound 8b as a white solid (198 mg, 82%): 1H NMR (500 MHz, CDCl3): δ = 6.85 (d, JNH,5 
= 9.7 Hz, 1H; NHCOCH3), 6.20 (d, J3,4 = 5.4 Hz, 1H; H-3), 5.44 (dd, J7,6 = 2.5, J7,8 = 4.4 Hz, 
1H; H-7), 5.32-5.27 (2H; overlapping, H-8 and H-4), 4.69 (dd, J9a,8 = 2.8, J9a,9b = 12.5 Hz, 
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1H; H-9a), 4.55 (ddd, J5,4 = 4.4, J5,NH = 9.7, J5,6 = 10.3 Hz, 1H; H-5), 4.39 (dd, J6,7 = 2.5, J6,5 
= 10.3 Hz, 1H; H-6), 4.16 (dd, J9b,8 = 7.0, J9b,9a = 12.5 Hz, 1H; H-9b), 3.80 (s, 3 H; OCOCH3), 
2.09 (6 H; overlapping, 2 X OCOCH3), 2.07 (s, 3 H; OCOCH3), 2.04 ppm (s, 3 H; OCOCH3). 
The other physico-chemical properties were in agreement with those previously reported110. 
Preparation of methyl 4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-5-(2,2,3,3,4,4,4-
heptafluorobutanamido)-D-glycero-D-talo-non-2-enonate (8c) 
 
The 4β-acetoxy glycal 7110 (200 mg, 0.42 mmol) was directly N-transacylated with 
heptafluorobutyric anhydride 0.45 mL, 1.9 mmol) according to general procedure, to afford, 
after flash chromatography (eluting with hexane/AcOEt; 6:4, v/v), the fluorinated compound 
8c as a white solid (210 mg, 80%): 1H NMR (500 MHz, CDCl3): δ = 6.62 (br s, 1H; NH), 6.22 
(d, J3,4 = 5.3 Hz, 1H; H-3), 5.46 (dd, J7,6 = 2.6, J7,8 = 4.5 Hz, 1H; H-7), 5.32 (ddd, J8,9a = 2.9, 
J8,7 = 4.5, J8,9b = 6.8 Hz, 1H; H-8), 5.28 (dd, J4,5 = 4.3, J4,3 = 5.3 Hz, 1H; H-4), 4.70 (dd, J9a,8 
= 2.9, J9a,9b = 12.4 Hz, 1H; H-9a), 4.60 (ddd, J5,4 = 4.3, J5,6 = J5,NH = 10.2 Hz, 1H; H-5), 4.39 
(dd, J6,7 = 2.6, J6,5 = 10.2 Hz, 1H; H-6), 4.18 (dd, J9b,8 = 6.8, J9b,9a = 12.4 Hz, 1H; H-9b), 3.81 
(s, 3H; COOCH3), 2.11–2.08 (overlapping, 9H; 3 X OCOCH3), 2.06 ppm (s, 3 H; OCOCH3). 
The other physico-chemical properties were in agreement with those previously reported110. 
5.1.1.3 Acylation procedure for the synthesis of 4-hydroxy N-perfluoro acylneuraminic acid 
glycals 10a,b and N-unfluoroacylneuraminic acid glycals 11a,b. 
To a solution of 94 (250 mg, 0.56 mmol) in CH2Cl2 (8 mL), under argon, Et3N (401 µL, 2.90 
mmol) and the appropriate perfluoroacyl chloride or normal acyl chloride (0.87 mmol) were 
added at 0 °C. The mixture was stirred at 23°C for 3-5 h and then purified by silica gel 
chromatography (hexane/AcOEt, 7:3, v/v) to achieve the desired compound 10a,b and 11a,b. 
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Preparation of methyl 4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-5-(perfluoropentan 
amido)-D-glycero-D-galacto-non-2-enonate (10a):  
 
Starting from intermediate 94 (250 mg, 0.56 mmol), according to general procedure using 
perfluoropentanoyl chloride (147 µL, 0.87 mmol), compound 10a was obtained (296 mg, 
78%) as a white solid, showing: [α]D23 = +58.6 (c=1.0 in chloroform); 1H NMR (500 MHz, 
CDCl3): δ = 7.37 (d, JNH,5 = 9.3 Hz, 1H; NHCOCH3), 5.95 (d, J3,4 = 2.6 Hz, 1H; H-3), 5.71 
(dd, J4,3 = 2.6, J4,5 = 8.2 Hz, 1H; H-4), 5.43 (dd, J7,6 = 2.4, J7,8 = 4.2 Hz, 1H; H-7), 5.29-5.26 
(m, 1H; H-8), 4.69 (dd, J9a,8 = 2.7, J9a,9b = 12.4 Hz, 1H; H-9a), 4.50 (dd, J6,7 = 2.4, J6,5 = 9.9 
Hz, 1H; H-6), 4.41-4.33 (m, 1H; H-5), 4.20 (dd, J9b,8 = 7.0, J9b,9a = 12.4 Hz, 1H; H-9b), 3.81 
(s, 3H; COOCH3), 2.13 (s, 3H; OCOCH3), 2.07 (s, 3H; OCOCH3), 2.05 (s, 3H; OCOCH3), 
2.04 ppm (s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): δ = 170.8, 170.8, 170.7, 170.0 
(4C; OCOCH3), 161.2 (C-1), 157.8 (t, JC,F = 27.2 Hz, COC4F9), 145.2 (C-2), 122.8-110.0 (4C; 
COC4F9), 107.7 (C-3), 75.8 (C-6), 71.3 (C-8), 67.6 and 67.4 (C-4 and C-7), 61.9 (C-9), 52.6 
(COOCH3), 47.5 (C-5), 20.8, 20.6, 20.5, 20.5 ppm (4C; OCOCH3); MS (ESI negative): m/z 
676.2 [M-H]-; elemental analysis calcd (%) for C23H24F9NO12: C 40.78, H 3.57, N 2.07; found: 
C 40.65, H 3.28, N 2.20.  
Preparation of methyl 4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-5 (perfluoro 
hexanamido)-D-glycero-D-galacto-non-2-enonate (10b):  
 
Starting from intermediate 94 (250 mg, 0.56 mmol), according to general procedure using 
perfluorohexanoyl chloride (174 µL, 0.87 mmol), compound 10b was obtained (306 mg, 75%) 
as a white solid, showing: [α]D23 = +53.0 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): 
δ = 7.40 (d, JNH,5 = 9.3 Hz, 1H; NHCOCH3), 5.94 (d, J3,4 = 2.7 Hz, 1H; H-3), 5.71 (dd, J4,3 = 
2.7, J4,5 = 8.3 Hz, 1H; H-4), 5.44 (dd, J7,6 = 2.6, J7,8 = 4.4 Hz, 1H; H-7), 5.27 (ddd, J8,9a = 2.8, 
J8,7 = 4.4, J8,9b = 7.1 Hz, 1H; H-8), 4.70 (dd, J9a,8 = 2.8, J9a,9b = 12.4 Hz, 1H; H-9a), 4.50 (dd, 
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J6,7 = 2.6, J6,5 = 10.0 Hz, 1H; H-6), 4.43-4.31 (m, 1H; H-5), 4.20 (dd, J9b,8 = 7.1, J9b,9a = 12.4 
Hz, 1H; H-9b), 3.81 (s, 3H; COOCH3), 2.12 (s, 3H; OCOCH3), 2.06 (s, 3H; OCOCH3), 2.05 
(s, 3H; OCOCH3), 2.04 ppm (s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): δ = 170.9, 
170.8, 170.7, 170.0 (4C; OCOCH3), 161.2 (C-1), 157.9 (t, JC,F = 27.0 Hz, COC5F11), 145.2 
(C-2), 122.8-110.0 (5C; COC5F11), 107.8 (C-3), 75.9 (C-6), 71.3 (C-8), 67.7 and 67.4 (C-4 
and C-7), 61.9 (C-9), 52.6 (COOCH3), 47.6 (C-5), 20.8, 20.6, 20.5, 20.4 ppm (4C; OCOCH3); 
MS (ESI negative): m/z 726.3 [M-H]- ; elemental analysis calcd (%) for C24H24F11NO12: C 
39.63, H 3.33, N 1.93; found: C 39.75, H 3.18, N 2.11.  
Acylation of compounds 11a and 11b: the data are not reported in this thesis but they were 
obtained according to general acylation procedure.  
5.1.1.4 Deacetylation and selective removal of esteric function  
General procedure. All the peracetylated glycals 5105, 6a-c, 3a, 8a-c, 10a,b and 11a,b  (0.14 
or 0.20 mmol) were treated with a methanolic solution of NaOMe, freshly prepared by 
dissolving sodium metal (5 mg, 0.22 mmol,) in anhydrous MeOH (2 mL). Each reaction 
mixture was stirred at 23°C for 1 h, and then quenched with acidic resin (Dowex 50WX8, H+). 
The resin was filtered off and washed with MeOH (2 mL X 3) and the combined filtrate and 
washes were evaporated under vacuum. Each crude compound was purified with flash 
chromatography and directly subjected to opportune selective hydrolysis (Method A or B): 
Method A: Selective hydrolysis using moist K2CO3 methanol solution. The free glycals 1a-c, 
2b-e, 3a, 4b,c were prepared by selective hydrolysis of appropriate methyl ester derivatives 
(0.10 mmol) performed in a methanol-water solution (0.54 mL, 10:1 v/v) containing K2CO3 
(9 mg), kept at 23°C for 6-24 h. At this time, the reaction mixture was treated with acidic resin 
(Dowex 50WX8, H+) until acidic pH, and then, the resin was filtered and washed with MeOH 
(2 mL X 3). Finally, the solvent was removed under reduced pressure and the residue was 
recovered with aqueous methanol and lyophilized to afford, after preparative HPLC, the 
desired free glycals.  
Method B: Selective hydrolysis using moist Et3N methanol solution. The free glycals 2a and 
3a was prepared by selective hydrolysis of its methyl ester derivative (0.10 mmol) performed 
in a methanol-water solution (1.0 mL, 2:1 v/v) containing Et3N (0.60 mL), kept at 23 °C for 
12 h. Then the mixture was treated with acidic resin (Dowex 50WX8, H+) until acidic pH and 
the resin was filtered and washed with MeOH (2 mL × 3). Finally, the solvent was removed 
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under reduced pressure and the residue was recovered with aqueous methanol and lyophilized, 
to afford, after preparative HPLC, the desired free glycals. 
Preparation of 2,6-anhydro-5-(2,2,3,3,3-pentafluoropropionamido)-3,5-dideoxy-D-glycero-
D-galacto-non-2-enoic acid (2b). 
O CO2H
OH
HN
HO
H
OH
OH
C2F5
O
2b
 
Starting from protected glycal 6b (80 mg, 0.14 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 2b was 
obtained (48 mg, 86%), as a white solid, showing: [α]D23= + 26.7 (c=1 in MeOH); 1H NMR 
(500 MHz, CD3OD): δ = 5.96 (d, J3,4 = 2.2 Hz, 1H; H-3), 4.50 (dd, J4,3 = 2.2, J4,5 = 9.0 Hz, 
1H; H-4), 4.41 (d app, J6,5 = 11.0 Hz, 1H; H-6), 4.24 (dd, J5,4 = 9.0, J5,6 = 11.0 Hz, 1H; H-5), 
3.86 (ddd, J8,9a = 2.9, J8,9b = 5.6, J8,7 = 9.2 Hz, 1H; H-8), 3.80 (dd, J9a,8 = 2.9, J9a,9b = 11.4 Hz, 
1H; H-9a), 3.62 (dd, J9b,8 = 5.6, J9b,9a 11.4 Hz, 1H; H-9b), 3.51 ppm (d app, J7,8 = 9.2 Hz, 1H; 
H-7); 13C NMR (125 MHz, CD3OD): δ = 165.6 (C-1), 160.0 (t, JC,F = 26 Hz, COC2F5), 145.3 
(C-2), 125.0–110.0 (2C; COC2F5), 113.6 (C-3), 77.2 (C-6), 71.5 (C-8), 70.1 (C-7), 68.0 (C-
4), 65.0 (C-9), 52.2 ppm (C-5); HRMS (ESI-TOF, m/z): calcd for C12H13F5NO8 [M-H]- 
394.0567, found 394.0559. 
Preparation of 2,6-anhydro-5-(2,2,3,3,4,4,4-heptafluorobutanamido)-3,5-dideoxy-D-glycero 
-D-galacto-non-2-enoic acid (2c).  
O CO2H
OH
HN
HO
H
OH
OH
C3F7
O
2c
 
Starting from protected glycal 6c (88 mg, 0.14 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 6c was 
obtained (52 mg, 84%), as a white solid, showing: [α]D23 = +19.9 (c=1 in MeOH); 1H NMR 
(500 MHz, CD3OD): δ = 5.96 (d, J3,4 = 2.3 Hz, 1H; H-3), 4.50 (dd, J4,3 = 2.3, J4,5 = 8.9 Hz, 
1H; 4-H), 4.41 (dd, J6,7 < 1.0, J6,5 = 11.0 Hz, 1H; H-6), 4.24 (dd, J5,4 = 8.9, J5,6 = 11.0 Hz, 1H; 
H-5), 3.89 (ddd, J8,9a = 2.8, J8,9b = 5.6, J8,7 = 9.2 Hz, 1H; H-8), 3.82 (dd, J9a,8 = 2.8, J9a,9b = 
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11.4 Hz, 1H; H-9a), 3.56 (dd, J9b,8 = 5.6, J9b,9a = 11.4 Hz, 1H; H-9b), 3.52 ppm (dd, J6,7 < 1.0, 
J7,8 = 9.2 Hz, 1H; H-7); 13C NMR (125 MHz, CD3OD): δ = 165.6 (C-1), 159.8 (t, JC–F = 26 
Hz, COC3F7), 145.3 (C-2), 122.0–110.0 (3C, COC3F7), 113.6 (C-3), 77.2 (C-6), 71.5 (C-8), 
70.2 (C-7), 67.9 (C-4), 65.0 (C-9), 52.3 ppm (C-5); HRMS (ESI-TOF, m/z): calcd for 
C13H13F7NO8 [M-H]- 444.0535, found 444.0551. 
Preparation of 2,6-anhydro-3,5-dideoxy-5-(perfluoropentanamido)-D-glycero-D-galacto-
non-2-enoic acid (2d) 
 
Starting from protected glycal 10a (135 mg, 0.20 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 2d was 
obtained (74 mg, 75%) as a white solid, showing: [α]D23= + 20.9 (c=1.0 in methanol); 1H NMR 
(500 MHz, CD3OD): δ = 5.95 (d, J3,4 = 2.2 Hz, 1H; H-3), 4.51 (dd, J4,3 = 2.2, J4,5 = 8.8 Hz, 
1H; H-4), 4.41 (dd, J6,7 < 1.0, J6,5 = 10.9 Hz, 1H; H-6), 4.24 (dd, J5,4 = 8.8, J5,6 = 10.9 Hz, 1H; 
H-5), 3.88 (ddd, J8,9a = 3.0, J8,9b = 5.7, J8,7 = 9.1 Hz, 1H; H-8), 3.84 (dd, J9a,8 = 3.0, J9a,9b = 
11.4 Hz, 1H; H-9a), 3.62 (dd, J9b,8 = 5.7, J9b,9a = 11.4 Hz, 1H; H-9b), 3.53 ppm (dd, J7,6 < 1.0, 
J7,8 = 9.1 Hz, 1H; H-7); 13C NMR (125 MHz, CD3OD): δ = 165.8 (C-1), 159.8 (t, JC,F = 26.1 
Hz, 1C; COC4F9), 145.4 (C-2), 122.8-110.0 (4C; COC4F9), 113.5 (C-3), 77.2 (C-6), 71.6 (C-
8), 70.2 (C-7), 67.9 (C-4), 65.0 (C-9), 52.4 ppm (C-5); MS (ESI negative): m/z 494.2 [M-H]- 
; elemental analysis calcd (%) for C14H14F9NO8: C 33.95, H 2.85, N 2.83; found: C 33.87, H 
2.97, N 2.70. 
Preparation of 2,6-anhydro-3,5-dideoxy-5-(perfluorohexanamido)-D-glycero-D-galacto non -
2-enoic acid (2e).  
 
Starting from protected glycal 10b (145 mg, 0.20 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 2e was 
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obtained (82 mg, 75%) as a white solid, showing: [α]D23= +19.7 (c=1.0 in methanol); 1H NMR 
(500 MHz, CD3OD): δ = 5.97 (d, J3,4 < 1.0 Hz, 1H; H-3), 4.50 (dd, J4,3 < 1.0, J4,5 = 8.8 Hz, 
1H; H-4), 4.43 (dd, J6,7 < 1.0, J6,5 = 10.9 Hz, 1H; H-6), 4.27-4.21 (m, 1H; H-5), 3.91-3.86 (m, 
1H; H-8), 3.83 (dd, J9a,8 = 2.5, J9a,9b = 11.4 Hz, 1H; H-9a), 3.62 (dd, J9b,8 = 5.7, J9b,9a = 11.4 
Hz, 1H; H-9b), 3.54 ppm (dd, J7,6 < 1.0, J7,8 = 9.2 Hz, 1H; H-7); 13C NMR (125 MHz, 
CD3OD): δ = 165.7 (C-1), 159.8 (t, JC,F = 26.1 Hz, COC5F11), 145.2 (C-2), 122.8-110.0 (5C; 
COC5F11), 113.7 (C-3), 77.1 (C-6), 71.5 (C-8), 70.2 (C-7), 67.9 (C-4), 65.0 (C-9), 52.3 ppm 
(C-5); MS (ESI negative): m/z 544.2 [M-H]-; elemental analysis calcd (%) for C15H14F11NO8: 
C 33.04, H 2.59, N 2.57; found: C 33.22, H 2.48, N 2.44. 
Preparation of 2,6-anhydro-5-acetamido-3,5-dideoxy-D-glycero-D-talo-non-2-enoic acid 
(3a).  
 
Starting from protected glycal 7110 (66 mg, 0.14 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 3a was 
obtained (31 mg, 75%), as a white solid, showing: [α]D23 = -98.9 (c=1 in MeOH); 1H NMR 
(500 MHz, CD3OD): δ = 6.02 (d, J3,4 = 5.0 Hz, 1H; H-3), 4.27-4.14 (overlapping, 3H; H-4, 
H-6 and H-5), 3.92 (ddd, J8,9a = 2.3, J8,9b = 5.3, J8,7 = 9.2 Hz, 1H; H-8), 3.83 (dd, J9a,8 = 2.3, 
J9a,9b = 11.4 Hz, 1H; H-9a), 3.67 (dd, J9b,8 = 5.3, J9b,9a = 11.4 Hz, 1H; H-9b), 3.58 (d app, J7,8 
= 9.2 Hz, 1H; 7-H), 2.05 ppm (s, 3H; NHCOCH3); 13C NMR (125 MHz, CD3OD): δ = 174.2 
(C-1), 167.5 (NHCOCH3), 148.2 (C-2), 108.6 (C-3), 73.3 (C-6), 71.5 (C-8), 70.1 (C-7), 65.0 
(C-9), 62.1 (C-5), 49.4 (C-4), 22.8 ppm (NHCOCH3); HRMS (ESI-TOF, m/z): calcd for 
C11H16NO8 [M-H]- 290.0881, found 290.0855. 
Preparation of 2,6-anhydro-5-(2,2,2-trifluoroacetamido)-3,5-dideoxy-D-glycero-D-talo-non-
2-enoic acid (4a). 
 
 
Starting from protected glycal 8a (74 mg, 0.14 mmol), according to the general two-step 
5. Experimental 
 
 
97 
 
procedure Zemplén reaction followed by selective hydrolytic method B, glycal 4a was 
obtained (42 mg, 87%), as a white solid, showing: m.p. 112–114 °C (from MeOH-
diisopropylether); [α]D23 = -98.8 (c=1 in MeOH); 1H NMR (500 MHz, CD3OD): δ = 6.14 (d, 
J3,4 = 5.6 Hz, 1H; H-3), 4.45 (d app, J6,5 = 11.3 Hz, 1H; 6-H), 4.32 (dd, J5,4 = 3.4, J5,6 = 11.3 
Hz, 1H; H-5), 4.28-4.23 (m, 1H; H-4), 4.00 (ddd, J8,9a = 2.1, J8,9b = 5.4, J8,7 = 9.2 Hz, 1H; H-
8), 3.84 (dd, J9a,8 = 2.1, J9a,9b = 11.4 Hz, 1H; 9a-H), 3.67 (dd, J9b,8 = 5.4, J9b,9a = 11.4 Hz, 1H; 
9b-H), 3.67 ppm (d app, J7,8 = 9.2 Hz, 1H; 7-H); 13C NMR (125 MHz, CD3OD): δ = 165.8 (C-
1), 158.9 (q, JC,F = 37 Hz, 1C; COCF3), 146.4 (C-2), 121.0-114.0 (q, JC,F = 287 Hz, COCF3), 
110.4 (C-3), 72.9 (C-6), 71.8 (C-8), 69.9 (C-7), 64.9 (C-9), 61.3 (C-5), 50.1 ppm (C-4); HRMS 
(ESI-TOF, m/z): calcd for C11H13F3NO8 [M-H]- 344.0599, found 344.0583. 
Preparation of 2,6-anhydro-5-(2,2,3,3,3-pentafluoropropionamido)-3,5-dideoxy-D-glycero-
D-talo-non-2-enoic acid (4b).  
 
Starting from protected glycal 8b (81 mg, 0.14 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 4b was 
obtained (40 mg, 72%), as a white solid, showing: m.p. 107-109 °C (from MeOH-
diisopropylether); [α]D23 = -119.2 (c=1 in methanol); 1H NMR (500 MHz, CD3OD): δ = 6.14 
(d, J3,4 = 5.7 Hz, 1H; H-3), 4.46 (d app, J6,5 = 11.4 Hz, 1H; H-6), 4.36 (dd, J5,4 = 3.6, J5,6 = 
11.4 Hz, 1H; H-5), 4.27–4.23 (m, 1H; H-4), 3.91 (ddd, J8,9a = 2.7, J8,9b = 5.6, J8,7 = 9.2 Hz, 
1H; H-8), 3.84 (dd, J9a,8 = 2.7, J9a,9b = 11.4 Hz, 1H; H-9a), 3.65 (dd, J9b,8 = 5.6, J9b,9a = 11.4 
Hz, 1H; H-9b), 3.57 ppm (d app, J7,8 = 9.2 Hz, 1H; H-7); 13C NMR (125 MHz, CD3OD): δ = 
165.8 (C-1), 159.4 (t, JC,F = 26 Hz, COC5F5), 146.4 (C-2), 123.0-106.0 (2C, C5F5), 110.5 (C-
3), 72.9 (C-6), 71.8 (C-8), 70.0 (C-7), 65.0 (C-9), 61.3 (C-5), 50.1 ppm (C-4); HRMS (ESI-
TOF, m/z): calcd for C12H13F5NO8 [M-H]- 394.0567, found 394.0560. 
  
5. Experimental 
 
 
98 
 
Preparation of 2,6-anhydro-5-(2,2,3,3,4,4,4-heptafluorobutanamido)-3,5-dideoxy-D-glycero 
-D-talo-non-2-enoic acid (4c).  
 
Starting from protected glycal 8c (88 mg, 0.14 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 4c was 
obtained (44 mg, 71%), as a white solid, showing: [α]D23 = -103.6 (c=1 in methanol); 1H NMR 
(500 MHz CD3OD): δ = 6.13 (d, J3,4 = 5.6 Hz, 1H; H-3), 4.47 (d app, J6,5 = 11.3 Hz, 1H; H-
6), 4.36 (dd, J5,4 = 3.2, J5,6 = 11.3 Hz, 1H; H-5), 4.24 (dd, J4,5 = 3.2, J4,3 = 5.6 Hz, 1H; H-4), 
3.91 (ddd, J8,9a = 2.1, J8,9b = 5.6, J8,7  = 9.1 Hz, 1H; H-8), 3.85 (dd, J9a,8 = 2.1, J9a,9b = 11.4 Hz, 
1H; H-9a), 3.65 (dd, J9b,8 = 5.6, J9b,9a = 11.4 Hz, 1H; H-9b), 3.58 (d app, J7,8 = 9.1 Hz, 1H; H-
7); 13C NMR (125 MHz, CD3OD): δ = 166.0 (C-1), 159.2 (t, JC,F 26 Hz, 1C COC3F7), 146.5 
(C2), 121.0–106.0 (3C, COC3F7), 110.3 (C-3), 72.9 (C-6), 71.9 (C8), 70.1 (C-7), 65.0 (C-9), 
61.3 (C-5), 50.2 ppm (C-4); HRMS (ESI-TOF, m/z): calcd for C13H13F7NO8 [M-H]− 
444.0535, found 444.0535. 
Preparation of 2,6-anhydro-5-propionamido-3,5-dideoxy-D-glycero-D-galacto-non-2-enoic 
acid (1b).  
 
Starting from protected glycal 11a (68 mg, 0.14 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 1b was 
obtained (30 mg, 71%), as a white solid, showing: 1H NMR (500 MHz, CD3OD): δ = 5.87 (br 
s, 1H; H-3), 4.42 (d app, J4,5 = 8.3 Hz, 1H; H-4), 4.15 (d app, J6,5 = 10.7 Hz, 1H; H-6), 3.99 
(dd, J5,4 = 8.7, J5,6 = 10.7 Hz, 1H; H-5), 3.93–3.86 (m, 1H; H-8), 3.82 (d app, J9a,9b = 11.3 Hz, 
1H; H-9a), 3.65 (dd, J9b,8 = 4.9, J9b,9a = 11.3 Hz, 1H; H-9b), 3.55 (d app, J7,8 = 8.9 Hz, 1H; H-
7), 2.32 (q, JH,H = 7.5 Hz, 2H; COCH2), 1.16 ppm (t, JH,H = 7.5 Hz, 3H; COCH2CH3); 13C 
NMR (125 MHz, CD3OD): δ = 178.7 (C-1), 165.6 (NHCOCH3), 145.5 (C-2), 111.8 (C-3), 
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77.9 (C-6), 71.3 (C-8), 70.3 (C-7), 68.2 (C-4), 65.0 (C-9), 51.9 (C5), 30.2 (COCH2), 10.3 ppm 
(COCH2CH3); MS (ESI negative, m/z): calcd for C12H19NO8 [M-H]- 304.1, found 304.2. 
Preparation of 2,6-anhydro-5-butyramido-3,5-dideoxy-D-glycero-D-galacto-non-2-enoic acid 
(1c).  
 
Starting from protected glycal 11b (70 mg, 0.14 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 1c was 
obtained (32 mg, 71%), as a white solid, showing: 1H NMR (500 MHz, CD3OD): δ = 5.97 (d, 
J3,4 = 2.1 Hz, 1H; H-3), 4.46 (dd, J4,3 = 2.1, J4,5 = 8.7 Hz, 1H; H-4), 4.19 (d app, J6,5 = 10.8 
Hz, 1H; H-6), 4.02 (dd, J5,4 = 8.7, J5,6 = 10.8 Hz, 1H; H-5), 3.92 (ddd, J8,9a=  2.6, J8,9b = 5.4, 
J8,7 = 9.1 Hz, 1H; H-8), 3.85 (dd, J9a,8 = 2.6, J9a,9b = 11.4 Hz, 1H; H-9a), 3.66 (dd, J9b,8 = 5.4, 
J9b,9a = 11.4 Hz, 1H; H-9b), 3.59 (d app, J7,8 = 9.1 = Hz, 1H; H-7), 2.30 (t, JH,H = 7.2 Hz, 2H; 
COCH2CH2CH3, 1.70 (m, 2H COCH2CH2CH3), 1.00 ppm (t, JH,H = 7.2 Hz, 3H; 
COCH2CH2CH3); 13C NMR (125 MHz, CD3OD): δ = 178.1 (C-1), 165.6 (NHCOCH3), 145.5 
(C-2), 113.5 (C-3), 78.2 (C-6), 71.1 (C-8), 70.4 (C-7), 68.0 (C-4), 65.1 (C-9), 51.9 (C-5), 39.0 
(COCH2CH2CH3), 20.3 (COCH2CH2CH3), 14.1 ppm (COCH2CH2CH3); MS (ESI negative, 
m/z): calcd for C13H21NO8 [M-H]- 318.1, found 318.1. 
  
5. Experimental 
 
 
100 
 
5.1.2 The 2,3-unsaturated derivatives: C4/C5 combined substitutions 
5.1.2.1 N-transacylation procedure for the synthesis of 4-azido N-perfluoro acylneuraminic 
acid glycals (18b-d).  
General procedure. To a solution of compound 154 (1.32 mmol) in CH3CN (6.6 mL) was 
added Et3N (11.9 mmol) and the appropriate perfluorinated anhydride (5.94 mmol) at 0 °C. 
The mixture was warmed at 135 °C for 5-15 min in a sealed tube. Then, the reaction mixture 
was cooled, quenched with methanol (0.20 mL) and evaporated under reduced pressure to 
afford a crude residue. The crude was diluted with AcOEt and the organic layers were, at first, 
washed with saturated NH4Cl solution then with water and dried over anhydrous Na2SO4. The 
organic solvent was concentrated under vacuum and the residue purified by silica gel 
chromatography using a suitable solvent system. 
Preparation of methyl 7,8,9-tri-O-acetyl-2,6-anhydro-4-azido-3,4,5-trideoxy-5-(2,2,2- 
trifluoroacetamido)-D-glycero-D-galacto-non-2-enonate (18b):  
 
Starting from protected glycal 154 (600 mg, 1.32 mmol), according to the general procedure 
using trifluoroacetic anhydride (832 µL, 5.94 mmol) and after purification by silica gel 
chromatography (hexane/AcOEt, 65:35, v/v), glycal 18b was obtained (538 mg, 80%) as a 
white solid, showing: [α]D23 = +106.2 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ 
= 7.36 (d, JNH,5 = 8.5 Hz, 1H; NH), 6.00 (d, J3,4 = 2.6 Hz, 1H; H-3), 5.40 (dd, J7,6 = 2.2, J7,8 = 
5.2 Hz, 1H; H-7), 5.30 (ddd, J8,9a = 2.8, J8,7 = 5.2, J8,9b = 6.7 Hz, 1H; H-8), 4.69 (dd, J9a,8 = 
2.8, J9a,9b = 12.4 Hz, 1H; H-9a), 4.51 (dd, J6,7 = 2.2, J6,5 = 10.1 Hz, 1H; H-6), 4.46 (dd, J4,3 = 
2.6, J4,5 = 9.0 Hz, 1H; H-4), 4.15 (dd, J9b,8 = 6.7, J9b,9a = 12.4 Hz, 1H; H-9b), 3.99-3.92 (m, 
1H; H-5), 3.81 (s, 3H; COOCH3), 2.13 (s, 3H; OCOCH3), 2.06 (s, 3H; OCOCH3), 2.04 ppm 
(s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): δ = 171.0, 170.4, 170.3 (3C; OCOCH3), 
161.3 (C-1), 157.7 (q, JC,F = 38.1 Hz, 1C; COCF3), 145.2 (C-2), 115.4 (q, JC,F = 287.8 Hz, 1C; 
COCF3), 107.1 (C-3), 75.0 (C-6), 70.5 (C8), 67.5 (C-7), 61.8 (C-9), 57.0 (C-4), 52.7 
(COOCH3), 49.1 (C-5), 20.8, 20.6, 20.6 ppm (3C; OCOCH3); MS (ESI negative): m/z 509.3 
[M-H]- ; elemental analysis calcd (%) for C18H21F3N4O10: C 42.36, H 4.15, N 10.98; found: C 
42.15, H 4.11, N 10.80.  
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Preparation of methyl 7,8,9-tri-O-acetyl-2,6-anhydro-4-azido-3,4,5-trideoxy-5-(2,2,3,3,3- 
pentafluoropropionamido)-D-glycero-D-galacto-non-2-enonate (18c): 
 
Starting from protected glycal 154 (600 mg, 1.32 mmol), according to the general procedure 
using pentafluoropropionic anhydride (1.15 mL, 5.94 mmol) and after purification by silica 
gel chromatography (hexane/AcOEt, 7:3, v/v), glycal 18c was obtained (576 mg, 78%) as a 
white solid, showing: [α]D23 = +71.3 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 
7.57 (d, JNH,5 = 8.3 Hz, 1H; NHCOCH3), 5.98 (d, J3,4 = 2.6 Hz, 1H; H-3), 5.35 (dd, J7,6 = 1.9, 
J7,8 = 5.2 Hz, 1H; H-7), 5.26 (ddd, J8,9a = 2.7, J8,7 = 5.2, J8,9b = 6.6 Hz, 1H; H-8), 4.67 (dd, J9a,8 
= 2.7, J9a,9b = 12.5 Hz, 1H; H-9a), 4.53 (dd, J6,7 = 1.9, J6,5 = 10.3 Hz, 1H; H-6), 4.48 (dd, J4,3 
= 2.6, J4,5 = 9.1 Hz, 1H; H-4), 4.15 (dd, J9b,8 = 6.6, J9b,9a = 12.5 Hz, 1H; H-9b), 3.96-3.89 (m, 
1H; H-5), 3.80 (s, 3H; COOCH3), 2.11 (s, 3H; OCOCH3), 2.03 (s, 3H; OCOCH3), 2.02 ppm 
(s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): δ = 171.0, 170.4, 170.3 (3C; OCOCH3), 
161.2 (C1), 158.3 (t, JC,F = 26.6 Hz, 1C; COC2F5), 145.2 (C-2), 122.0-104.0 (2C; COC2F5), 
107.1 (C-3), 74.9 (C-6), 70.6 (C-8), 67.5 (C-7), 61.8 (C-9), 57.1 (C-4), 52.6 (COOCH3), 49.3 
(C-5), 20.6, 20.5, 20.4 ppm (3C; OCOCH3); MS (ESI negative): m/z 559.3 [M-H]- ; elemental 
analysis calcd (%) for C19H21F5N4O10: C 40.72, H 3.78, N 10.00; found: C 40.57, H 3.75, N 
10.21. 
Preparation of methyl 7,8,9-tri-O-acetyl-2,6-anhydro-4-azido-3,4,5-trideoxy-5-(2,2,3,3, 
4,4,4- heptafluorobutyramido)-D-glycero-D-galacto-non-2-enonate (18d):  
 
Starting from protected glycal 154 (600 mg, 1.32 mmol), according to the general procedure 
using heptafluorobutyric anhydride (1.43 mL, 5.94 mmol) and after purification by silica gel 
chromatography (hexane/AcOEt, 7:3, v/v), glycal 18d was obtained (628 mg, 78%) as a white 
solid, showing: [α]D23 = +67.3 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ =7.29 
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(d, JNH,5 = 8.2 Hz, 1H; NHCOCH3), 6.04 (d, J3,4 = 2.7 Hz, 1H; H-3), 5.38-5.31 (overlapping, 
2H; H-7 and H-8), 4.72 (dd, J4,3 = 2.7, J4,5 = 8.9 Hz, 1H; H-4), 4.65-4.59 (overlapping, 2H; 
H-6 and H-9a), 4.23 (dd, J9b,8 = 5.1, J9b,9a = 12.4 Hz, 1H; H-9b), 3.85 (s, 3H; COOCH3), 3.76-
3.68 (m, 1H; H-5), 2.17 (s, 3H; OCOCH3), 2.08 (s, 3H; OCOCH3), 2.05 ppm (s, 3H; 
OCOCH3); 13C NMR (125 MHz, CDCl3): δ =170.8, 170.7, 170.1 (3C; OCOCH3), 161.3 (C-
1), 158.2 (JC,F = 38.1 Hz, 1C; COC3F7), 145.1 (C-2), 122.0-108.0 (3C; COC3F7), 106.9 (C-3), 
73.9 (C-6), 69.8 (C-8), 67.5 (C-7), 61.6 (C-9), 56.1 (C-4), 52.7 (COOCH3), 50.4 (C-5), 20.7, 
20.6, 20.4 ppm (3C; OCOCH3); MS (ESI negative): m/z 609.3 [M-H]-; elemental analysis 
calcd (%) for C20H21F7N4O10: C 39.35, H 3.47, N 9.18; found: C 39.56, H 3.38, N 9.21. 
5.1.2.2 Hydrogenation procedure for the synthesis of 4-amino N-perfluoro acylneuraminic 
acid glycals (19b-d).  
General procedure. To a solution of each azido derivative 18b-d (0.80 mmol) in EtOH (10 
mL) was added Lindlar catalyst (80 mg), and the mixture was stirred at 23°C o/n under H2 
atmosphere. Then, the catalyst was filtered off over Celite, and the “Celite bed” was washed 
with MeOH (10 mL X 3). The combined filtrates were evaporated under reduced pressure, 
and the residue was purified by silica gel chromatography using the appropriate solvent 
system to achieve the desired amino compounds 19b-d. 
Preparation of methyl 7,8,9-tri-O-acetyl-4-amino-2,6-anhydro-3,4,5-trideoxy-5-(2,2,2- 
trifluoroacetamido)-D-glycero-D-galacto-non-2-enonate (19b): 
 
Starting from protected compound 18b (408 mg, 0.80 mmol), according to general 
hydrogenation procedure followed by silica gel purification chromatography (eluting with 
AcOEt/hexane, 9:1, v/v to AcOEt/MeOH, 95:5, v/v), the glycal 19b was obtained (264 mg, 
68%) as a white solid, showing: [α]D23= + 66.3 (c=1.0 in chloroform); 1H NMR (500 MHz, 
CDCl3): δ = 7.46 (d, JNH,5 = 9.2 Hz, 1H; NHCOCH3), 6.95 (d, J3,4 = 2.4 Hz, 1H; H-3), 5.43 
(dd, J7,6 = 2.4, J7,8 = 4.5 Hz, 1H; H-7), 5.27 (ddd, J8,9a = 2.8, J8,7 = 4.5, J8,9b = 7.3 Hz, 1H; H-
8), 4.72 (dd, J9a,8 = 2.8, J9a,9b = 12.4 Hz, 1H; H-9a), 4.36 (dd, J6,7 = 2.4, J6,5 = 9.8 Hz, 1H; H-
5. Experimental 
 
 
103 
 
6), 4.14 (dd, J9b,8 = 7.3, J9b,9a = 12.4 Hz, 1H; H-9b), 3.88-3.81 (m, 1H; H-5), 3.77 (s, 3H; 
COOCH3), 3.66 (dd, J4,3 = 2.4, J4,5 = 8.8 Hz, 1H; H-4), 2.09 (s, 3H; OCOCH3), 2.02 (s, 6H; 
OCOCH3), 1.75-1.70 ppm (br s, 2H; NH2); 13C NMR (125 MHz, CDCl3): δ = 170.9, 170.4, 
170.1 (3C; OCOCH3), 161.9 (C-1), 157.9 (q, JC,F = 37.8 Hz, 1C; COCF3), 143.2 (C-2), 115.6 
(q, JC,F = 288.0 Hz, 1C; COCF3), 114.0 (C-3), 75.8 (C-6), 71.2 (C-8), 67.9 (C-7), 62.0 (C-9), 
52.4 (COOCH3), 51.8 (C-5), 49.8 (C-4), 20.7, 20.6, 20.5 ppm (3C; OCOCH3); MS (ESI 
negative): m/z 483.2 [M-H]- ; elemental analysis calcd (%) for C18H23F3N2O10: C 44.63, H 
4.79, N 5.78, O 33.03; found: C 44.89, H 4.92, N 5.60.  
Preparation of methyl 7,8,9-tri-O-acetyl-4-amino-2,6-anhydro-3,4,5-trideoxy-5-(2,2,3,3,3- 
pentafluoropropionamido)-D-glycero-D-galacto-non-2-enonate (19c):  
 
Starting from protected compound 18c (446 mg, 0.80 mmol), according to general 
hydrogenation procedure followed by silica gel purification chromatography (eluting with 
AcOEt/hexane, 85:15, v/v), the glycal 19c was obtained (321 mg, 75%) as a white solid, 
showing: [α]D23 = +67.8 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 7.05 (d, JNH,5 
= 7.9 Hz, 1H; NHCOCH3), 5.98 (d, J3,4 = 2.3 Hz, 1H; H-3), 5.40 (dd, J7,6 = 2.5, J7,8 = 5.1 Hz, 
1H; H-7), 5.33 (ddd, J8,9a = 2.8, J8,7 = 5.1, J8,9b = 6.4 Hz, 1H; H-8), 4.64 (dd, J9a,8 = 2.8, J9a,9b 
= 12.4 Hz, 1H; H-9a), 4.45 (dd, J6,7 = 2.5, J6,5 = 9.1 Hz, 1H; H-6), 4.18 (dd, J9b,8 = 6.4, J9b,9a = 
12.4 Hz, 1H; H-9b), 3.85-3.72 (overlapping, 5H; H-4, COOCH3 and H-5), 2.12 (s, 3H; 
OCOCH3), 2.06 (s, 3H; OCOCH3), 2.04 (s, 3H; OCOCH3), 1.70-1.57 ppm (br s, 2H; NH2); 
13C NMR (125 MHz, CDCl3): δ = 170.9, 170.6, 170.0 (3C; OCOCH3), 162.0 (C-1), 158.5 (t, 
JC,F = 26.3 Hz, 1C; COC2F5), 143.1 (C-2), 122.0-103.0 (2C; COC2F5), 113.8 (C-3), 75.6 (C-
6), 71.3 (C-8), 67.9 (C-7), 62.0 (C-9), 52.3 (COOCH3), 52.0 (C-5), 49.6 (C-4), 20.6, 20.5, 
20.4 ppm (3C; OCOCH3); MS (ESI negative): m/z 533.2 [M-H]-; elemental analysis calcd (%) 
for C19H23F5N2O10: C 42.70, H 4.34, N 5.24; found: C 42.45, H 4.12, N 4.99.  
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Preparation of methyl 7,8,9-tri-O-acetyl-4-amino-2,6-anhydro-3,4,5-trideoxy-5-(2,2,3,3, 
4,4,4-heptafluorobutyramido)-D-glycero-D-galacto-non-2-enonate (19d):  
 
Starting from protected compound 18d (488 mg, 0.80 mmol), according to general 
hydrogenation procedure followed by silica gel purification chromatography (eluting with 
AcOEt/hexane, 9:1, v/v to AcOEt/MeOH, 95:5, v/v), the glycal 19d was obtained (328 mg, 
70%) as a white solid, showing: [α]D23 = +62.5 (c=1.0 in chloroform); 1H NMR (500MHz, 
CDCl3): δ = 7.09 (d, JNH,5 = 8.3 Hz, 1H; NHCOCH3), 5.99 (d, J3,4 = 2.7 Hz, 1H; H-3), 5.40 
(dd, J7,6 = 2.4, J7,8 = 5.7 Hz, 1H; H-7), 5.36 (ddd, J8,9a = 2.8, J8,7 = 5.7, J8,9b = 5.9 Hz, 1H; H-
8), 4.59 (dd, J9a,8 = 2.8, J9a,9b = 12.5 Hz, 1H; H-9a), 4.50 (dd, J6,7 = 2.4, J6,5 = 9.7 Hz, 1H; H-
6), 4.21 (dd, J9b,8 = 5.9, J9b,9a = 12.5 Hz, 1H; H-9b), 3.93 (dd, J4,3 = 2.7, J4,5 = 8.5 Hz, 1H; H-
4), 3.80 (s, 3H; COOCH3), 3.74-3.66 (m, 1H; H-5), 2.72-2.59 (br s, 2H; NH2), 2.13 (s, 3H; 
OCOCH3), 2.06 (s, 3H; OCOCH3), 2.04 ppm (s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): 
δ = 170.7, 170.3, 170.0 (3C; OCOCH3), 162.0 (C-1), 158.2 (t, JC,F = 26.3 Hz, 1C; COC3F7), 
143.2 (C-2), 123.0-107.0 (3C; COC3F7), 113.6 (C-3), 75.1 (C-6), 70.6 (C-8), 67.9 (C-7), 61.9 
(C-9), 53.0 (COOCH3), 52.4 (C-5), 48.9 (C-4), 20.7, 20.5, 20.5 ppm (3C; OCOCH3); MS (ESI 
negative): m/z 583.3 [M-H]-; elemental analysis calcd (%) for C20H23F7N2O10: C 41.11, H 
3.97, N 4.79; found: C 44.31, H 3.80, N 4.92. 
5.1.2.3 Acylation procedure for the synthesis of 4-p-toluensolfonamido N-perfluoro 
acylneuraminic acid glycals (20b-d).  
General procedure. To a solution of each C4 amino N-perfluoro glycal 19b-d (0.50 mmol) in 
CH2Cl2 (6.7 mL) containing Et3N (246 µL, 2.50 mmol), cooled at 0 °C, the p-toluenesulfonyl 
chloride (143 mg, 0.75 mmol) was added. The mixture was stirred at 23°C for 2-5 h and then 
purified by silica gel chromatography (hexane/AcOEt, 7:3, v/v) to achieve the desired 
compounds 20b-d. 
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Preparation of methyl 7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-trideoxy-5-(2,2,2-trifluoro 
acetamido)-4-[(4- methylphenyl)sulfonamide]-D-glycero-D-galacto-non-2-enonate (20b)  
 
Starting from protected glycal 19b (255 mg, 0.50 mmol), according to the general acylation 
procedure glycal 20b was obtained (273 mg, 81%) as a white solid, showing: [α]D23 = +59.5 
(c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 7.68 (overlapping, 2H; Ph), 7.55 (d, 
JNH,5 = 9.1 Hz, 1H; NHCOCH3 at C-5), 7.27 (overlapping, 2H; Ph), 5.69 (d, J3,4 = 2.3 Hz, 1H; 
H-3), 5.60 (d, JNH,4 = 9.4 Hz, 1H; NHCOCH3 at C-4), 5.39 (dd, J7,6 = 1.8, J7,8 = 5.2 Hz, 1H; 
H-7), 5.28 (ddd, J8,9a = 2.6, J8,7 = 5.2, J8,9b = 6.9 Hz, 1H; H-8), 4.62 (dd, J9a,8 = 2.6, J9a,9b = 
12.4 Hz, 1H; H-9a), 4.55 (dd, J6,7 = 1.8, J6,5 = 10.3 Hz, 1H; H-6), 4.36 (ddd, J4,3 = 2.3, J4,5 = 
J4,NH = 9.4 Hz, 1H; H-4), 4.15 (dd, J9b,8 = 6.9, J9b,9a = 12.4 Hz, 1H; H-9b), 4.02-4.94 (m, 1H; 
H5), 3.74 (s, 3H; COOCH3), 2.40 (s, 3H; PhCH3), 2.05 (s, 3H; OCOCH3), 2.03 (s, 3H; 
OCOCH3), 2.01 ppm (s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): δ = 170.6, 170.4, 169.7 
(3C; OCOCH3), 161.3 (C-1), 158.1 (q, JC,F = 37.8 Hz, 1C; COCF3), 144.6 (1C; Ph), 144.0 (C-
2), 137.1, 129.8, 126.7 (5C; Ph), 115. 3 (q, JC,F = 288.0 Hz, 1C; COCF3), 109.9 (C-3), 75.9 
(C-6), 70.7 (C-8), 67.6 (C-7), 61.9 (C-9), 52.3 and 51.2 (COOCH3 and C-4), 48.7 (C-5), 21.3 
(1C; PhCH3), 20.6, 20.5, 20.2 ppm (3C; OCOCH3); MS (ESI negative): m/z 637.4 [M-H]-; 
elemental analysis calcd (%) for C25H29F3N2O12S: C 47.02, H 4.58, N 4.39; found: C 47.35, 
H 4.64, N 4.43.  
  
5. Experimental 
 
 
106 
 
Preparation of methyl 7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-trideoxy-5-(2,2,3,3,3-pentafluoro 
propionamido)-4-[(4-methylphenyl)sulfonamide]-D-glycero-D-galacto-non-2-enonate (20c): 
 
Starting from protected glycal 19c (260 mg, 0.50 mmol), according to the general acylation 
procedure glycal 20c was obtained (250 mg, 75%) as a white solid, showing: [α]D23 = +51.3 
(c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 7.71 (overlapping, 2H; Ph), 7.63 (d, 
JNH,5 = 8.9 Hz, 1H; NHCOCH3 at C-5), 7.29 (overlapping, 2H; Ph), 5.60 (d, J3,4 = 2.4 Hz, 1H; 
H-3), 5.55 (d, JNH,4 = 9.4 Hz, 1H; NHCOCH3 at C-4), 5.34 (dd, J7,6 = 1.6, J7,8 = 5.6 Hz, 1H; 
H7), 5.27 (ddd, J8,9a = 2.6, J8,7 = 5.6, J8,9b = 6.3 Hz, 1H; H-8), 4.61-4.56 (overlapping, 2H; H-
6 and H-9a), 4.45 (ddd, J4,3 = 2.4, J4,5 = J4,NH = 9.4 Hz, 1H; H-4), 4.16 (dd, J9b,8 = 6.3, J9b,9a = 
12.5 Hz, 1H; H-9b), 3.97-3.91 (m, 1H; H-5), 3.73 (s, 3H; COOCH3), 2.41 (s, 3H; PhCH3), 
2.06 (s, 3H; OCOCH3), 2.04 (s, 3H; OCOCH3), 2.03 ppm (s, 3H; OCOCH3); 13C NMR (125 
MHz, CDCl3): δ = 170.7, 170.5, 169.8 (3C; OCOCH3), 161.4 (C-1), 158.8 (t, JC,F = 26.5 Hz, 
1C; COC2F5), 144.6 (1C; Ph), 144.2 (C-2), 137.1, 129.9, 126.8 (5C; Ph), 124.0-104.0 (2C; 
COC2F5), 109.5 (C-3), 75.4 (C-6), 70.6 (C-8), 67.5 (C-7), 61.8 (C-9), 52.4 and 50.7 (COOCH3 
and C-4), 49.1 (C-5), 21.4 (1C; PhCH3), 20.6, 20.5, 20.3 ppm (3C; OCOCH3); MS (ESI 
negative): m/z 687.3 [M-H]- ; elemental analysis calcd (%) for C26H29F5N2O12S: C 45.35, H 
4.25, N 4.07; found: C 45.18, H 4.38, N 4.20.  
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Preparation of methyl 7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-trideoxy-5-(2,2,3,3,4,4,4-hepta 
fluorobutyramido)-4-[(4-methylphenyl)sulfonamide]-D-glycero-D-galacto-non-2-enonate 
(20d):  
 
Starting from protected glycal 19d (291 mg, 0.50 mmol), according to the general acylation 
procedure glycal 20d was obtained (295 mg, 80%) as a white solid, showing: [α]D23 = +51.2 
(c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 7.69 (overlapping, 2H; Ph), 7.55 (d, 
JNH,5 = 8.6 Hz, 1H; NHCOCH3 at C-5), 7.28 (overlapping, 2H; Ph), 5.58 (d, J3,4 = 2.5 Hz, 1H; 
H-3), 5.42 (d, JNH,4 = 9.4 Hz, 1H; NHCOCH3 at C-4), 5.31 (dd, J7,6 = 1.5, J7,8 = 6.0 Hz, 1H; 
H7), 5.25 (ddd, J8,9a = 2.3, J8,7 = 6.0, J8,9b = 5.9 Hz, 1H; H-8), 4.61 (dd, J6,7 = 1.5, J6,5 = 10.3 
Hz, 1H; H-6), 4.54 (dd, J9a,8 = 2.3, J9a,9b = 12.6 Hz, 1H; H-9a), 4.49 (ddd, J4,3 = 2.5, J4,5 = J4,NH 
= 9.4 Hz, 1H; H-4), 4.15 (dd, J9b,8 = 5.9, J9b,9a = 12.6 Hz, 1H; H-9b), 3.88-3.80 (m, 1H; H-5), 
3.72 (s, 3H; COOCH3), 2.40 (s, 3H; PhCH3), 2.05 (s, 3H; OCOCH3), 2.03 (s, 3H; OCOCH3), 
2.01 ppm (s, 3H; OCOCH3); 13C NMR (125 MHz, CDCl3): δ = 170.7, 170.5, 170.0 (3C; 
OCOCH3), 161.4 (C-1), 158.6 (t, JC,F = 26.7 Hz, 1C; COC3F7), 144.6 (1C; Ph), 144.2 (C-2), 
137.0, 130.0, 126.9 (5C; Ph), 122.0-111.0 (3C; COC3F7), 109.3 (C-3), 75.0 (C-6), 70.4 (C-8), 
67.5 (C-7), 61.7 (C-9), 52.5 and 50.2 (COOCH3 and C-4), 49.7 (C-5), 21.4 (1C; PhCH3), 20.7, 
20.4, 20.4 ppm (3C; OCOCH3); MS (ESI negative): m/z 737.3 [M-H]-; elemental analysis 
calcd (%) for C27H29F7N2O12S: C 43.91, H 3.96, N 3.79; found: C 44.28, H 4.13, N 3.65. 
5.1.2.4 Deacetylation and selective removal of esteric function  
General procedure. All the peracetylated glycals 154, 17117, 18b-d, 20b,d (0.20 mmol) were 
treated with a methanolic solution of NaOMe, freshly prepared by dissolving sodium metal (5 
mg, 0.22 mmol) in anhydrous MeOH (2 mL). Each reaction mixture was stirred at 23°C for 1 
h, and then quenched with acidic resin (Dowex 50WX8, H+). The resin was filtered off and 
washed with MeOH (2 mL X 3) and the combined filtrate and washes were evaporated under 
vacuum. Each crude compound was purified with flash chromatography and directly subjected 
to opportune selective hydrolysis (Method A or B): 
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Method A: Selective hydrolysis using moist K2CO3 methanol solution. The free glycals 154, 
17117, 18c,d and 19c,d were prepared by selective hydrolysis of appropriate methyl ester 
derivatives performed in a methanol-water solution (0.75 mL, 10:1 v/v) containing K2CO3 (13 
mg), kept at 23°C for 6-24 h. At this time, the reaction mixture was treated with acidic resin 
(Dowex 50WX8, H+) until acidic pH, and then, the resin was filtered and washed with MeOH 
(2 mL X 3). Finally, the solvent was removed under reduced pressure and the residue was 
recovered with aqueous methanol and lyophilized to afford, after preparative HPLC, the 
desired free glycals.  
Method B: Selective hydrolysis using moist Et3N methanol solution. The free glycals 18b and 
20b was prepared by selective hydrolysis of its methyl ester derivative performed in a 
methanol-water solution (1.5 mL, 2:1 v/v) containing Et3N (0.90 mL), kept at 23 °C for 12 h. 
Then the mixture was treated with acidic resin (Dowex 50WX8, H+) until acidic pH and the 
resin was filtered and washed with MeOH (2 mL × 3). Finally, the solvent was removed under 
reduced pressure and the residue was recovered with aqueous methanol and lyophilized, to 
afford, after preparative HPLC, the desired free glycals. 
Preparation of 5-(acetamido)-2,6-anhydro-3,4,5-trideoxy-4-[(4-methylphenyl)sulfonamide]-
D-glyceroD-galacto-non-2-enoic acid (12a):  
 
Starting from protected glycal 17117 (117 mg, 0.20 mmol), according to the general two-step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 12a was 
obtained (68 mg, 77%) white solid, showing: [α]D23 = +11.7 (c=1.0 in water); 1H NMR (500 
MHz, CD3OD): δ = 7.79 (overlapping, 2H; Ph), 7.43 (overlapping, 2H; Ph), 5.54 (br s, 1H; 
H-3), 4.26 (br d, J6,5 = 10.7 Hz, 1H; H-6), 4.21 (br d, J4,5 = 9.4 Hz, 1H; H-4), 4.03-3.94 (m, 
1H; H-5), 3.91-3.78 (overlapping, 2H; H-8 and H-9a), 3.65 (dd, J9b,8 = 4.1, J9b,9a = 11.5 Hz, 
1H; H-9b), 3.57 (br d, J7,8 = 9.2 Hz, 1H; H-7), 2.46 (s, 3H; PhCH3), 1.85 ppm (s, 3H; 
NHCOCH3); 13C NMR (125 MHz, CD3OD:D2O, 1:1 v/v): δ = 175.2 (C-1), 167.2 
(NHCOCH3), 146.8 (1C; Ph), 145.9 (C-2), 137.9, 131.2, 127.6 (5C; Ph), 110.0 (C-3), 77.2 (C-
5. Experimental 
 
 
109 
 
6), 70.8 (C-8), 69.1 (C-7), 64.1 (C-9), 52.7 (C-4), 49.01 (C-5 under methanol signal), 23.0 
(1C; NHCOCH3), 21.6 ppm (1C; PhCH3); MS (ESI negative): m/z 443.2 [M-H]-; elemental 
analysis calcd (%) for C18H24N2O9S: C 48.64, H 5.44, N 6.30; found: C 48.51, H 5.35, N 6.42.  
Preparation of 2,6-anhydro-3,4,5-trideoxy-5-(2,2,2-trifluoroacetamido)-4-[(4- methylphenyl) 
sulfonamide]-D-glycero-D-galacto-non-2-enoic acid (12b):  
 
 
 
 
Starting from protected glycal 20b (128 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method B, glycal 12b was 
obtained (72 mg, 72%) as a white solid, showing: [α]D23 = +13.5 (c=1.0 in methanol); 1H NMR 
(500 MHz, CD3OD): δ = 7.73 (overlapping, 2H; Ph), 7.41 (overlapping, 2H; Ph), 5.42 (br s, 
1H; H-3), 4.44 (br d, J6,5 = 10.7 Hz, 1H; H-6), 4.27 (br d, J4,5 = 9.4 Hz, 1H; H-4), 4.20-4.11 
(m, 1H; H-5), 3.89-3.79 (overlapping, 2H; H-8 and H-9a), 3.63 (dd, J9b,8 = 5.5, J9b,9a = 11.5 
Hz, 1H; H-9b), 3.54 (br d, J7,8 = 9.2 Hz, 1H; H-7), 2.42 ppm (s, 3H; PhCH3); 13C NMR (125 
MHz, CD3OD): δ = 165.6 (C-1), 159.5 (q, JC,F = 37.8 Hz, 1C; COCF3), 146.1 (1C; Ph), 145.6 
(C-2), 138.8, 131.1, 127.7 (5C; Ph), 116.0 (q, JC,F = 288.0 Hz, 1C; COCF3), 110.4 (C-3), 77.2 
(C-6), 71.1 (C-8), 69.4 (C-7), 64.3 (C-9), 52.2 and 49.7 (C-4 and C-5), 21.5 ppm (1C; PhCH3); 
MS (ESI negative): m/z 497.3 [M-H]-; elemental analysis calcd (%) for C18H21F3N2O9S: C 
43.38, H 4.25, N 5.62; found: C 43.55, H 4.34, N 5.45.  
Preparation of 2,6-anhydro-3,4,5-trideoxy-5-(2,2,3,3,3-pentafluoropropionamido)-4-[(4- 
methylphenyl)sulfonamide]-D-glycero-D-galacto-non-2-enoic acid (12c):  
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Starting from protected glycal 20c (133 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 20c was 
obtained (80 mg, 75%) as a white solid, showing: [α]D20=+10.9 (c=1.0 in methanol); 1 H NMR 
(500 MHz, CD3OD): δ = 7.77 (overlapping, 2H; Ph), 7.40 (overlapping, 2H; Ph), 5.37 (d, J3,4 
= 2.1 Hz, 1H; H-3), 4.43 (br d, J6,5 = 10.6 Hz, 1H; H-6), 4.28 (dd, J4,3 = 2.1, J4,5 = 9.7 Hz, 1H; 
H6), 4.24-4.18 (m, 1H; H-5), 3.85-3.78 (overlapping, 2H; H-8 and H-9a), 3.61 (dd, J9b,8 = 5.4, 
J9b,9a = 11.2 Hz, 1H; H-9b), 3.50 (br d, J7,8 = 9.0 Hz, 1H; H-7), 2.44 ppm (s, 3H; PhCH3); 13C 
NMR (125 MHz, CD3OD): δ = 165.2 (C-1), 159.9 (t, JC,F = 25.8 Hz, 1C; COC2F5), 146.2 (1C; 
Ph), 145.0 (C-2), 140.2, 130.9, 127.9 (5C; Ph), 121.0- 107.0 (2C; COC2F5), 110.5 (C-3), 77.7 
(C-6), 71.4 (C-8), 70.1 (C-7), 64.9 (C-9), 52.5 and 49.9 (C-5 and C-4), 21.5 ppm (1C; PhCH3); 
MS (ESI negative): m/z 547.3 [M-H]- ; elemental analysis calcd (%) for C19H21F5N2O9S: C 
41.61, H 3.86, N 5.11; found: C 41.46, H 3.67, N 5.23.  
Preparation of 2,6-anhydro-3,4,5-trideoxy-5-(2,2,3,3,4,4,4-heptafluorobutyramido)-4-[(4- 
methylphenyl)sulfonamide]-D-glycero-D-galacto-non-2-enoic acid (12d):  
 
 
 
 
Starting from protected glycal 20d (147 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, glycal 12d was 
obtained (89 mg, 74%) as a white solid, showing: [α]D23 = +9.1 (c=1.0 in methanol); 1H NMR 
(500 MHz, CD3OD): δ = 7.76 (overlapping, 2H; Ph), 7.39 (overlapping, 2H; Ph), 5.34 (br s, 
1H; H-3), 4.40 (br d, J6,5 = 10.4 Hz, 1H; H-6), 4.30-4.17 (overlapping, 2H; H-4 and H-5), 
3.87- 3.76 (overlapping, 2H; H-8 and H-9a), 3.60 (dd, J9b,8 = 4.9, J9b,9a = 10.7 Hz, 1H; H-9b), 
3.49 (br d, J7,8 = 9.0 Hz, 1H; H-7), 2.43 ppm (s, 3H; PhCH3); 13C NMR (125 MHz, CD3OD): 
δ = 165.5 (C-1), 159.7 (t, JC,F = 25.6 Hz, 1C; COC3F7), 146.5 (1C; Ph), 144.9 (C-2), 140.3, 
131.0, 128.0 (5C; Ph), 122.0-111.0 (3C; COC3F7), 110.0 (C-3), 77.6 (C-6), 71.4 (C-8), 70.1 
(C-7), 64.9 (C-9), 52.6 and 50.0 (C-5 and C-4), 21.5 ppm (1C; PhCH3); MS (ESI negative): 
m/z 597.2 [M-H]-; elemental analysis calcd (%) for C20H21F7N2O9S: C 40.14, H 3.54, N 4.68; 
found: C 40.06, H 3.67, N 4.71. 
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Preparation of 5-acetamido-2,6-anhydro-4-azido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-
enoic acid (13a): 
 
 
 
Starting from protected glycal 154, 37 (91 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, the glycal 13a was 
obtained (46 mg, 72%) as a white solid, showing: [α]D23 = +39.8 (c=1.0 in methanol); 1H NMR 
(500 MHz, D20): δ= 5.97 (br s, 1H; H-3), 4.34 (br d, J4,5 = 9.4 Hz, 1H; H-4), 4.30 (br d, J6,5 = 
10.8 Hz, 1H; H-6), 4.22-4.15 (m, 1H; H-5), 3.91-3.85 (m, 1H; H-8), 3.83 (dd, J9a,8 = 1.8, J9a,9b 
= 12.0 Hz, 1H; H-9a), 3.63 (br d, J7,8 = 9.7 Hz, 1H; H-7), 3.60 (dd, J9b,8 = 6.1, J9b,9a = 12.0 Hz, 
1H; H-9b), 2.02 ppm (s, 3H; NHCOCH3). All other physico-chemical properties are 
superimposable to those previously reported4, 37. 
Preparation of 2,6-anhydro-4-azido-3,4,5-trideoxy-5-(2,2,2-trifluoroacetamido)-D-glycero-
D-galactonon-2-enoic acid (13b):  
 
Starting from protected glycal 18b (102 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method B, the glycal 13b was 
obtained (50 mg, 68%) as a white solid, showing: [α]D23 = + 28.1 (c=1.0 in methanol); 1H 
NMR (500 MHz, CD3OD): δ = 5.96 (d, J3,4 = 2.1 Hz, 1H; H-3), 4.49 (dd, J6,7 < 1.0, J6,5 = 10.4 
Hz, 1H; H-6), 4.36 (dd, J4,3 = 2.1, J4,5 = 9.4 Hz, 1H; H4), 4.32 (dd, J5,4 = 9.4, J5,6 = 10.4 Hz, 
1H; H-5), 3.88 (ddd, J8,9a = 2.8, J8,9b = 5.4, J8,7 = 9.4 Hz, 1H; H-8), 3.82 (dd, J9a,8 = 2.8, J9a,9b 
= 11.5 Hz, 1H; H-9a), 3.66 (dd, J9b,8 = 5.4, J9b,9a 11.5 = Hz, 1H; H-9b), 3.57 ppm (dd, J7,6 < 
1.0, J7,8 = 9.4 Hz, 1H; H-7); 13C NMR (125 MHz, CD3OD): δ = 164.9 (C-1), 159.2 (q, JC,F = 
37.0 Hz, 1C; COCF3), 147.4 (C-2), 120.8-114.0 (1C; COCF3), 107.8 (C-3), 77.3 (C-6), 71.4 
(C-8), 69.8 (C-7), 64.8 (C-9), 59.8 (C-4), 49.9 ppm (C-5); HRMS (TOF-ESI, m/z): calcd for 
C11H12F3N4O7 [M-H]- 369.0664, found 369.0659.  
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Preparation of 2,6-anhydro-4-azido-3,4,5-trideoxy-5-(2,2,3,3,3-pentafluoropropionamido)-
D-glycero-Dgalacto-non-2-enoic acid (13c):  
 
Starting from protected glycal 18c (112 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, the glycal 13c was 
obtained (55 mg, 65%) as a white solid, showing: [α]D23 = +28.4 (c=1.0 in methanol); 1H NMR 
(500 MHz, CD3OD): δ = 5.96 (d, J3,4 = 2.1 Hz, 1H; H-3), 4.52-4.45 (m, 1H; H-6), 4.37-4.28 
(overlapping, 2H; H-4 and H5), 3.88 (ddd, J8,9a = 2.9, J8,9b = 5.5, J8,7 = 9.0 Hz, 1H; H-8), 3.83 
(dd, J9a,8 = 2.9, J9a,9b = 11.4 Hz, 1H; H-9a), 3.64 (dd, J9b,8 = 5.5, J9b,9a = 11.4 Hz, 1H; H-9b), 
3.53 ppm (dd, J6,7 < 1.0, J7,8 = 9.0 Hz, 1H; H-7); 13C NMR (125 MHz, CD3OD): δ = 165.0 
(C-1), 159.7 (t, JC,F = 27.0 Hz, 1C; COC2F5), 147.5 (C-2), 120.2-110.1 (2C; COC2F5), 107.8 
(C-3), 77.2 (C-6), 71.4 (C-8), 69.8 (C-7), 64.8 (C-9), 60.0 (C-4), 49.8 ppm (C-5); MS (ESI 
negative): m/z 419.1 [M-H]-; elemental analysis calcd (%) for C12H13F5N4O7: C 34.30, H 3.12, 
N 13.33; found: C 34.56, H 3.22, N 13.13.  
Preparation of 2,6-anhydro-4-azido--3,4,5-trideoxy-5-(2,2,3,3,4,4,4-heptafluorobutyramido) 
-D-glyceroD-galacto-non-2-enoic acid (13d): 
 
Starting from protected glycal 18d (122 mg, 0.20 mmol), according to the general two step 
procedure Zemplén reaction followed by selective hydrolytic method A, the glycal 13d was 
obtained (64 mg, 68%) as a white solid, showing: [α]D23 = +37.6 (c=1.0 in methanol); 1H NMR 
(500 MHz, CD3OD): δ = 5.98 (br s, 1H; H-3), 4.48 (dd, J6,7 < 1.0, J6,5 = 10.3 Hz, 1H; H-6), 
4.37-4.29 (overlapping, 2H; H4 and H-5), 3.88 (ddd, J8,9a = 2.9, J8,9b = 5.6, J8,7 = 9.8 Hz, 1H; 
H-8), 3.82 (dd, J9a,8 = 2.9, J9a,9b = 11.4 Hz, 1H; H-9a), 3.64 (dd, J9b,8 = 5.6, J9b,9a = 11.4 Hz, 
1H; H-9b), 3.55 ppm (dd, J6,7 < 1.0, J7,8 = 9.8 Hz, 1H; H-7); 13C NMR (125 MHz, CD3OD): 
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δ = 165.0 (C-1), 159.6 (t, JC,F = 27.0 Hz, 1C; COC3F7), 147.5 (C-2), 122.0-110.0 (3C; 
COC3F7), 107.8 (C-3), 77.2 (C-6), 71.4 (C-8), 69.9 (C-7), 64.9 (C-9), 59.9 (C-4), 50.0 ppm 
(C-5); HRMS (TOF-ESI, m/z): calcd for C13H12F7N4O7 [M-H]- 469.0600, found 469.0588. 
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5.1.3 The 3,4-unsaturated derivatives (Chapter 3.3) 
5.1.3.1 Setting up of optimal Ferrier reaction conditions, using MeOH as a nucleophile 
 
 
 
 
 
To a solution of oxazoline 14110 (300 mg, 0.73 mmol) in CH3CN (7.2 mL) under argon MeOH 
(7.20 mmol) was added as nucleophile. Then, also the appropriate catalyst was introduced in 
the reaction and the mixture was stirred at the selected temperature until the disappearance of 
the starting material, according to the specific method (Method 1-10). Subsequently, the 
reaction was filtered over Celite and the solvent was then evaporated. Finally, the residue was 
purified by silica gel chromatography with the appropriate solvent system to achieve the 
desired mixture of the chromatographically inseparable compounds 23a and 24a.  
 Method 1: Bi(OTf)3-Montomorillonite K-10 (40% w/w; loading of 20% w/w 
Bi(OTf)3) were selected as catalysts and the reaction was stirred at 23°C, 30h. 
 Method 2: Bi(OTf)3-Montomorillonite K-10 (40% w/w; loading of 20% w/w 
Bi(OTf)3) were selected as catalysts and the reaction was stirred at 50°C, 1 h. 
 Method 3: Bi(OTf)3-Montomorillonite K-10 (40% w/w; loading of 20% w/w 
Bi(OTf)3) were selected as catalysts and the reaction was stirred at 80°C, 30 min. 
 Method 4: Bi(OTf)3 (40% w/w) was selected as catalyst and the reaction was stirred 
at 23°C, 5h. 
 Method 5: Bi(OTf)3 (40% w/w) was selected as catalyst and the reaction was stirred 
at 30°C, 1h. 
 Method 6: Bi(OTf)3 (40% w/w) was selected as catalyst and the reaction was stirred 
at 50°C, 1h. 
 Method 7: Bi(OTf)3 (40% w/w) was selected as catalyst and the reaction was stirred 
at 80°C, 30 min. 
 Method 8: Montmorillonite K-10 (40% w/w) was selected as catalyst and the reaction 
was stirred at 23°C, 256h. 
 Method 9: Montmorillonite K-10 (40% w/w) was selected as catalyst and the reaction 
was stirred at 50°C, 28h. 
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 Method 10: Montmorillonite K-10 (40% w/w) was selected as catalyst and the reaction 
was stirred at 80°C, 2/3h. 
For the obtained mixtures of 23a and 24a the 1H and 13C NMR assignments refer to: 
 
Preparation of the α/β-anomeric mixture of methyl (methyl-5-acetamido-7,8,9-tri-O-acetyl-
3,4,5-trideoxy-D-manno-non-3-en-2-ulopyranosid)-onates (23a+24a) 
 
Starting from oxazoline 14110 (300 mg, 0.73 mmol) and using methanol as nucleophile (0.296 
mL, 7.30 mmol), according to the general procedure, Method 10, mixture of 23a and 24a was 
obtained (276 mg, 85%; 2:8 α/β), after flash chromatographic separation using ethyl 
acetate/hexane (95:5, v/v), as a solvent system. The white solid mixture of 23a+24a showed: 
1H NMR (500 MHz, CDCl3): δ = 6.04 (d, J3’,5’ = 1.9, J3’,4’ = 10.1 Hz, 1H; H-3’), 5.91-5.84 
(overlapping, 2H; H-3 and H-4), 5.75 (dd, J4’,5’ = 2.6, J4’,3’ = 10.1 Hz, 1H; H-4’), 5.66 (d, JNH’,5’ 
= 9.2 Hz, 1H; NHCOCH3’), 5.61 (d, JNH,5 = 9.5 Hz, 1H; NHCOCH3), 5.41 (ddd, J8’,9a’ = 2.5, 
J8’,7’ = 6.3, J8’,9b’ = 8.9 Hz, 1H; H-8’), 5.39 (dd, J7,6 = 2.4, J7,8 = 5.4 Hz, 1H; H-7), 5.34-5.28 
(overlapping, 2H; H-7’ and H-8), 4.64-4.58 (overlapping, 2H; H-9a and H-5), 4.50 (dddd, 
J5’,3’ = 1.9, J5’,4’ = 2.6, J5’,6’ = J5’,NH’ = 9.2 Hz, 1H; H-5’), 4.46 (dd, J9a’,8’ = 2.5, J9a’,9b’ = 12.3 
Hz, 1H; H-9a’), 4.24-4.18 (overlapping, 3H; H-6’, H-9b and H-9b’), 4.06 (dd, J6,7 = 2.4, J6,5 
= 10.3 Hz, 1H; 6-H), 3.78 (s, 3H; COOCH3), 3.75 (s, 3H; COOCH3’), 3.31 (s, 3H; OCH3’), 
3.27 (s, 3H; OCH3), 2.13 (s, 3H; OCOCH3), 2.11 (s, 3H; OCOCH3’), 2.08 (s, 3H; OCOCH3’), 
2.06 (s, 3H; OCOCH3), 2.05-2.02 (overlapping, 6H; OCOCH3 and OCOCH3’), 1.98-1.96 ppm 
(overlapping, 6H; NHCOCH3 and NHCOCH3); 13C NMR (125 MHz, CDCl3): δ = 170.6 (2C, 
OCOCH3 and OCOCH3’), 170.4 (OCOCH3), 170.3 (OCOCH3’), 170.2 (OCOCH3’), 170.1 
(OCOCH3), 169.8 (2C, NHCOCH3 and NHCOCH3’), 166.5 (C-1’), 167.5 (C-1), 135.6 (C-3’), 
133.7 (C-3), 125.8 (C-4), 125.6 (C’-4), 97.7 (C-2’), 96.5 (C-2), 74.4 (C-6’), 70.9 (C-8), 70.4 
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(C-6), 69.9 (C-8’), 68.1 (2C, C-7 and C-7’), 62.2 (2C, C-9 and C-9’), 52.8 (2C, COOCH3 and 
COOCH3’), 52.0 (OCH3), 51.2 (OCH3’), 43.1 (2C, C-5 and C-5’), 23.3 (2C, NHCOCH3 and 
NHCOCH3’), 21.1 (OCOCH3’), 21.0 (OCOCH3), 20.8 (OCOCH3’), 20.7 ppm (3C, OCOCH3, 
OCOCH3, OCOCH3’); MS (ESI positive): m/z 446.4  [M+H]+, 468.4 [M+Na]+. 
5.1.3.2 Synthesis of the intermediate 27 and demonstration of its structure 
Preparation of the intermediate 27 
 
Oxazoline 14110 (100 mg, 0.24 mmol) was dissolved in 1.2 ml of a 0.1 M TFA solution in 
CH3CN/H20 (1:1, v/v) and the reaction was stirred at 23°C. The oxazoline depletion was 
monitored by TLC and after 5-15 min, the time necessary to transform the starting material 
entirely in the intermediate 27, the reaction was quenched by the addition of a weak basic 
resin (IRA-67), until neutral pH. Successively, the obtained compound, was rapidly 
characterized: 1H NMR (500 MHz, CDCl3): δ =  6.17 (d, J3,4 = 5.7 Hz, 1H; H-3), 5.65 (dd, J7,6 
= 1.4, J7,8 = 6.0 Hz, 1H; H-7), 5.47 (ddd, J8,9a = 2.3, J8,7 = J8,9b = 6.0 Hz, 1H; H-8), 5.30 (dd, 
J4,5 = 4.2, J4,3 5.7 Hz, 1H; H-4), 4.70 (dd, J9a,8 = 2.3, J9a,9b = 12.6 Hz, 1H; H-9a), 4.29 (dd, J9b,8 
= 6.0, J9b,9a = 12.6 Hz, 1H; H-9b), 4.04 (dd, J6.7 = 1.4, J6,5 = 10.8 Hz, 1H; H-6), 3.81 (s, 3H; 
COOCH3), 2.95 (dd, J5,4  = 4.2, J5,6  = 10.8 Hz, 1H; H-5), 2.18 (s, 3H; OCOCH3), 2.12 
(overlapping, 6H; 2 X OCOCH3), 2.08 (s, 3H; OCOCH3), 1.67-1.49 ppm (overlapping, 2H; 
NH2); 13C NMR (125 MHz, CDCl3): δ = 170.6 (2C; OCOCH3 at C-7 and OCOCH3 at C-9), 
170.2 (OCOCH3 at C-4), 169.9 (1C, OCOCH3 at C-8), 162.1 (C-1), 146.2 (C-2), 105.9 (C-3), 
75.5 (C-6), 70.8 (C-8), 68.6 (C-7), 65.7 (C-4), 62.0 (C-9), 52.5 (COOCH3), 47.3 (C-5), 20.9 
(2C; 2 X OCOCH3), 20.7 (OCOCH3), 20.6 ppm (OCOCH3). MS (ESI positive): m/z 432.1  
[M+H]+, 454.1 [M+Na]+.  
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Synthesis of compound 28 
 
Starting from intermediate 27 (50 mg, 0.12 mmol) in 1.0 ml CH2Cl2 with weak basic resin 
(IRA-67) propionyl chloride (0.045mL, 0.54 mmol) was added. After purification and gel 
chromatography (eluting with AcOEt), compound 28 was obtained (44 mg, 75%) showing: 
[α]D23 = -136.5 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 6.19 (d, J3,4 = 5.6 Hz, 
1H; H-3), 5.51 (d, JNH,5 = 10.2 Hz, 1H; NHCOCH3), 5.47 (1H, dd, J7,6 = 2.2, J7,8 = 4.2 Hz, 
1H; H-7), 5.30 (ddd, J8,9a = 2.6, J8,7 = 4.2, J8,9b = 7.6 Hz, 1H; H-8), 5.14 (dd, J4,5 = 4.1, J4,3 = 
5,6 Hz, 1H; H-4), 4.77 (dd, J9a,8 = 2.6, J9a,9b = 12.5 Hz, 1H; H-9a), 4.60 (m, 1H; H-5), 4.28 
(dd, J6.7 = 2.2, J6,5 = 11.0 Hz, 1H; H-6), 4.17 (dd, J5,4 = 7.6, J5,6 = J5,NH = 11.0 Hz, 1H; H-9a), 
3.79 (s, 3H; COOCH3), 2.18-2.11 (overlapping, 2H; NHCOCH2CH3), 2.10 (s, 3H; OCOCH3), 
2.09 (s, 3H; OCOCH3), 2.07 (s, 3H; OCOCH3), 2.05 (s, 3H; OCOCH3), 1.05 ppm (m, 3H; 
NHCOCH2CH3); 13C NMR (125 MHz, CDCl3): δ = 173.2 (NHCOCH2CH3), 170.5 (2C, 
OCOCH3 at C-8, OCOCH3 at C-9), 170.0 (OCOCH3 at C-7), 169.5 (OCOCH3 at C-4), 161.7 
(C-1), 146.3 (C-2), 105.9 (C-3), 74.0 (C-6), 71.9 (C-8), 67.7 (C-7), 64.9 (C-4), 62.1 (C-9), 
52.5 (COOCH3), 44.0 (C-5), 29.5 (NHCOCH2CH3), 20.9 (2C, 2 X OCOCH3), 20.7 (2C, 2 X 
OCOCH3), 9.2 ppm (NHCOCH2CH3); MS (ESI positive): m/z 488.2 [M+H]+, 510.2 [M+Na]+. 
Synthesis of oxazoline derivative 29 
 
Starting from compound 28 (38 mg, 0.08 mmol) in CH2Cl2 (1 mL) containing BF3Et2O (0.05 
mL, 0.4 mmol) was heated at 80°C for 15 min. The crude was diluted with AcOEt containing 
Et3N and the organic layers were, at first, washed with saturated NH4Cl solution then with 
water and dried over anhydrous Na2SO4. Then, a rapid chromatography (AcOEt/hexane 7:3, 
v/v, with 0.3% of Et3N) afforded the desired compound (24 mg, 70%) showing: 1H NMR (500 
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MHz, CDCl3): δ = 6.33 (d, J3,4 = 4.0 Hz, 1H; H-3), 5.57 (dd, J7,6 = 3.0, J7,8 = 5.7 Hz, 1H; H-
7), 5.40 (ddd, J8,9a = 2.6, J8,7 = 5.7, J8,9b = 6.6 Hz, 1H; H-8), 4.77 (dd, J4,3 = 4.0, J4,5 = 8.6 Hz, 
1H; H-4), 4.51 (dd, J9a,8 = 2.6, J9a,9b = 12.4 Hz, 1H; H-9a), 4.17 (dd, J9b,8 = 6.6, J9b,9a = 12.4 
Hz, 1H; H-9b), 3.92 (m, 1H, H-5), 3.76 (s, 3H; COOCH3), 3.38 (1H, dd, J6,7 = 3.0, J6,5 = 9.9 
Hz, H-6), 2.27 (overlapping, 2H; CCH2CH3), 2.10 (s, 3H; OCOCH3), 2.20-1.98 (overlapping, 
6H; 2 X OCOCH3), 1.11 ppm (s, 3H; CCH2CH3); 13C NMR (125 MHz, CDCl3): δ = 171.0, 
170.5, 169.7, 169.5 (4C, 3 X OCOCH3 and OCCH2CH3), 161.8 (C-1), 146.9 (C-2), 107.5 (C-
3), 76.7 (C-6), 71.9 (C-4), 70.3 (C-8), 69.2 (C-7), 61.9 (C-9), 61.8 (C-5), 52.3 (COOCH3), 
21.5 (OCOCH2CH3), 20.7 (OCOCH3), 20.6 (OCOCH3), 20.5 (OCOCH3), 10.1 ppm 
(OCOCH2CH3). 
Synthesis of compound 31 
 
Oxazoline 29 (34 mg, 0.08 mmol) was dissolved in 0.8 ml of a 0.1 M TFA solution in 
CH3CN/H2O (1:1 v/v) and the reaction was stirred at 23°C. The oxazoline depletion was 
monitored by TLC and after 5-15 min, the reaction was quenched by the addition of a weak 
basic resin (IRA-67), until neutral pH. Then, acetyl chloride (29 mg, 0.4 mmol) was added. 
After purification and gel chromatography, compound 31 was obtained (31 mg, 80%) 
showing: [α]D23 = -131.0 (c=1.0 in chloroform); 1H NMR (500 MHz, CDCl3): δ = 6.18 (d, J3,4 
= 5.6 Hz, 1H; H-3), 5.64 (d, JNH,4 = 4.7, JNH,5 = 10.9 Hz, 1H; NHCOCH3), 5.47 (dd, J7,6 = 2.2, 
J7,8 = 4.1 Hz, 1H; H-7), 5.29 (ddd, J8,9a = 2.6, J8,7 = 4.1 Hz, J8,9b = 7.3 Hz, 1H; H-8), 5.14 (dd, 
J4,5 = 4.1, J4,3 = 5,6 Hz, 1H; H-4), 4.74 (dd, J9a,8 = 2.6, J9a,9b = 12.4 Hz, 1H; H-9a), 4.56 (dd, 
J5,4 = 4.1, J5,6 = J5,NH = 10.9 Hz, 1H; H-5), 4.26 (dd, J6.7 = 2.2, J6,5 = 10.9 Hz, 1H; H-6), 4.17 
(dd, J9b,8 = 7.3, J9b,9a = 12.4 Hz, 1H; H-9b), 3.77 (s, 3H; COOCH3), 2.38-2.30 (overlapping, 
2H; OCOCH2CH3), 2.08 (s, 3H; OCOCH3), 2.05 (s, 3H; OCOCH3), 2.03 (s, 3H; OCOCH3), 
1.91 (s, 3H; NHCOCH3), 1.14 ppm (3H, t, J5,4 = 4.1 Hz, OCOCH2CH3); 13C NMR (125 MHz, 
CDCl3): δ = 173.0 (OCOCH2CH3), 170.5 (OCOCH3 at C-8 or C-9), 170.4 (OCOCH3 at C-8 
or C-9), 170.1 (OCOCH3 at C-7), 169.6 (NHCOCH3), 161.7 (C-1), 146.2 (C-2), 106.0 (C-3), 
73.9 (C-6), 71.8 (C-8), 67.7 (C-7), 64.9 (C-4), 62.1 (C-9), 52.5 (COOCH3), 44.3 (C-5), 27.4 
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(OCOCH2CH3), 23.1 (NHCOCH3), 20.9 (OCOCH3), 20.7 (OCOCH3), 20.6 (OCOCH3), 8.9 
ppm (OCOCH2CH3). MS (ESI positive): m/z 488.2 [M+H]+, 510.3 [M+Na]+. 
5.1.3.3 Synthesis of 3,4-unsaturated derivatives using other alcoholic or thiolic 
nucleophiles, via Ferrier reaction 
General procedure. To a solution of oxazoline 14110 (300 mg, 0.73 mmol) in CH3CN (7.2 
mL) under argon the appropriate nucleophile (7.20 mmol) and Montmorillonite K-10 (40% 
w/w) were added and the reaction was stirred at 80 °C for 2-5 h. Subsequently the reaction 
was filtered over Celite and the solvent was then evaporated. Finally, the residue was purified 
by silica gel chromatography with the appropriate solvent system to achieve the desired 
mixture of compounds 23b+24b, 23c+24c, 23d+24d, 23e+24e and 23f+24f.  
For the obtained chromatographically inseparable mixtures the 1H and 13C NMR assignments 
refer to: 
 
Preparation of the α/β-anomeric mixture of methyl (2S-ethyl-5-acetamido-7,8,9-tri-O-acetyl-
2,3,4,5-tetradeoxy-D-manno-non-3-en-2-ulopyranosid)-onates (23b+24b) 
 
Starting from oxazoline 14110 (300 mg, 0.73 mmol) and using ethanethiol as nucleophile 
(0.527 mL, 7.30 mmol), according to general procedure, mixture of 23b+24b was obtained 
(253 mg, 68%, 1:9 α/β), after flash chromatographic separation using ethyl acetate/hexane 
(eluting with AcOEt/hexane, 99:1 to 95:5, v/v), as a solvent system. The white solid mixture 
of 23b+24b showed: 1H NMR (500 MHz, CDCl3): δ = 6.10 (dd, J3,5 = 2.5, J3,4 = 10.1 Hz, 1H; 
H-3), 5.91 (d, J3’,5’ = 2.5, J3’,4’ = 10.1 Hz, 1H; H-3’), 5.84 (dd, J4’,5’ = 1.7, J4’,5’ = 10.1 Hz, 1H; 
H-4’), 5.74 (dd, J4,5 = 1.9, J4,3 = 10.1 Hz, 1H; H-4), 5.57-5.52 (overlapping, 2H; NHCOCH3 
and NHCOCH3’), 5.42 (ddd, J8’,9a’ = 2.5, J8’,7’ = 6.1, J8’,9b’ = 8.6 Hz, 1H; H-8’), 5.37 (dd, J7,6 
5. Experimental 
 
 
120 
 
= 2.4, J7,8 = 4.8 Hz, 1H; H-7), 5.33 (dd, J7’,6’ = 2.0, J7’,8’ = 6.1 Hz, 1H; H-7’), 5.22 (ddd, J8,9a = 
2.4, J8,7 = 4.8, J8,7 = 6.8 Hz, 1H; H-8), 4.65-4.58 (overlapping, 2H; H-5 and H-9a), 4.53 (dd, 
J9a’,8’ = 2.5, J9a’,9b’ = 12.4 Hz, 1H; H-9a’), 4.45 (ddd, J5’,4’ = 2.5, J5’,6’ = J5’,NH’ = 9.8 Hz, 1H; H-
5’), 4.33 (dd, J6,7 = 2.4, J6,5 = 10.0 Hz, 1H; 6-H), 4.28-4.20 (overlapping, 2H; H-9b and H-
9b’), 3.92 (dd, J6’,7’ = 2.0, J6’,5’ = 9.8 Hz, 1H; H-6’), 3.80 (s, 3H; COOCH3), 3.75 (s, 3H; 
COOCH3’), 3.72-3.50 (overlapping, 4H; SCH2CH3 and SCH2CH3’), 2.13 (s, 3H; OCOCH3), 
2.12 (s, 3H; OCOCH3’), 2.10 (s, 3H; OCOCH3’), 2.08 (s, 3H; OCOCH3), 2.03 (s, 3H; 
OCOCH3’), 2.02 (s, 3H; OCOCH3), 1.96 (s, 3H; NHCOCH3), 1.95 (s, 3H; NHCOCH3’), 1.24 
(m, 3H; SCH2CH3’), 1.16 ppm (m, 3H; SCH2CH3); 13C NMR (125 MHz, CDCl3): δ=170.6 
(OCOCH3’), 170.5 (2C, OCOCH3 and OCOCH3’), 170.4 (OCOCH3), 170.1 (2C, OCOCH3 
and OCOCH3’), 169.8 (NHCOCH3’), 169.7 (NHCOCH3), 168.8 (C-1’), 167.3 (C-1), 131.4 
(C-4’), 130.7 (C-4), 126.5 (C-3’), 126.3 (C-3), 85.7 (C-2), 84.6 (C-2’), 74.2 (C-6’), 71.4 (C-
8), 70.6 (C-6), 70.4 (C-8’), 68.5 (C-7), 68.0 (C-7’) 62.5 (C-9), 62.2 (C-9’), 52.9 (COOCH3’), 
52.8 (COOCH3), 43.1 (C-5’), 43.0 (C-5), 24.4 (1C, SCH2CH3), 23.3 (3C, NHCOCH3, 
NHCOCH3’ and SCH2CH3’), 21.1 (2C, OCOCH3 and OCOCH3’), 20.8 (OCOCH3’), 20.7 (3C, 
2 X OCOCH3 and OCOCH3’), 14.5 (SCH2CH3’), 14.0 ppm (SCH2CH3); MS (ESI positive): 
m/z 476.1  [M+H]+, 498.5 [M+Na]+. 
Preparation of the α/β-anomeric mixture of methyl (ethyl-5-acetamido-7,8,9-tri-O-acetyl-
3,4,5-trideoxy-D-manno-non-3-en-2-ulopyranosid)-onates (23c+24c) 
 
Starting from oxazoline 14110 (300 mg, 0.73 mmol) and using ethanol as nucleophile (0.426 
mL, 7.30 mmol), according to general procedure, mixture of 23c+24c was obtained (268 mg, 
80%; 2:8 α/β), after flash chromatographic separation using AcOEt/hexane (eluting with 
AcOEt/hexane, 95:5, v/v) as a solvent system. The white solid mixture of 23c+24c showed: 
1H NMR (500 MHz, CDCl3): δ = 5.98 (d, J3’,5’ = 1.3, J3’,4’ = 10.1 Hz, 1H; H-3’), 5.90 (d, J4,5 
= 2.2, J4,3 = 10.2 Hz, 1H; H-4), 5.85 (br d, J3,4 = 10.2 Hz, 1H; H-3), 5.78 (dd, J4’,5’ = 2.5, J4’,3’ 
= 10.1 Hz, 1H; H-4’), 5.66 (d, JNH’,5’ = 9.3 Hz, 1H; NHCOCH3’), 5.58 (d, JNH,5 = 9.6 Hz, 1H; 
NHCOCH3), 5.41 (ddd, J8’,9a’ = 2.2, J8’,7’ = 6.2, J8’,9b’ = 8.4 Hz, 1H; H-8’), 5.36 (dd, J7,6 = 2.4, 
J7,8 = 4.8 Hz, 1H; H-7), 5.31 (dd, J7,6 = 1.7, J7,8 = 6.2 Hz, 1H; H-7’), 5.26 (m, 1H; H-8), 4.68-
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4.60 (overlapping, 2H; H-5 and H-9a), 4.51-4.43 (overlapping, 2H; H-5’ and H-9a’), 4.24-
4.17 (overlapping, 3H; H-6’, H-9b and H-9b’), 4.04 (dd, J6,7 = 2.1, J6,5 = 10.2 Hz, 1H; H-6), 
3.77 (s, 3H; COOCH3), 3.74 (s, 3H; COOCH3’), 3.71-3.57 (overlapping, 2H; OCH2CH3 and 
OCH2CH3’), 3.50-3.34 (overlapping, 2H; OCH2CH3 and OCH2CH3’), 2.12 (s, 3H; OCOCH3), 
2.11 (s, 3H; OCOCH3’), 2.09 (s, 3H; OCOCH3’), 2.06 (s, 3H; OCOCH3), 2.02-2.01 
(overlapping, 6H; OCOCH3 and OCOCH3’), 1.98-1.95 (overlapping, 6H; NHCOCH3 and 
NHCOCH3’), 1.23-1.13 ppm (overlapping, 6H; OCH2CH3 and OCH2CH3’); 13C NMR (125 
MHz, CD3OD): δ = 170.6 (OCOCH3’), 170.5 (OCOCH3), 170.4 (2C; OCOCH3 and 
OCOCH3’), 170.1 (OCOCH3’), 170.0 (OCOCH3), 169.8 (2C; NHCOCH3 and NHCOCH3’), 
168.7 (C-1’), 167.7 (C-1), 134.9 (C-3’), 133.3 (C-3), 126.2 (C-4’), 126.1 (C-4), 97.6 (C-2’), 
96.1 (C-2), 74.4 (C-6’), 71.3 (C-8), 70.6 (C-6), 70.1 (C-8’), 68.5 (C-7), 68.2 (C-7’), 62.3 (2C, 
C-9 and C-9’), 60.3 (OCH2CH3), 59.9 (OCH2CH3’), 52.7 (COOCH3), 52.6 (COOCH3’), 43.1 
(C-5’), 43.0 (C-5), 23.2 (2C; NHCOCH3 and NHCOCH3’), 21.0 (OCOCH3’), 20.9 
(OCOCH3), 20.7 (OCOCH3’), 20.6 (3C; 2 X OCOCH3 and OCOCH3’), 15.3 ppm (2C; 
OCH2CH3 and OCH2CH3’). MS (ESI positive): m/z 460.2 [M+H]+, 482.2 [M+Na]+. 
Preparation of the α/β-anomeric mixture of methyl (isopropyl-5-acetamido-7,8,9-tri-O-
acetyl-3,4,5-trideoxy-D-manno-non-3-en-2-ulopyranosid)-onates (23d+24d) 
 
Starting from oxazoline 14110 (300 mg, 0.73 mmol) and using isopropanol as nucleophile 
(0.555 mL, 7.30 mmol), according to general procedure, mixture of 23d+24d was obtained 
(242 mg, 70%; 2:8 α/β), after flash chromatographic separation using AcOEt/hexane (eluting 
with AcOEt/hexane, 95:5, v/v) as a solvent system. The white solid mixture of 23d+24d 
showed: 1H NMR (500 MHz, CDCl3): δ = 6.02-5.95 (overlapping, 2H; H-4, H-3’), 5.83-5.77 
(overlapping, 2H; 3-H, H-4’), 5.56 (d, JNH’,5’ = 9.1 Hz, 1H; NHCOCH3’), 5.52 (1H, d, JNH,5 = 
9.7 Hz, NHCOCH3), 5.41-5.36 (overlapping, 2H; H-8’, H-7), 5.30 (dd, J7’,6’ = 1.9, J7’,8’ = 6.3 
Hz, 1H; H-7’), 5.26 (ddd, J8,9a = 2.5, J8,7 = 5.2, J8,9b = 7.7 Hz, 1H; H-8), 4.80 (dd, J9a,8 = 2.5, 
J9a,9b = 12.4 Hz, 1H; H-9a), 4.68 (ddd, J5,4 = 2.1, J5,6 = J5,NH = 9.7 Hz, 1H; H-5), 4.51-4.43 
(overlapping, 2H; H-9a’ and H-5’), 4.28-4.21 (overlapping, J9b,8 = 7.7, J9b,9a = 12.4, 2H; H-9b 
and H-9b’), 4.19 (dd, J6’,7’ = 1.9, J6’,5’ = 9.9 Hz, 1H; H’-6), 4.14-4.07 (overlapping, 2H; H-6 
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and OCH(CH3)2), 3.99- 3.91 (m, 1H; OCH(CH3)2’), 3.77 (s, 3H; COOCH3), 3.74 (s, 3H; 
COOCH3’), 2.12 (s, 3H; OCOCH3), 2.11 (s, 3H; OCOCH3’), 2.09 (s, 3H; OCOCH3’), 2.06 (s, 
3H; OCOCH3), 2.03-2.00 (overlapping, 6H; OCOCH3 and OCOCH3’), 1.97 (s, 3H; 
NHCOCH3’), 1.94 (s, 3H; NHCOCH3), 1.22-1.18 (overlapping, 6H; OCH(CH3)2 and 
OCH(CH3)2’), 1.17 (m, 3H; OCH(CH3)2’), 1.07 ppm (m, 3H; OCH(CH3)2); 13C NMR (125 
MHz, CDCl3): δ = 170.8 (2C; OCOCH3’ and OCOCH3), 170.5 (OCOCH3), 170.4 (OCOCH3’), 
170.1 (OCOCH3’), 170.0 (OCOCH3), 169.8 (NHCOCH3’), 169.7 (NHCOCH3), 168.9 (C-1’), 
168.0 (C-1), 134.7, 132.3, 126.7, 126.6 (C-3’, C-3, C-4’, C-4), 98.0 (C-2’), 95.0 (C-2),  74.4 
(C-6’), 72.4 (C-8), 71.2 (C-6), 70.3 (C-8’), 69.4 (C-7), 68.4 (C-7’), 68.2 (OCH(CH3)2’), 67.8 
(OCH(CH3)2), 62.7 (C-9), 62.2 (C-9’), 52.6 (COOCH3), 52.5 (COOCH3’), 43.2 (C-5’), 43.0 
(C-5), 24.5 (OCH(CH3)2), 24.2 (OCH(CH3)2’), 23.7 (OCH(CH3)2’), 23.2 (2C; NHCOCH3, 
NHCOCH3’), 22.7 (OCH(CH3)2), 21.1 (OCOCH3’), 21.0 (OCOCH3), 20.7 (3C; OCOCH3’, 2 
X OCOCH3), 20.6 ppm (OCOCH3’). MS (ESI positive) m/z 474.5 [M+H]+, 496.4 [M+Na]+. 
Preparation of the α/β-anomeric mixture of methyl (buthyl-5-acetamido-7,8,9-tri-O-acetyl-
3,4,5-trideoxy-D-manno-non-3-en-2-ulopyranosid)-onates (23e+24e) 
 
Starting from oxazoline 14110 (300 mg, 0.73 mmol) and using butanol as nucleophile (0.668 
mL, 7.30 mmol), according to general procedure, mixture of 23e+24e was obtained (242 mg, 
68%; 1:9 α/β), after flash chromatographic separation using AcOEt/hexane (eluting with 
AcOEt/hexane, 85:15 to 10:0, v/v) as a solvent system. The white solid mixture of 23e+24e 
showed:1H NMR (500 MHz, CDCl3): δ = 5.97 (dd, J3’,5’ = 1.9, J3’,4’ = 10.1 Hz, 1H; H-3’or H-
4’), 5.91 (dd, J4,5 = 2.5, J4,3 = 10.1 Hz, 1H; H-4 or H-3), 5.84 (dd, J3,5 = 1.7, J3,4=10.1 Hz, 1H; 
H-3 or H-4), 5.78 (dd, J4’,5’ = 2.6, J4’,3’=10.1 Hz, 1H; H-4’or H-3’), 5.70 (1H; d, JNH’,5’ = 9.3 
Hz, NHCOCH3’), 5.61 (d, JNH,5 = 9.4 Hz, 1H; NHCOCH3), 5.39 (1H; J8’,9a’ = 2.5, J8’,7’ = 6.1, 
J8’,9b’ = 8.7 Hz, H-8’), 5.37 (dd, J7,6 = 2.5, J7,8 = 4.2 Hz, 1H; H-7), 5.32 (dd, J7’,6’ = 2.1, J7’,8’ = 
6.1 Hz, 1H; H-7’), 5.23 (ddd, J8,9a = 2.3, J8,7 = 4.2, J8,9b = 6.8 Hz, 1H; H-8), 4.70-4.61 
(overlapping, 2H; H-9a and H-5), 4.52-4.45 (overlapping, 2H; H-9a’ and H-5’), 4.26-4.18 
(overlapping, 3H; H-9b, H’-9b’ and H-6’), 4.04 (dd, J6,7 = 2.5, J6,5 = 10.2 Hz, 1H; H-6), 3.77 
(s, 3H; COOCH3), 3.73 (s, 3H; COOCH3’), 3.64-3.50 (overlapping, 2H; OCH2(CH2)2CH3 and 
OCH2(CH2)2CH3’), 3.39 (m, 1H; OCH2(CH2)2CH3’), 3.29 (m, 1H; OCH2(CH2)2CH3), 2.14 (s, 
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3H; OCOCH3’), 2.09 (s, 3H; OCOCH3’), 2.08 (s, 3H; OCOCH3’), 2.05 (s, 3H; OCOCH3), 
2.01 (s, 3H; OCOCH3), 1.96-1.94 (6H; overlapping, NHCOCH3 and NHCOCH3’), 1.59-1.45 
(overlapping, 4H; OCH2(CH2)2CH3 and OCH2(CH2)2CH3’), 1.39-1.29 (overlapping, 4H; 
OCH2(CH2)2CH3 and OCH2(CH2)2CH3’), 0.92-0.86 ppm (overlapping, 6H; OCH2(CH2)2CH3 
and OCH2(CH2)2CH3’); 13C NMR (125 MHz, CDCl3): δ = 170.6 (OCOCH3’), 170.5 
(OCOCH3), 170.4 (OCOCH3), 170.3 (OCOCH3’), 170.1 (OCOCH3’), 170.0 (OCOCH3), 
169.8 (2C, NHCOCH3 and NHCOCH3’), 168.7 (C-1’), 167.7 (C-1), 134.9 (C-3’or C-4’), 
133.2 (C-3 or C-4), 126.2 (2C, C-4 or C-3 and C-4’ or C-3’), 97.6 (C-2’), 96.0 (C-2), 74.4 (C-
6’), 71.8 (C-8), 70.8 (C-6), 70.3 (C-8’), 68.7 (C-7), 68.2 (C-7’), 64.6 (C-9), 63.8 (C-9’), 62.5 
(OCH2(CH2)2CH3), 62.3 (OCH2(CH2)2CH3’), 52.6 (2C; COOCH3 and COOCH3’), 43.1 (C-
5’), 43.0 (C-5), 31.8 (OCH2CH2CH2CH3), 31.6 (OCH2CH2CH2CH3’), 23.2 (2C; NHCOCH3 
and NHCOCH3’), 21.0 (OCOCH3’), 20.9 (OCOCH3), 20.7 (OCOCH3’), 20.6 (3C; OCOCH3, 
OCOCH3 and OCOCH3’), 19.1 (OCH2CH2CH2CH3), 19.0 (OCH2CH2CH2CH3’), 13.8 
(OCH2CH2CH2CH3), 13.6 ppm (OCH2CH2CH2CH3’). MS (ESI positive) m/z 488.5 [M+H]+, 
510.5 [M+Na]+. 
Preparation of the α/β-anomeric mixture of methyl (2S-octyl-5-acetamido-7,8,9-tri-O-acetyl-
2,3,4,5-tetradeoxy-D-manno-non-3-en-2-ulopyranosid)-onates (23f+24f) 
 
Starting from oxazoline 14110 (300 mg, 0.73 mmol) and using octanethiol as nucleophile (1.27 
mL, 7.30 mmol), according to general procedure, mixture of 23f+24f was obtained (286 mg, 
70%; 2:8 α/β), after flash chromatographic separation using CH2Cl2/MeOH (eluting with 
CH2Cl2/MeOH, 10:0 to 96:4, v/v) as a solvent system. The white solid mixture of 23f+24f 
showed: 1H NMR (500 MHz, CDCl3): 6.09 (dd, J4,5 = 2.4, J4,3 = 10.1 Hz, 1H; H-4 or H-3), 
5.90 (dd, J4’,5’ = 2.5, J4’,3’ = 10.1 Hz, 1H; H-4’ or H-3’), 5.83 (dd, J3’,5’ = 1.3, J3’,4’ = 10.1 Hz, 
1H; H-3’ or H-4’), 5.72 (dd, J3,5 = 1.7, J3,4 = 10.1 Hz, 1H; H-3 or H-4), 5.63 (d, JNH,5 = 9.6 Hz, 
1H; NHCOCH3), 5.54 (d, JNH’,5’ = 9.8 Hz, 1H; NHCOCH3’), 5.42-5.35 (overlapping, 2H; H-
8’ and H-7), 5.32 (dd, J7’,6’ = 1.8, J7’,8’ = 6.3 Hz, 1H; H-7’), 5.17 (ddd, J8,9a = 2.1, J8,7 = 4.0, 
J8,9b = 7.2 Hz, H-8), 4.67-4.60 (overlapping, H-5 and H-9a), 4.51 (dd, J9a’,8’ = 2.4, J9a’,9b’ = 12.4 
Hz, 1H; H-9a’), 4.43 (m; 1H; H-5’), 4.33 (dd, 1H; J6,7 = 2.3, J6,5 = 10.0 Hz, H-6), 4.28-4.21 
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(overlapping, 2H; H-9b and H-9b’), 3.90 (dd, J6’,7’ = 1.8, J6’,5’ = 9.9 Hz, 1H; H-6’), 3.78 (s, 
3H; COOCH3), 3.74 (s, 3H; COOCH3’), 3.68-3.43 (overlapping, 4H; SCH2CH2(CH2)5CH3, 
SCH2CH2(CH2)5CH3’), 2.13-2.09 (overlapping, 6H; OCOCH3 and OCOCH3’), 2.09-2.04 
(overlapping, 6H; OCOCH3 and OCOCH3’), 2.03-1.99 (overlapping, 6H; OCOCH3 and 
OCOCH3’), 1.96-1.91 (overlapping, 6H; NHCOCH3 and NHCOCH3’), 1.59-1.37 
(overlapping, 4H; SCH2CH2(CH2)5CH3 and SCH2CH2(CH2)5CH3’), 1.35-1.15 (overlapping, 
20H; SCH2CH2(CH2)5CH3, SCH2CH2(CH2)5CH3’), 0.88-0.80 ppm (overlapping, 6H; 
SCH2CH2(CH2)5CH3, SCH2CH2(CH2)5CH3’);13C NMR (125 MHz, CDCl3) : δ = 170.4 (4C; 
OCOCH3, OCOCH3’, OCOCH3 and OCOCH3’), 170.1 (2C, OCOCH3 and OCOCH3’), 169.8 
(2C; NHCOCH3 and NHCOCH3’), 168.8 (C-1’), 167.3 (C-1), 131.4 (C-3’ or C-4’), 130.6 (C-
3 or C-4), 126.5 (C-4’ or C-3’), 126.4 (C-4 or C-3), 85.4 (C-2), 84.5 (C-2’), 74.3 (C-6’), 71.6 
(C-8), 70.8 (C-6), 70.6 (C-8’), 68.7 (C-7), 68.1 (C-7’), 62.5 (C-9), 62.2 (C-9’), 52.8 (2C; 
COOCH3 and COOCH3’), 43.1 (C-5’), 42.9 (C-5), 31.7, 30.1, 29.2, 29.1, 29.0 (12C, 
SCH2CH2(CH2)5CH3 and SCH2CH2(CH2)5CH3’), 23.2 (2C, NHCOCH3 and NHCOCH3’), 
22.5 (2C, SCH2CH2(CH2)5CH3 and SCH2CH2(CH2)5CH3’), 21.1 (OCOCH3’), 20.9 
(OCOCH3), 20.7 (2C, OCOCH3 and OCOCH3’), 20.6 (2C, OCOCH3 and OCOCH3’), 14.0 
ppm (SCH2CH2(CH2)5CH3 and SCH2CH2(CH2)5CH3’). MS (ESI positive) m/z 560.7 [M+H]+, 
582.7 [M+Na]+. 
5.1.3.4 Deacetylation to achieve compounds 32a,b and 33a-f  
General Zemplén reaction procedure. The peracetylated mixtures of 32a,b or 33a-f (200 mg, 
0.45 mmol) was treated with a methanolic solution of NaOMe, freshly prepared by dissolving 
sodium metal (0.22 mmol, 5 mg) in anhydrous MeOH (2 mL). The reaction mixture was 
stirred at 23 °C for 1 h, and then quenched with acidic resin (Dowex 50WX8, H+). The resin 
was filtered off and washed with MeOH (4 mL) and the combined filtrates were evaporated 
under vacuum. The crude compound was purified with flash chromatography to give 
compounds 32a and 32b or 33a, 33b, 33c, 33d, 33e and 33f. 
Preparation of the methyl (methyl-5-acetamido-3,4,5-trideoxy-D-manno-non-3-en-2-
ulopyranosid)-onates (32a and 33a). 
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Starting from mixture of 
23a+24a (200 mg, 0.45 mmol) and according to general Zemplén procedure, column 
chromatography (eluting with AcOEt/MeOH, 9:1 to 8:2, v/v) first afforded compound 32a as 
a white solid (24 mg, 16%), showing: [α]D23 = -64.7 (c=1 in methanol); 1H NMR (500 MHz, 
CD3OD): δ = 6.13 (d, J3,4 = 10.1 Hz, 1H; H-3), 5.88 (dd, J4,5 = 2.5, J4,3 = 10.1 Hz, 1H; H-4), 
4.72 (br d, J5,6 = 9.7 Hz, 1H; H-5), 3.92-3.90 (m, 1H; H-8), 3.88 (d, J6,5 = 9.7 Hz, 1H; H-6), 
3.86 (dd, J9a,8 = 2.1, J9a,9b = 11.4 Hz, 1H; H-9a), 3.81 (s, 3H; COOCH3), 3.66 (dd, J9b,8 = 5.8, 
J9b,9a = 11.4 Hz; 1H; H-9b), 3.56 (d, J7,8 = 9.1 Hz, 1H; H-7), 3.33 (s, 3H; OCH3), 1.97 ppm (s, 
3H; NHCOCH3); 13C NMR (125 MHz, CD3OD): δ = 174.0 (NHCOCH3), 171.8 (C-1), 137.1 
(C-3), 127.1 (C-4), 99.2 (C-2), 77.2 (C-6), 72.4 (C-8), 70.0 (C-7), 64.7 (C-9), 53.6 (COOCH3), 
51.3 (OCH3), 44.5 (C-5), 22.6 ppm (NHCOCH3). Other chemical-physical properties were 
superimposable with those previously reported in literature42. Further elution afforded 
compound 33a (94 mg, 66 %): [α]D23 = -183.1 (c=1 in methanol); 1H NMR (500 MHz, 
CD3OD): δ = 5.92 (d, J3,4 = 10.1 Hz, 1H; H-3), 5.86 (dd, J4,5 = 1.7, J4,3 = 10.1 Hz, 1H; H-4), 
4.72 (d, J5,6 = 10.2 Hz, 1H; H-5), 4.03 (d, J6,5 = 10.2 Hz, 1H; H-6), 3.82-3.76 (overlapping, 
5H; H-8, H-9a and COOCH3), 3.65 (dd, J9b,8 = 5.4, J9b,9a = 11.4 Hz, 1H; H-9b), 3.47 (d, J7,8 = 
9.4 Hz, 1H; H-7), 3.28 (s, 3H; OCH3), 1.93 ppm (s, 3H; NHCOCH3); 13C NMR (125 MHz, 
CD3OD): δ = 173.7 (NHCOCH3), 171.0 (C-1), 135.1 (C-3), 127.1 (C-4), 97.8 (C-2), 71.7 (C-
6), 71.4 (C-8), 70.2 (C-7), 65.3 (C-9), 53.5 (COOCH3), 52.3 (OCH3), 44.5 (C-5), 22.7 ppm 
(NHCOCH3). Other chemical-physical properties were superimposable with those previously 
reported in literature42. 
Preparation of the methyl (2S-ethyl-5-acetamido-2,3,4,5-tetradeoxy-D-manno-non-3-en-2-
ulopyranosid)-onates (32b and 33b). 
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Starting from compound 23b+24b (214 mg, 0.45 mmol) and according to general procedure,  
column chromatography (eluting with AcOEt/MeOH, 9:1 to 85:15, v/v) first afforded 
compound 32b as a white solid (13 mg, 9%), showing: [α]D23 = -59.8 (c=1 in methanol); 1H 
NMR (500 MHz, CD3OD): δ = 6.02 (ddd, J4,6 < 1.0, J4,5 = 2.5, J4,3 = 10.1 Hz, 1H; H-3), 5.94 
(dd, J3,5 = 1.4, J3,4 = 10.1 Hz, 1H; H-4), 4.71 (br d, J5,6 = 9.6 Hz, 1H; H-5), 3.93 (ddd, J8,9a = 
2.4, J8,9b = 5.9, J8,7 = 9.1 Hz, 1H; H-8), 3.86 (dd, J9a,8 = 2.4, J9a,9b = 11.4 Hz, 1H; H-9a), 3.81 
(s, 3H; COOCH3), 3.65 (dd, J9b,8 = 5.9, J9b,9a = 11.4 Hz, 1H; H-9b), 3.60 (dd, J6,7 = 1.3, J6,5 = 
9.6 Hz, 1H; H-6), 3.54 (dd, J7,6 = 1.3, J7,8 = 9.1 Hz, 1H; H-7), 2.80-2.62 (overlapping, 2H; 
SCH2CH3), 1.97 (s, 3H; NHCOCH3), 1.24 ppm (m, 3H; SCH2CH3); 13C NMR (125 MHz, 
CD3OD): δ = 174.1 (NHCOCH3), 172.8 (C-1), 132.5 (C-4), 127.8 (C-3), 85.5 (C-2), 77.3 (C-
6), 72.6 (C-8), 69.9 (C-7), 64.7 (C-9), 53.9 (COOCH3), 44.3 (C-5), 24.2 (SCH2CH3), 22.6 
(NHCOCH3), 14.9 ppm (SCH2CH3). MS (ESI positive) m/z 350.1 [M+H]+, 372.2 [M+Na]+. 
Further elution afforded compound 33b (115 mg, 73%) showing: [α]D23 = -213.7 (c=1 in 
methanol); 1H NMR (500 MHz, CD3OD): δ = 6.13 (dd, J4,5 = 2.3, J4,3 = 10.1 Hz, 1H; H-3), 
5.83 (dd, J3,5 = 1.7, J3,4 = 10.1 Hz, 1H; H-4), 4.79 (d, J5,6 = 10.0 Hz, 1H; H-5), 4.36 (d, J6,5 = 
10.0 Hz, 1H; H-6), 3.86-3.75 (overlapping, 5H; H-8, H-9a and COOCH3), 3.68 (dd, J9b,8 = 
5.3, J9b,9a = 11.3 Hz, 1H; H-9b), 3.53 (d, J7,8 = 9.1 Hz, 1H; H-7), 2.78-2.69 (m, 1H; SCH2CH3), 
2.64-2.54 (m, 1H; SCH2CH3), 1.97 (s, 3H; NHCOCH3), 1.17 ppm (m, 3H; SCH2CH3); 13C 
NMR (125 MHz, CD3OD): δ = 173.6 (NHCOCH3), 170.8 (C-1), 132.1 (C-3), 127.5 (C-4), 
86.2 (C-2), 71.8 (C-6), 71.6 (C-8), 70.4 (C-7), 65.3 (C-9), 53.6 (COOCH3), 44.5 (C-5), 25.0 
(SCH2CH3), 22.7 (NHCOCH3), 14.4 ppm (SCH2CH3). MS (ESI positive) m/z 350.1 [M+H]+, 372.2 
[M+Na]+. 
Preparation of the β-anomer of methyl (ethyl-5-acetamido-3,4,5-trideoxy-D-manno-non-3-en-
2-ulopyranosid)-onates (33c).  
 
Starting from mixture of 23c+24c (207 mg, 0.45 mmol) and according to general Zemplén 
procedure, column chromatography (AcOEt/MeOH, 9:1 to 8:2, v/v) afforded compound 33c 
(98 mg, 65%): 1H NMR (500 MHz, CD3OD):δ = 5.96 (dd, J3,5 = 1.5, J3,4 = 10.1 Hz, 1H; H-3), 
5.93 (dd, J4,5 = 2.1, J4,3 = 10.1 Hz, 1H; H-4), 4.80 (br d, J5,6 = 10.3 Hz, 1H; H-5), 4.13 (dd, 
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J6,7<1.0, J6,5 = 10.3 Hz, 1H; H-6), 3.89-3.78 (overlapping, 6H; H-8, H-9a, COOCH3 and 
OCH2CH3), 3.67 (dd, J9b,8 = 5.0, J9b,9a = 11.0 Hz, 1H; H-9b), 3.52 (br d, J7,8 = 9.3 Hz, 1H; H-
7), 3.31 (m, 1H; OCH2CH3), 1.99 (s, 3H; NHCOCH3), 1.19 ppm (t, JCH2,CH3 = 7.0 Hz, 3H; 
OCH2CH3); 13C NMR (125 MHz, CD3OD): δ = 173.7 (NHCOCH3), 171.4 (C-1), 134.8 (C-
3), 127.4 (C-4), 97.4 (C-2), 71.6 (C-6), 71.5 (C-8), 70.1 (C-7), 65.3 (C-9), 61.1 (OCH2CH3), 
53.5 (COOCH3), 44.5 (C-5), 22.7  (NHCOCH3), 15.5 (OCH2CH3). MS (ESI positive): m/z 
334.1 [M+H]+, 356.2 [M+Na]+. 
Preparation of the β-anomer of methyl (isopropyl-5-acetamido-3,4,5-trideoxy-D-manno-non-
3-en-2-ulopyranosid)-onates (33d).  
 
 
Starting from mixture of 23d+24d (213 mg, 0.45 mmol) and according to general procedure, 
column chromatography (AcOEt/MeOH, 9:1 to 8:2, v/v) afforded compound 33c (102 mg, 
65%):  [α]D23= -139.4 (c=1 in methanol); 1H NMR (500 MHz, CD3OD): δ = 5.97 (dd, J4,5 = 
2.4, J4,3 = 10.2 Hz, 1H; H-3), 5.91 (dd, J3,5 = 1.7, J3,4 = 10.2 Hz, 1H; H-4), 4.75 (dd, J5,6 = 10.2 
Hz, 1H; H-5), 4.16 (m, 1H; OCH(CH3)2),  4.09 (d, J6,5 = 10.2 Hz, 1H; H-6), 3.86-3.75 
(overlapping, 5H; H-8, H-9a and COOCH3), 3.68 (dd, J9b,8 = 5.2, J9b,9a = 11.2 Hz, 1H; H-9b), 
3.48 (d, J7,8 = 9.5 Hz, 1H; H-7), 1.97 (s, 3H; NHCOCH3), 1.22 (d, JH,H = 6.2 Hz, 3H; 
OCH(CH3)2), 1.05 ppm (d, JH,H = 6.2 Hz, 3H; OCH(CH3)2); 13C NMR (125 MHz, CD3OD): δ 
= 173.6 (NHCOCH3), 171.8 (C-1), 134.1 (C-3 or C-4), 127.8 (C-3 or C-4), 96.2 (C-2), 71.8 
(C-6), 71.4 (C-8), 70.6 (C-7), 68.9 (OCH(CH3)2), 65.3 (C-9), 53.4 (COOCH3), 44.4 (C-5), 
24.8 (OCH(CH3)2), 22.9 (OCH(CH3)2), 22.7 ppm (NHCOCH3); MS (ESI positive): m/z 348.4 
[M+H]+, 370.3 [M+Na]+. 
Preparation of the β-anomer of methyl (buthyl-5-acetamido-3,4,5-trideoxy-D-manno-non-3-
en-2-ulopyranosid)-onates (33e).  
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Starting from mixture of 23e+24e (219 mg, 0.45 mmol) and according to general Zemplén 
procedure, column chromatography (AcOEt/MeOH, 9:1 to 8:2, v/v) afforded compound 33e 
as a white solid (120 mg, 74%): [α]D23 = -145.3 (c=1 in MeOH); 1H NMR (500 MHz, CD3OD): 
δ = 5.94 (d, J3,4 = 10.1 Hz, 1H; H-3 or H-4), 5.93 (dd, J4,5 = 1.9, J4,3 = 10.1 Hz, 1H; H-4 or H-
3), 4.78 (d, J5,6 = 10.3 Hz, 1H; H-5), 4.09 (d, J6,5 = 10.3 Hz, 1H; H-6), 3.85-3.77 (overlapping, 
6H; H-8, H-9a, COOCH3 and OCH2(CH2)2CH3), 3.69 (dd, J9b,8 = 5.0, J9b,9a = 11.1 Hz, 1H; H-
9b), 3.52 (d, J7,8 = 9.1 Hz, 1H; H-7), 3.23 (m, 1H; OCH2(CH2)2CH3), 1.97 (s, 3H; NHCOCH3), 
1.54 (m, 2H; OCH2CH2CH2CH3), 1.39 (m, 2H; OCH2CH2CH2CH3), 0.91 ppm (m, 3H; 
OCH2CH2CH2CH3); 13C NMR (125 MHz, CD3OD): δ = 173.6 (NHCOCH3), 171.4 (C-1), 
134.7 (C-3 or C-4), 127.4 (C-4 or C-3), 97.4 (C-2), 71.7 (C-6), 71.5 (C-8), 70.2 (C-7), 65.3 
(2C; overlapping C-9 and OCH2(CH2)2CH3), 53.5 (COOCH3), 44.4 (C-5), 32.9 
(OCH2CH2CH2CH3), 22.7 (NHCOCH3), 20.2 (OCH2CH2CH2CH3), 14.3 ppm 
(OCH2(CH2)2CH3). MS (ESI positive): m/z 362.2 [M+H]+, 384.1 [M+Na]+.  
 
Preparation of the β-anomer of methyl (S-octhyl-5-acetamido-2,3,4,5-tetradeoxy-D-manno-
non-3-en-2-ulopyranosid)-onates (33f).  
 
Starting from mixture of 23f+24f (252 mg, 0.45 mmol) and according to general procedure, 
column chromatography (AcOEt/MeOH, 9:1 to 8:2, v/v) first afforded compound 33f a as a 
white solid (128 mg, 66 %), showing: [α]D23 = -178.2 (c=1 in methanol); 1H NMR (500 MHz, 
CD3OD): δ = 6.12 (d, J4,3 = 10.1 Hz, 1H; H-4 or H-3), 5.82 (d, J3,4 = 10.1 Hz, 1H; H-3 or H-
4), 4.80 (d, J5,6 = 10.0 Hz, 1H; H-5), 4.35 (d, J6,5 = 10.0 Hz, 1H; H-6), 3.85-3.75 (overlapping, 
5H; H-8, H-9a and COOCH3), 3.68 (dd, J9b,8 = 5.2, J9b,9a = 11.1 Hz, 1H; H-9b), 3.51 (d, J7,8 = 
9.1 Hz, 1H; H-7), 2.73 (m, 1H; SCH2CH2(CH2)5CH3), 2.59 (m, 1H; SCH2CH2(CH2)5CH3), 
1.97 (s, 3H; NHCOCH3), 1.60-1.42 (overlapping, 2H; SCH2CH2(CH2)5CH3), 1.42-1.20 
(overlapping, 10H; SCH2CH2(CH2)5CH3), 0.90 ppm (m, 3H; SCH2CH2(CH2)5CH3); 13C NMR 
(125 MHz, D2O): δ = 173.6 (NHCOCH3), 170.9 (C-1), 132.1 (C-4 or C-3), 127.5 (C-3 or C-
4), 86.1 (C-2), 71.8 (C-6), 71.7 (C-8), 70.5 (C-7), 66.2 (C-9), 53.6 (COOCH3), 44.5 (C-5), 
33.0, 30.8, 30.3, 30.1, 23.7 (7C, SCH2CH2(CH2)5CH3), 22.7 (NHCOCH3), 14.4 
(SCH2CH2(CH2)5CH3). (ESI positive): m/z 434.4 [M+H]+, 456.4 [M+Na]+. 
5.1.3.5 Removal of esteric function to obtain the final compounds 21a,b and 22a-f 
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General procedure. The final 3,4-unsaturated compounds 21a,b and 22a-f were prepared by 
hydrolysis of appropriate methyl ester derivatives 32a,b and 33a-f  (0.10 mmol) performed in 
aqueous solution of KOH 0.5 M (0.8 mL) kept at 23°C for 1 h. Then, the reaction mixture was 
treated using Method A or B: 
Method A: Weak acidic resin (Amberlite CG50, H+) until neutral pH, and then, the resin was 
filtered and washed with H2O (2 mL X 3). 
Method B: Strong acidic resin (Dowex 50WX8, H+) treatment until acidic pH, and then, the 
resin was filtered and washed with MeOH-H2O (1:1, v/v; 2 mL X 3); 
Finally, the solvent was removed under reduced pressure to give the desired deprotected 3,4-
unsaturated compounds.  
Preparation of the potassium salt of 2αO-methyl (5-acetamido-3,4,5-trideoxy-D-manno-non-
3-en-2-ulopyranosid) acid (21a) 
 
Starting from compound 32a (32 mg, 0.10 mmol), according to general procedure using 
Method A, the desired compound 21a was obtained as white solid potassium salt (30 mg, 
87%), showing: [α]D23 = - 22.1 (c=1.0 in water); 1H NMR (500 MHz, D2O): δ = 6.03 (br d, 
J4,3 = 10.1 Hz, 1H; H-3), 5.98 (br d, J3,4 = 10.1 Hz, 1H; H-4), 4.69 (br d, J5,6 = 10.3 Hz, 1H; 
H-5), 3.98-3.85 (overlapping, 3H; H-6, H-8 and H-9a), 3.65 (dd, J9b,8 = 6.4, J9b,9a = 11.9 Hz, 
1H; H-9b), 3.60 (dd, J7,6 < 1.0, J7,8 = 9.5 Hz, 1H; H-7), 3.32 (s, 3H; OCH3), 2.06 (s, 3H; 
NHCOCH3); 13C NMR (125 MHz, D2O): δ = 175.1 (C-1), 175.0 (NHCOCH3), 133.7 (C-3), 
128.7 (C-4), 100.2 (C-2), 75.8 (C-6), 71.8 (C-8), 68.7 (C-7), 63.4 (C-9), 51.5 (OCH3), 43.7 
(C-5), 22.5 ppm (NHCOCH3) ppm; MS (ESI negative): m/z 304.1 [M-H]-; elemental analysis 
calcd (%) for C12H18KNO8: C 41.98, H 5.28, N 4.08; found: C 42.09, H 5.34, N 4.15. 
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Preparation of the potassium salt of 2βO-methyl (5-acetamido-3,4,5-trideoxy-D-manno-non-
3-en-2-ulopyranosid) acid (22a). 
 
Starting from compound 33a (32 mg, 0.10 mmol), according to general procedure using 
method A, the desired compound 22a was obtained as white solid potassium salt (29 mg, 85%), 
showing: [α]D24 = -184.7 (c=1.0 in water); 1H NMR (500 MHz, D2O): δ = 5.96-5.91 
(overlapping, 2H; H-3 and H-4),  4.72 (d app, J5,6 = 10.3 Hz, 1H; H-5), 3.95 (dd, J6,7 < 1.0, J6,5 
= 10.3 Hz, 1H; H-6), 3.91 (ddd, J8,9a = 2.5, J8,9b = 5.6, J8,7=9.5 Hz, 1H; H-8), 3.87 (dd, J9a,8 = 
2.5, J9a,9b = 12.0 Hz, 1H; H-9a), 3.69 (dd, J9b,8 = 5.6, J9b,9a=12.0 Hz, 1H; H-9b), 3.57 (dd, J7,6 
< 1.0, J7,8 = 9.5 Hz, 1H; H-7), 3.27 (s, 3H; OCH3), 2.01 ppm (s, 3H; NHCOCH3); 13C NMR 
(125 MHz, D2O): δ = 175.0 (C-1), 174.9 (NHCOCH3), 133.2 (C-3), 128.2 (C-4), 98.4 (C-2), 
70.5 (C-8), 70.3 (C-6), 69.0 (C-7), 64.1 (C-9), 51.7 (OCH3), 43.9 (C-5), 22.7 ppm 
(NHCOCH3); MS (ESI negative): m/z 304.1 [M-H]-; elemental analysis calcd (%) for 
C12H18KNO8: C 41.98, H 5.28, N 4.08; found: C 42.00, H 5.26, N 4.01. 
 
Preparation of the 2αS-ethyl (5-acetamido-2,3,4,5-tetradeoxy-D-manno-non-3-en-2-
ulopyranosid) acid (21b) 
 
Starting from compound 32b (35 mg, 0.10 mmol), according to general procedure using 
method B, the desired compound 21b was obtained as white solid in acidic form (29 mg, 87%), 
showing: [α]D24 = -69.4 (c=1.0 in methanol); 1H NMR (500 MHz, CD3OD): δ = 6.06 (dd, J4,5 
= 2.5, J4,3 = 10.1 Hz, 1H; H-3), 5.92 (dd, J3,5 = 1.7, J3,4 = 10.1 Hz, 1H; H-4), 4.69 (ddd, J5,3 = 
1.7, J5,4 = 2.5, J5,6 = 9.5 Hz, 1H; H-5), 3.92 (ddd, J8,9a = 2.6, J8,9b = 5.8, J8,7 = 9.2 Hz, 1H; H-
8), 3.85 (dd, J9a,8 = 2.6, J9a,9b = 11.4 Hz, 1H; H-9a), 3.65 (dd, J9b,8 = 5.8, J9b,9a = 11.4 Hz, 1H; 
H-9b), 3.61 (dd, J6,7 = 2.0, J6,5 = 9.5 Hz, 1H; H-6), 3.56 (dd, J7,6 = 2.0, J7,8 = 9.2 Hz, 1H; H-7), 
2.80-2.65 (overlapping, 2H; SCH2CH3), 1.97 (s, 3H; NHCOCH3), 1.25 ppm (t, JCH2,CH3 = 7.5 
5. Experimental 
 
 
131 
 
Hz, 3H; SCH2CH3); 13C NMR (125 MHz, CD3OD): δ = 174.2 (C-1), 173.5 (NHCOCH3), 
132.0 (C-4), 128.5 (C-3), 85.6 (C-2), 77.4 (C-6), 72.7 (C-8), 69.8 (C-7), 64.7 (C-9), 44.4 (C-
5), 24.3 (SCH2CH3), 22.6 (NHCOCH3), 14.9 ppm (SCH2CH3); MS (ESI negative): m/z 334.1 
[M-H]-; elemental analysis calcd (%) for C13H21NO7S: C 46.56, H 6.31, N 4.18; found: C 
46.40, H 6.42, N 4.12. 
 
Preparation of the 2βS-ethyl (5-acetamido-2,3,4,5-tetradeoxy-D-manno-non-3-en-2-
ulopyranosid) acid (22b) 
 
Starting from compound 33b (35 mg, 0.10 mmol), according to general procedure using 
method B, the desired compound 22b was obtained as white solid in acidic form (30 mg, 89%), 
showing [α]D23 = -217.2 (c=1 in methanol); 1H NMR (500 MHz, CD3OD): δ = 6.12 (dd, J4,5 = 
2.4, J4,3 = 10.1 Hz, 1H; H-3), 5.81 (dd, J3,5 = 1.9, J3,4 = 10.1 Hz, 1H; H-4), 4.80 (ddd, J5,3 = 
1.9, J5,4 = 2.4, J5,6 = 10.1 Hz, 1H; H-5), 4.38 (dd, J6,7 < 1.0, J6,5=10.1 Hz, 1H; H-6), 3.83 (dd, 
J9a,8 = 2.9, J9a,9b = 11.3 Hz, 1H; H-9a), 3.77 (ddd, J8,9a = 2.9, J8,9b = 5.4, J8,7 = 9.2 Hz, 1H; H-
8), 3.68 (dd, J9b,8 = 5.4, J9b,9a = 11.3 Hz, 1H; H-9b), 3.52 (dd, J7,6 < 1.0, J7,8 = 9.2 Hz, 1H; H-
7), 2.79-2.67 (m, 1H; CH2CH3), 2.66-2.55 (m, 1H; SCH2CH3), 1.97 (s, 3H; NHCOCH3), 1.21 
ppm (t, JCH2,CH3 = 7.5 Hz, 3H; SCH2CH3); 13C NMR (125 MHz, CD3OD, 23 °C): δ = 173.6 
(C-1), 172.2 (NHCOCH3), 131.9 (C-4), 128.0 (C-3), 86.5 (C-2), 71.8 (C-6), 71.6 (C-8), 70.4 
(C-7), 65.2 (C-9), 44.5 (C-5), 25.1 (SCH2CH3), 22.7 (NHCOCH3), 14.3 ppm (SCH2CH3); MS 
(ESI negative): m/z 334.2 [M-H]-; elemental analysis calcd (%) for C13H21NO7S: C 46.56, H 
6.31, N 4.18; found: C 46.64, H 6.41, N 4.23. 
 
Preparation of the potassium salt of 2βO-ethyl (5-acetamido-3,4,5-trideoxy-D-manno-non-3-
en-2-ulopyranosid) acid (22c). 
 
Starting from compound 33c (33 mg, 0.10 mmol), according to general procedure using 
method A, the desired compound 22c was obtained as white solid potassium salt (29 mg, 80%), 
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showing: [α]D23= -142.5 (c=1.0 in water); 1H NMR (500 MHz, D2O): δ = 5.97-5.91 
(overlapping, 2H; H-3 and H-4), 4.73 (d app, J5,6 = 10.3 Hz, 1H; H-5), 3.99 (d, J6,5 = 10.3 Hz, 
1H; H-6), 3.88 (ddd, J8,9a = 2.6, J8,9b = 5.4, J8,7 = 9.4 Hz, 1H; H-8), 3.84 (dd, J9a,8 = 2.6, J9a,9b 
= 12.0 Hz, 1H; H-9a), 3.74-3.68 (overlapping, 2H; H-9b and OCH2CH3), 3.56 (d app, J7,8 = 
9.4 Hz, 1H; 7-H), 3.41 (1H; m, OCH2CH3), 2.03 (s, 3H; NHCOCH3), 1.18 ppm (t, JCH2,CH3 = 
7.0 Hz, 3H; OCH2CH3); 13C NMR (125 MHz, D2O): δ = 175.2 (NHCOCH3 or C-1), 175.0 
(NHCOCH3 or C-1), 133.0 (C-3), 128.5 (C-4), 98.1 (C-2), 70.6 (C-8), 70.3 (C-6), 69.0 (C-7), 
64.1 (C-9), 60.7 (OCH2CH3), 44.0 (C-5), 22.7 (NHCOCH3), 15.1 ppm (OCH2CH3). MS (ESI 
negative): m/z 318.1 [M-H]-; elemental analysis calcd (%) for C13H20KNO8: C 43.69, H 5.64, 
N 3.92; found: C 43.78, H 5.60, N 3.82. 
Preparation of the potassium salt of 2βO-isopropyl (5-acetamido-3,4,5-trideoxy-D-manno-
non-3-en-2-ulopyranosid) acid (22d). 
 
 
Starting from compound 33d (35 mg, 0.10 mmol), according to general procedure using 
method A, the desired compound 22d was obtained as white solid potassium salt (30 mg, 
81%), showing: [α]D23= -117.2 (c=1 in water); 1H NMR (500 MHz, D2O) : δ = 6.03 (dd, J4,5 
= 2.4, J4,3 = 10.1 Hz, 1H; H-3 or H-4), 5.88 (dd, J3,5 = 1.8, J3,4 = 10.1 Hz, 1H; H-3 or H-4), 
4.70 (ddd, J3,5 = 1.8, J4,5 = 2.4, J5,6 = 10.2 Hz, 1H; H-5), 4.15-4.05 (m, 1H; OCH(CH3)2), 3.98-
3.89 (overlapping, 2H; H-6 and H-8), 3.85 (dd, J9a,8 = 2.7, J9a,9b = 12.1 Hz, 1H; H-9a), 3.72 
(J9b,8 = 5.4, J9a,9b = 12.1 Hz, 1H; H-9b), 3.53 (d app, J7,8 = 9.5 Hz, 1H; H-7), 2.02 (s, 3H; 
NHCOCH3), 1.21 (m, 3H; OCH(CH3)2), 1.14 ppm (m, 3H; OCH(CH3)2); 13C NMR (125 MHz, 
D2O): δ = 175.5 (C-1), 174.9 (NHCOCH3), 131.8 (C-3 or C-4), 129.3 (C-3 or C-4), 97.1 (C-
2), 70.4, 70.3 (C-6 and C-8), 69.5 (C-7), 69.2 (OCH(CH3)2), 64.1 (C-9), 43.9 (C-5), 24.4 
(OCH(CH3)2), 22.7, 22.6 and (CH3CONH and OCH(CH3)2); MS (ESI negative): m/z 332.1 
[M-H]-; elemental analysis calcd (%) for C14H22KNO8: C 45.27, H 5.97, N 3.77; found: C 
45.31, H 5.90, N 3.81. 
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Preparation of the potassium salt of 2βO-buthyl (5-acetamido-3,4,5-trideoxy-D-manno-non-
3-en-2-ulopyranosid) acid (22e). 
 
Starting from protected compound 33e (36 mg, 0.10 mmol), according to general procedure 
using method A the desired compound 22e was obtained as white solid potassium salt (31 mg, 
80%), showing: [α]D23 = -122.2 (c=1 in water); 1H NMR (500 MHz, D2O): δ = 5.99-5.90 
(overlapping, 2H; H-3 and H-4), 4.71 (d app, J5,6 = 10.2 Hz, 1H; H-5), 3.98 (d app, J6,5 = 10.2 
Hz, 1H; H-6), 3.93-3.84 (m, J9a,9b = 12.1 Hz, 2H; H-8 and H-9a), 3.76-3.73 (overlapping, 2H; 
H-9b and OCH2CH2CH2CH3), 3.56 (d app, 1H; J7,8 = 9.3 Hz H-7), 3.35 (1H; m, 
OCH2CH2CH2CH3), 2.03 (s, 3H; NHCOCH3), 1.55 (m, 2H; OCH2CH2CH2CH3), 1.34 (m, 2H; 
OCH2CH2CH2CH3), 0.89 (m, 3H; OCH2CH2CH2CH3); 13C NMR (125 MHz, D2O): δ = 175.2 
(NHCOCH3 or C-1), 174.9 (NHCOCH3 or C-1), 132.8 (C-3 or C-4), 128.5 (C-4 or C-3), 98.0 
(C-2), 70.6 (C-8), 70.3 (C-6), 69.1 (C-7), 65.0 (OCH2CH2CH2CH3), 64.1 (C-9), 43.9 (C-5), 
31.7 (OCH2CH2CH2CH3), 22.7 (NHCOCH3), 19.4 (OCH2CH2CH2CH3), 13.9 
(OCH2CH2CH2CH3). MS (ESI negative): m/z 346.2 [M-H]-; elemental analysis calcd (%) for 
C15H24KNO8: C 46.74, H 6.28, N 3.63; found: C 46.81, H 6.32, N 3.65. 
 
Preparation of the of 2βS-octyl (5-acetamido-2,3,4,5-tetradeoxy-D-manno-non-3-en-2-
ulopyranosid) acid (22f). 
 
Starting from protected compound 33f (43 mg, 0.10 mmol), according to general procedure 
using method B, the desired compound 22f was obtained as white solid potassium salt (34 mg, 
80%), showing: [α]D23 = -182.6 (c=1 in methanol); 1H NMR (500 MHz, CD3OD): δ = 6.13 
(dd, J4,5 = 2.4, J4,3 = 10.1 Hz, 1H; H-4), 5.81 (dd, J3,5 = 1.9, J3,4 = 10.1 Hz, 1H; H-3), 4.81 (dd, 
J5,3 = 1.9, J5,4 = 2.4, J5,6 = 10.1 Hz, 1H; H-5), 4.37 (dd, J6,7 = 0.9, J6,5 = 10.1 Hz, 1H; H-6), 3.84 
(dd, J9a,8  = 2.9, J9a,9b = 11.2 Hz, 1H; H-9a), 3.76 (J8,9a = 2.9, J8,9b = 5.4, J8,7 = 9.2 Hz, 1H; H-
8), 3.68 (dd, J9b,8 = 5.4, J9b,9a = 11.2, 1H; H-9b), 3.53 (dd, J7,6  = 0.9, J7,8 = 9.2 Hz, 1H; H-7), 
2.77-2.51 (m, 2H; SCH2(CH2)6CH3), 1.97 (s, 3H; NHCOCH3), 1.66-1.45 (m, 2H; 
SCH2CH2(CH2)5CH3), 1.44-1.17 (m, 10H; SCH2CH2(CH2)5CH3), 0.9 ppm (m, 3H; 
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SCH2(CH2)6CH3); 13C NMR (125 MHz, CD3OD): δ = 13C NMR (125 MHz, CD3OD): δ = 
173.6 (C-1), 172.3 (NHCOCH3), 131.9 (C-3), 128.0 (C-4), 86.4 (C-2), 71.8 (C-8), 71.7 (C-6), 
70.5 (C-7), 65.1 (C-9), 44.5 (C-5), 33.0, 31.0, 30.4 , 30.3, 30.3, 30.2 23.7 (7C, 
SCH2(CH2)6CH3), 22.7 (NHCOCH3), 14.5 ppm (SCH2(CH2)6CH3); MS (ESI negative): m/z 
418.2 [M-H]-; elemental analysis calcd (%) for C19H33NO7S: C 54.40, H 7.93, N 3.34; found: 
C 54.51, H 7.90, N 3.39. 
5.1.3.6 Synthesis of unsaturated 1,7-lactones 34 and 35 and saturated lactone 36. 
General procedure. The appropriate starting material 21a and 22a, or 21b and 22b (0.10 
mmol), dissolved in DMF (1.0 mL) under stirring, was cooled to 0 °C and diluted with THF 
(1.5 mL). Then CbzCl (0.03 mL; 0.25 mmol, 2.5 equiv) in THF (0.4 mL) was added in a single 
portion, followed by Et3N (0.04 mL; 0.3 mmol) in a single addition. The mixture was then 
stirred for 15-60 min at 23 °C. At this time, water (0.3 mL) was added and the stirring was 
continued for 15 min. Evaporation of the solvent under reduced pressure afforded a crude 
residue. The 1H-NMR were performed on crude products.  
 Compounds 21a and 21b did not give any 1,7-lactones and the only molecules present 
in the crude were the starting materials (Data not shown). 
 Compounds 22a and 22b give, after purification by flash chromatography, the 
appropriate pure lactones 34 or 35. 
Preparation of the 2O-methyl (5-acetamido-3,4,5-trideoxy-D-manno-non-3-en-2-
ulopyranosid) acid 1,7-lactone (34) 
34
O
NHAc
O
OMe
OH
HO
O
 
Starting from compound 22a (34 mg, 0.10 mmol), according to general procedure, compound 
34 was obtained (11 mg, 36%), after purification by flash chromatography (eluting with 
CH3CN/MeOH, 10:0 to 9:1, v/v) as a white solid, showing: 1H NMR (500 MHz, D2O) : δ = 
6.43 (ddd, J4,6 = 1.0, J4,5 = 5.0, J4,3 = 10.0 Hz, 1H; H-4), 6.13 (dd, J3,5 = 1.1, J3,4 = 10.0 Hz, 1H; 
H-3), 4.67 (dd, J6,4 = 1.0, J6,7 = 2.9 Hz, 1H; H-6), 4.56 (dd, J7,6 = 2.9, J7,8=5.3 Hz, 1H; H-7), 
4.27 (d, J5,4 = 5.0 Hz, 1H; H-5), 4.05 (m, 1H; H-8), 3.79 (dd, J9a,8 = 4.4, J9a,9b = 12.0 Hz, 1 H; 
H-9a), 3.75 (dd, J9b,8 = 6.1, J9b,9a = 12.0 Hz, 1H; H-9b), 3.50 (s, 3H; OCH3), 2.06 ppm (3H; s, 
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NHCOCH3); 13C NMR (125 MHz, CD3OD): δ = 172.6 (NHCOCH3), 166.9 (C-1), 130.4 (C-
4), 126.7 (C-3), 92.2 (C-2), 78.4 (C-7), 71.0 (C-6), 70.5 (C-8), 59.9 (C-9), 50.7 (OCH3), 44.8 
(C-5), 20.5 ppm (NHCOCH3).  
 
Preparation of the 2S-ethyl (5-acetamido-2,3,4,5-tetradeoxy-D-manno-non-3-en-2-
ulopyranosid) acid 1,7-lactone (35) 
 
Starting from compound 22b (34 mg, 0.10 mmol), according to general procedure, compound 
35 was obtained (13 mg, 40%), after purification by flash chromatography (eluting with 
acetonitrile/methanol, 10:0 to 9:1, v/v) as a white solid, showing: 1H NMR (500 MHz, D2O): 
δ = 6.29 (ddd, J4,6 = 1.0, J4,5 = 5.4, J4,3 = 9.9 Hz, 1H; H-4), 6.12 (dd, J3,5 = 1.1, J3,4 = 9.9 Hz, 
1H; H-3), 4.53 (br d, J6,7 = 3.6 Hz, 1H; H-6), 4.45 (dd, J7,6 = 3.6, J7,8 = 4.8 Hz, 1H; H-7), 4.11 
(d, J5,4 = 5.4 Hz, 1H; H-5), 4.01 (m, 1H; H-8), 3.74 (dd, J9a,8 = 4.6, J9a,9b = 12.0 Hz, 1H; H-9a), 
3.68 (dd, J9b,8 = 6.3, J9b,9a = 12.0 Hz, 1H; H-9b), 2.80-2.63 (overlapping, 2H; SCH2CH3), 2.00 
(3H; s, NHCOCH3), 1.22 ppm (m, 3H; SCH2CH3); 13C NMR (125 MHz, CD3OD): δ = 174.5 
(NHCOCH3), 169.2 (C-1), 129.2 and 129.1 (C-3 and C-4), 83.5 (C-2), 80.2 (C-7), 72.4 (C-8), 
72.0 (C-6), 61.6 (C-9), 46.3 (C-5), 23.5 (SCH2CH3), 22.4 (NHCOCH3), 14.4 ppm (SCH2CH3).  
Preparation of 5-acetamido-2,6-anhydro-2-methyl-3,4,5-trideoxy-D-glycero-D-galacto-non-
3-enoic acid 1,7-lactone (36) 
 
The saturated lactone 36 was obtained following two different synthetic pathways: 
Path 1: the unsaturated 1,7-lactone 34 (10 mg, 0.035 mmol) was diluted with AcOEt (4 mL), 
the catalyst Pd/C (10% w/w) was added and, then, the mixture was stirred at 23°C for 2.5 h 
under H2 atmosphere. The catalyst was filtered off and washed with AcOEt-THF (10 mL) and 
the combined filtrates were evaporated under vacuum, giving the compound 36 (5mg, 50%) 
after purification by flash chromatography (eluting with ethyl acetate/methanol, 95:5 to, 
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85:15, v/v) as a white solid, showing: 1H NMR (500 MHz, CD3OD): 4.59 (s, 1 H; H-6), 4.36 
(d, J7,8 = 8.1 Hz, 1 H; H-7), 3.99 (br s, 1H; H-5), 3.81-3.74 (overlapping, 2H; H-8 and H-9a), 
3.70 (dd, J9b,8 = 5.8, J9b,9a = 12.4 Hz, 1 H; H-9b), 3.37 (s, 3H; OCH3), 2.09-1.72 ppm 
(overlapping, 7H; NHCOCH3, H-3a, H-3b¸ H-4a, H-4b); 13C NMR (125 MHz, CD3OD): δ = 
173.0 (C-1), 168.8 (NHCOCH3), 99.0 (C-2), 80.9 (C-7), 73.3 (C-8), 72.9 (C-6), 63.5 (C-9), 
52.4 (C-5), 47.7 (OCH3), 30.0, 24.4 (C-3 and C-4), 22.5 ppm (NHCOCH3). MS (ESI 
negative): m/z 300.1 [M-H]-; elemental analysis calcd (%) for C13H19NO7: C 51.82, H 6.36, N 
4.65; found: C 51.67, H 6.42, N 4.61. 
Path 2: compound 37 (30 mg, 0.10 mmol), dissolved in DMF (1.0 mL) under stirring, was 
cooled to 0 °C and diluted with THF (1.5 mL). Then CbzCl (0.03 mL; 0.25 mmol, 2.5 equiv) 
in THF (0.4 mL) was added in a single portion, followed by Et3N (0.04 mL; 0.3 mmol) in a 
single addition. The mixture was then stirred for 30 min at 23 °C. At this time, methanol (0.3 
mL) was added and the stirring was continued for 15 min. Evaporation of the solvent under 
reduced pressure afforded a crude residue. Compound 36 was obtained (22 mg, 75%), after 
purification by flash chromatography (eluting with ethyl acetate/methanol, 95:5 to, 85:15, v/v) 
as a white solid, showing the same chemical-physical characteristic above reported130.  
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5.2 Biological materials and methods 
The above listed biological materials and methods were used for all the classes of compounds 
present in this thesis and described in Chapters 3.1, 3.2 and 3.3.  
5.2.1 Viruses and cell lines 
 NDV “Clone 30” (LaSota), used in neuraminidase inhibition assays (NI) and 
hemagglutinin inhibition assay (HI), was grown and purified as described previously 
in the literature75. Stock viruses were harvested, titrated, and stored at −80 °C until 
use. 
 COS7 cells were obtained from the American Type Culture Collection and maintained 
at 37 °C (in an atmosphere of 5% CO2) in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with L-glutamine (4 mM), penicillin–streptomycin (100 
U*ml−1 –100 µg*ml−1), and heat inactivated fetal bovine serum (FBS) at 10% v/v (all 
reagents were from Sigma).  
 Stable NEU3 overexpressing Hek293a cells were obtained as previously described132 
and maintained at 37°C in 5% CO2 and 95% air-humidified atmosphere in Dulbecco’s 
modified Eagle’s medium (DMEM) with high glucose, 4.5 g/L (Sigma-Aldrich) with 
10% (v/v) fetal bovine serum (FBS, Sigma-Aldrich), 2 mM glutamine (Sigma-
Aldrich), penicillin/streptomycin 1X (Euroclone). 
 cRBC used in HI assay were provided from “Istituto Zooprofilattico Sperimentale 
delle Venezie”. The freshly cRBC were washed 3 times in PBS and the obtained 
solution (0.5 or 1% of cRBC) was conserved for one week at 4°C. 
5.2.2 Neuraminidase inhibition assay (NI) on NDV-HN 
Neuraminidase activity inhibition assay was performed, according to Venerando et al.112, 
using 4-MU-Neu5Ac as the artificial substrate. Briefly, the incubation mixture (final volume 
of 100 µL) contained 0.2 µg of NDV “Clone 30”, different amounts of the inhibitors (0-2.0 
mM), 0.12 mM 4-MU-Neu5Ac, 600 µg of bovine serum albumin (BSA) and 200 mM sodium 
citrate/phosphate buffer pH 6.8. After incubation at 37 °C for 15 min, the reactions were 
stopped by the addition of 1.5 mL of 0.2 M glycine buffered with NaOH at pH 10.8, and the 
neuraminidase activity was determined by spectrofluorometric measurement (Varioskan LUX 
Multimode Microplate reader, Thermo Fisher Scientific) of the 4-methylumbelliferone 
released (λ excitation 365 nm, λ emission 448 nm). One mU of neuraminidase activity is 
defined as the amount of enzyme releasing 1 nmol product N-acetylneuraminic acid per 
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minute at 37 °C. Six/seven concentrations of each inhibitor were used to determine the IC50 
for all compounds maintaining a fixed concentration (0.12 mM) of 4-MUNeu5Ac. 
5.2.2 Hemagglutinin inhibition assay (NI) on NDV-HN 
This assay was performed according to the literature4. Briefly, the synthesized inhibitors 
DANA 1a, FANA 2a and compounds 12a,b and 13b,d were assessed in duplicate in V-bottom 
96 well plates. Compounds were diluted in PBS as a 4X solution for each concentration tested 
(25 µL/well, 1X final). Each dilution was mixed with 4 hemagglutination units (HAU) of 
NDV (25 µL/well, 1 HAU final) and incubated for 30min at room temperature. The plate was, 
then, transferred on ice, and an equivalent volume of ice-cold 0.5% cRBC (50 µL/well) was 
added to each well. Plate was incubated for 1.5h at 23°C before reading hemagglutination 
results. The IC50 value for HI assays was defined as the compound concentration that gives 
similar agglutination to that observed in a well containing only 0.5 HAU of NDV and cRBC. 
 
5.2.3 Protein extraction from stable NEU3 overexpressing Hek293a cells and 
quantification. 
Stable Neu3 overexpressing Hek293a cells, maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) were harvested by centrifugation and resuspended in PBS, containing 
protease and phosphatase inhibitor cocktail (Sigma-Aldrich). Total cells suspensions were 
lysed by sonication and then centrifuged at 800g for 10 min at 4°C to eliminate unbroken cells 
and nuclear components. The obtained supernatants were subsequently centrifuged at 115,000 
X g at 4°C for 90 min on an Avanti J-30I Ultracentrifuge (Beckman Coulter) to obtain 
cytosolic and particulate (or membrane) fractions. Total protein content was determined with 
the BCA Protein Assay Kit (Pierce) following, in detail, the manufacturer’s instructions.  
5.2.4 Neuraminidase inhibition assay (NI) on hNEU3 
The sialidase activity present in the particulate fraction from HEK293A cells was assayed 
according to the above protocol. Briefly, 40 µg of proteins from the particulate fraction were 
incubated with different amounts of the inhibitors (0-1.0 mM), 0.12 mM 4-MU-Neu5Ac, 600 
µg of bovine serum albumin (BSA) and 12.5 mM sodium citrate/phosphate buffer pH 3.8. 
After incubation at 37 °C for 1 hour, the reactions were stopped by the addition of 1.5 mL of 
0.2 M glycine buffered with NaOH at pH 10.8, and the neuraminidase activity was determined 
by spectrofluorometric measurement (Varioskan LUX Multimode Microplate reader, Thermo 
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Fisher Scientific). One mU of sialidase activity is defined as the amount of enzyme liberating 
1 nmol product N-acetylneuraminic acid per minute at 37 °C. Six concentrations of each 
inhibitor were used to determine the IC50 for all compounds maintaining a fixed concentration 
(0.12 mM) of 4-MUNeu5Ac. 
5.2.5 MTT assay (Citotoxicity assay) 
The cytotoxicity of the compounds was analyzed by MTT assay following the manufacturer's 
protocol (Sigma Aldrich). Briefly, COS7 cells were seeded in 6-well plates at an initial density 
of 1 X 105 cells per well. The cells were incubated with different concentrations of the 
compounds at 37 °C in 5% CO2 in an incubator for 24 h. MTT solution (5 mg mL−1) was 
added to the cells, which were further incubated for 30 min. Then, the medium was discarded 
and 1 ml of MTT solubilization solution (10% Triton X-100 plus 0.1 N HCl in anhydrous 
isopropanol) was added for 10 min to dissolve the resulting formazan product. The absorbance 
of each well was measured at 570 nm using a spectrophotometer (Jasco V-530 
Spectrophotometer). Each experiment was performed in triplicate, and experiments were 
repeated at least three times. The cytotoxicity was expressed as the CC50, which was the 
concentration of the test substances that inhibited the growth of COS7 cells by 50% compared 
with the growth of the untreated cells. 
5.3.6 Statistical analysis 
The IC50 values were determined by nonlinear regression analysis using GraphPad Prism 7 
(GraphPad Software Inc., La Jolla, CA). by nonlinear regression (curve fit), dose–response 
inhibition and three parameters logistic. Typical concentration–response plots were obtained 
from the average values of triplicate assay results. The results were presented as the mean of 
three independent experiments carried out in triplicate. IC50 values were compared with t-test 
using Prism 7. Values of p < 0.05 were considered statistically significant. 
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5.3 Computational methods 
5.3.1 Rigid Docking simulations for compounds 1a and 2a-c (Chapter 3.1) 
The protein structure of NDV (PDB 1e8v) was downloaded from PDB53. Then, it was 
prepared for docking using Schrödinger Protein Preparation Wizard (Schrödinger release 
2016-3)133 with standard settings, except that all water molecules were retained. DANA 1a 
and the perfluorinated derivatives 2a-c were prepared using Schrödinger LigPrep and the 
protonation state assessed with Epik133. The most stable ligand conformations were identified 
using Monte Carlo Multiple Minimum (MCMM) in Macromodel134, 135. OPLS3 force field 
(OPLS3, Schrödinger, Inc., New York, NY, 2013) was used136. Docking of the substrates was 
performed with Glide137, 138 using the extra precision (XP) mode139. Unless otherwise stated, 
default settings were applied. The best pose was selected using the glide E-model score (kcal 
mol-1), and the Glide XP score (kcal mol-1) was used to compare the docking poses of the 
different substrates.  
The small difference of the IC50 values measured for compounds 1a and 2a-c is reflected in 
the small variation of the Glide XP GScore. Poses with a difference in energy within 2 kcal 
mol−1 are often difficult to distinguish because of the limitations of the scoring function137, 138 
so the values of the GScore cannot be used to rank the quality of the interaction. In this case, 
only a qualitative analysis of the best scored poses, highlighting they key interactions, was 
done (see Results and Discussion 3.1.3). 
5.3.2 Rigid Docking simulations for compounds 1a, 12a (Chapter 3.2) and 22b (Chapter 
3.3) 
The protein structure (PDB 1e8v1) of NDV-NH was downloaded from PDB53. In this analysis 
Chain B was chosen (instead of A) so to keep the important water molecules (2108, 1209 and 
2110) that act as a bridge between the protein and the ligand53. The protein was prepared using 
Schrödinger Protein Preparation Wizard (Schrödinger release 2017- 3)133 using the standard 
settings. All water molecules more than 5Å away from the ligand (or making less than 2 non-
water contacts) were removed. The ligands 1a (DANA), p-toluensolfonamido derivative 12a 
and the 3,4-unsaturated Neu5Ac derivative 22b where prepared using Schrödinger LigPrep 
and the protonation state assessed with Epik133. After LigPrep, Macromodel134, 135 with Monte 
Carlo Multiple Minimum (MCMM) was used to select the most stable ligand conformation. 
For all simulations, the selected force field was OPLS3 (OPLS3, Schrödinger, Inc., New York, 
NY, 2013)136. 
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The rigid docking studies of compounds 1a (DANA),  12a and 22b were run with Glide137-139 
using the extra precision (XP) mode137. Unless otherwise stated, default settings were applied. 
Then, the best pose was selected using the glide E-model score (kcal mol-1) and the Glide XP 
GScore (kcal mol-1) was then used to compare the stability of the different ligands. The results 
were presented in Results and Discussion, paragraph 3.2.1 (for DANA 1a and compound 12a) 
and paragraph 3.3.1 (for compound 22b). 
5.3.3 Induced Fit Docking (IFD) simulations for compounds 1a and 12a (Chapter 3.2) 
The additional IFD studies, performed on DANA 1a and compound 12a, after the same 
preparation described in paragraph 5.3.2, were accomplished with Induced Fit (Schrödinger 
Suite 2017- 3 Induced Fit Docking protocol; Glide, Schrödinger, LLC, New York, NY, 2016; 
Prime, Schrödinger, LLC, New York, NY, 2017)140-142 using Glide extra precision (XP) 
mode137 for redocking.  
The best pose was selected using the glide E-model score (kcal mol-1) and the Glide XP (kcal 
mol-1) GScore was, then, used to compare the stability of the different ligands. The results 
were presented in Results and Discussion, paragraph 3.2.1
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